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CHAPTER 1 
General introduction and aims of the study 
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1.1. General introduction 
During the past few years, much attention has been given to a number of 
antibacterial agents which are chemically related to nalidixic acid. This group 
of compounds include several naphthyridine derivatives (such as enoxacin), 
cinnoline derivatives (Cinoxacin), pyridopyrimidine derivatives (pipemidic acid 
and others) and quinoline derivatives (such as quinolinic acid, oxolinic acid, 
flumequine, rosoxacin, ofloxacin, Pefloxacin, and ciprofloxacin). For practical 
reasons it has been proposed to call those compounds, that resemble nalidixic 
acid and inhibit bacterial DNA gyrase 'fluoro-quinolones' or 'quinolones' 
rather then referring to the different analogues by a name derived from their 
chemical structure (Smith, 1984). 
In 1962, the naphthyridine derivative nalidixic acid was synthetized (Lesher 
et al., 1962). This drug shows a moderate in vitro activity on Gram-negative 
bacteria. Because the ratio peak plasma and tissue concentrations to minimum 
inhibitory concentration (MIC) were low as a result of rapid metabolic 
degradation and subsequent urinary excretion, it was introduced only for 
treatment of urinary tract infections (Deitz et al., 1983). The same applies for 
pipemidic acid and oxolinic acid. Although rosoxacin and oxolinic acid 
appear to have a wider spectrum of activity, their kinetic characteristics are 
comparable to those of nalidixic acid. In addition to these unfavorable 
pharmacokinetic. properties, the compounds showed also severe adverse 
reactions, related mainly to the central nervous system. For these reasons, 
prescription of these drugs during the past few years was restricted. The recently 
synthesized fluorinated analogues, such as ciprofloxacin, ofloxacin, Pefloxacin 
and enoxacin show a good in vitro activity on a broad spectrum of Gram-
positive and Gram-negative pathogens, including Pseudomonas aeruginosa. 
The efficacy of these compounds in urinary tract infections on susceptible 
microorganisms has been documented in a number of studies (Ishigami, 1985; 
Thomas & Ellis Pegler, 1985; Di Silverio, 1986; Ludwig, 1986; Boerema et al., 
1986; Childs, 1985; Schalkhauser & Dalhoff, 1985). After oral dosing with 
ciprofloxacin, ofloxacin, Pefloxacin and enoxacin, plasma concentrations are 
reached that are well above the MIC values for a number of pathogens 
frequently involved in infections of the lower respiratory tract. These findings 
opened perspectives and prompted further research and clinical trials in this 
field, particularly since the main respiratory pathogens, i.e. Haemophilus 
influenzae, Branhamella catarrhalis and Pseudomonas aeruginosa show an 
increasing incidence of resistance to the present antimicrobial agents of choice. 
Since 1972 beta-lactamase producing Haemophilus influenzae strains have been 
isolated in the U.S.A. In 1975 the incidence of beta-lactamase producing 
Haemophilus influenzae was found to be 1-2% (van Klingeren, 1978). Bol et al. 
(1983) reported an increase from 0% in 1975 to 5.1% in 1982 of beta-lactamase 
producing Haemophilus influenzae strains isolated from cerebrospinal fluid. 
The same incidence has been found in England (Mehtar & Aminiafshar, 1983) 
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and Belgium (Piot et ai, 1983). In a recent survey in The Netherlands, 13% of 
the Haemophilus influenzae, type b strains and 5% of the non-b strains proved 
to produce beta-lactamases. In the beta-lactamase producing non-b group, a 
high incidence of resistance to tetracycline, chloramphenicol or co-trimoxazol 
was found (RIVM, 1986; unpublished data). The frequency of penicillin-
resistant Streptococcus pneumoniae strains worldwide is increasing (Ward, 
1981). However, in The Netherlands beta-lactamase producing strains have not 
as yet been isolated. A survey in The Netherlands in 1983 and 1984 to study the 
resistance of Pseudomonas aeruginosa showed a resistance to gentamicin in 
10% of the strains, with a nearly complete cross-resistance to tobramycin. Nine 
percent of the total number of isolates were resistant to carbenicillin; about 70% 
of these strains were also resistant to piperacillin and azlocillin (de Neeling et 
al., 1987). 
For the treatment of infections caused by Pseudomonas aeruginosa only 
antibacterial agents for parenteral administration are available, such as 
ureidopenicillins, aminoglycosides, and some cephalosporines. Enlargement of 
the therapeutic arsenal with a class of drugs that could be administered orally 
would be very valuable, for example to treat Pseudomonas infections of the 
lower respiratory tract that frequently occur in cystic fibrosis and other 
pulmonary diseases with severe anatomical disturbances of the bronchial tree. 
1.2. Aims of the study 
The present study was started in the rather early phase of clinical research when 
the pharmacokinetics of quinolones in patients were still incomplete, and 
clinical data on resistance had not yet appeared. Moreover an unexpectedly high 
incidence of adverse reactions, related mainly to the digestive tract and the 
central nervous system in patients treated with enoxacin for respiratory tract 
infections was reported by Davies et al. (1984). 
The aims of the different investigations, presented in this thesis are: 
To measure some pharmacokinetic parameters of enoxacin, ofloxacin, 
ciprofloxacin, Pefloxacin and their major metabolites in healthy volunteers and 
patients with obstructive pulmonary disease, on maintenance theophylline 
treatment. Also the penetration of enoxacin and ofloxacin into lung tissue was 
measured in patients undergoing thoracotomy (Chapters 3, 4, S and 6). 
To assess the efficacy and safety of enoxacin in respiratory tract infections 
(Chapter 7). 
To evaluate the emergence of resistance in Pseudomonas aeruginosa, 
observed during treatment with enoxacin (Chapter 8). 
To analyse the cause of the elevated plasma theophylline concentrations 
during enoxacin treatment (Chapter 9), and to assess if other quinolone 
derivatives, such as ciprofloxacin, ofloxacin, Pefloxacin and nalidixic acid 
produce a similar effect on theophylline clearance (Chapter 10). 
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To detect a possible hydroxylator or glucuronidator phenotype in the 
metabolism of nalidixic acid, because of considerable variations in the yield of 
7-hydroxynalidixic acid measured in the interaction study (Chapter 11). 
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The fluoroquinolones 
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2.1. Mechanism of action 
The fluorinated 4-quinolone derivatives have a bactericidal action on a broad 
spectrum of Gram-positive and Gram-negative bacteria. This effect results from 
an inhibition of bacterial DNA synthesis, as has been shown for nalidixic acid 
by Crumplin & Smith (1975). These agents inhibit the incorporation of H3 
thymidine (Sato et al., 1983; Hirai et al., 1982). There is good evidence that the 
inhibition of DNA synthesis results from a selective inhibition of the enzyme 
DNA gyrase, one of the so called topoisomerases i.e. enzymes controlling the 
spatial geometry of the DNA molecule (Crumplin & Smith, 1976; Geliert et al., 
1977; Wang, 1985). The enzyme is vital for DNA replication of plasmid, 
chromosome and bacteriophage (Itoh & Tomizawa, 1977). The bacterial 
chromosome is composed of helical double stranded DNA. In living cells, all 
circular DNA exists in a supercoiled form (Sinden et al., 1980). DNA gyrase 
catalyzes the ATP requiring negative supercoiling of the DNA strands, i.e. the 
insertion of left handed superhelical turns into the right handed helical twists. 
This process results in a torsional strain which puts the DNA molecule in a 
energetically activated state due to the superhelical tension (Cozzarelli, 1980). 
Supercoiling is necessary to condense the molecule and to allow a proper 
segregation of the two DNA strands during cell division. DNA gyrase also 
relaxes the supercoiled DNA in the absence of ATP and breaks the double 
strands at specific sites when the gyrase binds with the DNA molecule 
(Cozzarelli, 1980; Higgins et al., 1978). 
By inhibiting DNA gyrase, quinolone derivatives will disturb the process of 
segregation and replication. At concentrations lower than those of nalidixic acid 
they have a strong effect on the relaxation activity in the absence of ATP and 
on the ATP dependent supercoiling activity in Pseudomonas aeruginosa, 
Escherichia coli and Bacteroides fragilis (Sato et al., 1986). The DNA gyrase 
found in Escherichia coli is a complex of the two subunits A and В (Geliert, 
1981; Higgins et al., 1978). Subunit A is a homodimer of a protein encoded by 
the GyrA gene (formerly NalA). This protein is probably involved in the 
breakage and rejoining necessary in the interconversions of DNA (Geliert et al., 
1977). The subunit В is a homodimer of a protein encoded by the GyrB gene 
(formerly NalB) (Mizuuchi et al. 1978; Higgins et al., 1978). DNA gyrase 
activity of Escherichia coli and Micrococcus luteus can be specifically inhibited 
by two groups of antibiotics: one includes coumermycin Al and novobiocin, the 
second nalidixic acid and oxolinic acid (Kreuzer et al., 1978). The A protein is 
the target of the quinolones; it is not, or only slightly, inhibited by novobiocin 
(Sugino et al., 1977; Inoue et al., 1978). The В protein is inhibited by 
coumermycin and novobiocin which compete with ATP for binding. The 
bactericidal action of nalidixic acid and most of its analogues will be lost if 
protein synthesis is inhibited by chloramphenicol, or if RNA synthesis is 
inhibited by rifampin. There is evidence for a different bactericidal mechanism 
in some of these drugs, in particular ciprofloxacin and ofloxacin. The 
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bactericidal effect of ofloxacin and ciprofloxacin will not be entirely lost if 
protein or RNA synthesis is inhibited (Smith, 1984; Crumplin, 1985). The 
mechanism of this additional killing potency, that the other quinolone 
derivatives seem to lack, is still in study. For staphylococci, ofloxacin shows 
both the same rifampin dependent and independent bactericidal mechanism. 
However, ciprofloxacin does not exhibit this dual mechanism for staphylococci 
(Smith, 1987). 
Bacteria can become resistant to high levels of nalidixic acid by chromosomal 
mutation at the GyrA locus. Mutation at the В locus is related to coumermycin/ 
novobiocin resistance, in vitro and in vivo (Higgins et al., 1978). Mutations that 
alter the В protein will change the antibacterial activity of some but not all 
quinolones probably by a reduced permeability (Inoue et al., 1978; Smith, 1984). 
DNA gyrase has been found in every organism examined. However, only the 
type II enzyme of bacterial DNA gyrase is capable of inserting negative 
supercoils into DNA. The mammalian enzyme does not possess any negative 
supercoiling activity and is composed of only two monomers (Smith, 1986). 
This feature may account for the selective action of the quinolone derivatives 
upon the bacterial enzyme, as the isolated mammalian enzymes that have been 
studied to date show no inhibition by the quinolones (Crumplin, 1986). 
2.2. In vitro activity 
The antibacterial spectrum of nalidixic acid and oxolinic acid is limited to a 
number of Gram-negative bacteria. By substitutions to the chemical structures 
of compounds developed later, both the antibacterial activity and the spectrum 
of susceptible microorganisms have been markedly increased (Figure 1). 
Substitution of an ethyl group, or spatial equivalent, to the 1 position of the 
molecule has proven to be vital for antibacterial activity. Modifications at the 
2 to 5 position did not offer significant advantages. However, the addition of 
a fluorine atom at the 6 position resulted in a very significant increase in the 
antibacterial activity as compared to that of nalidixic acid. A further increase 
in the activity resulted from the substitution of a piperazine ring with a double 
nitrogen configuration at the 7 position. The activity on Gram-positive and 
anaerobic bacteria will increase by substitutions at the 8 position, as is the case 
in ofloxacin. The in vitro spectrum of the newer quinolones contains a wide 
range of Gram-negative and Gram-positive microorganisms; in general, Gram-
negative bacteria are more susceptible than Gram-positives (Wolfson & Hooper, 
1985; Janknegt, 1986). 
In lower respiratory tract infections the major pathogens currently include 
Streptococcus pneumonia, Haemophilus influenzae, Branhamella catarrhalis, 
Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas species and 
Legionella species. 
The activity on Streptococcus pneumoniae is limited: MIC values for 
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Figure 1 Chemical structure of the fluoroquinolone norfloxacin. 
enoxacin and Pefloxacin range from 8 to 16 mg/1 (Siporin & Towse, 1984; 
Shannon & Phillips, 1985; Chin & Neu, 1983; Auckenthaler et al., 1986; 
Ligtvoet & Wickerhoff-Minoggio, 1985). MIC values for ciprofloxacin and 
ofloxacin range from 1 to 2 mg/1 (Ligtvoet & Wickerhoff-Minoggio, 1985; 
Isaacson et al., 1986; Hoogkamp-Korstanje, 1984). 
Haemophilus influenzae is highly susceptible: MIC values for ciprofloxacin, 
ofloxacin and Pefloxacin range from less than 0.015 to 0.03 mg/1 (Hoogkamp-
Korstanje, 1984; Muytjens et al., 1983; Kumada & Neu, 1983; Auckenthaler et 
al., 1986), MIC values for enoxacin from 0.03 to 0.25 mg/1 (Reeves, 1984). 
In general, the new quinolones show a good activity on Branhamella 
catarrhalis, a microorganism, increasingly recognized as a respiratory pathogen 
(McLeod et al., 1986). Of the new quinolones, ciprofloxacin and ofloxacin are 
again the most active compounds with MIC values of 0.06 to 0.125 mg/1. MIC 
values for Pefloxacin and enoxacin in particular are slightly higher (Davies et 
al., 1986). 
The susceptibility of Staphylococcus aureus for the quinolones has been 
increased, particularly by modifications at the 8 position of the new analogues. 
However, reviewing the available in vitro data, MIC values are higher than 
found in most Gram-negative bacteria, ranging from 0.5 to 2 mg/1 (Janknegt, 
1986). 
Klebsiella species in general can be considered to be susceptible to the whole 
group; MIC values range from 0.25 to 1 mg/1 (Auckenthaler et al., 1986; 
Cullmann et al., 1985). 
The in vitro susceptibility of Pseudomonas species varies. Ciprofloxacin and 
ofloxacin can be considered to be active on most Pseudomonas aeruginosa 
strains, inclusive those resistant to aminoglycosides, ureidopenicillins and 
ceftazidime; MIC values for ciprofloxacin range from 0.06 to 1 mg/1 
(Hoogkamp-Korstanje, 1984); the in vitro activity of ofloxacin is slightly less 
with a mean MIC value of 2 mg/1. Pefloxacin and enoxacin are only moderately 
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active with MIC values ranging from 2-4 mg/l (Auckenthaler et al., 1986). Most 
strains of Pseudomonas cepacea and Pseudomonas maltophilia have to be 
considered resistant to these compounds. 
For the treatment of Legionella infections of the respiratory tract only few 
antibiotics are available. The new quinolones show an in vitro activity in 
between rifampin and erythromycin: the mean MIC values found are 0.12 mg/1 
for ofloxacin, 0.25 mg/1 for ciprofloxacin and Pefloxacin, and 1.0 mg/1 for 
enoxacin (Deforges et al., 1986). 
Ciprofloxacin and ofloxacin have been found to be active against 
Mycobacterium tuberculosis, including strains resistant to most of the first line 
antimycobacterial drugs (Berlin et al. 1987; Davies et al. 1987). Atypical 
mycobacteria like Mycobacterium fortuitum and Mycobacterium kansasii 
proved to be moderate susceptible (Marinis & Legakis-, 1985). 
At this moment a number of quinolones have been synthesized which show 
a significant increased in vitro activity on Gram-positive bacteria, particularly 
to streptococci. Examples of these group are S25930, S25932 (Felmingham et 
al., 1985), A-56619, A-56620 (Gordts et al., 1985; Fernandes et al., 1985), and 
CI-934 (King et al., 1986; Cohen et al., 1985). However, Pseudomonas 
aeruginosa in general is less susceptible to these compounds, then to 
ciprofloxacin and ofloxacin. 
2.3. Clinical experience 
The expectations for the fluorinated quinolones in infections of the lower 
respiratory tract still have to be confirmed. At the moment an extensive clinical 
effort is still going on, aimed at assessing the clinical efficacy of ciprofloxacin, 
ofloxacin, enoxacin, and Pefloxacin. Most of the data now available, that have 
been obtained in open, non-comparative studies, must be considered as only 
preliminary. 
Respiratory tract infections of bacterial origin frequently have a recurrent 
character in patients with chronic obstructive pulmonary disease or patients 
with severe anatomical disturbances of the bronchial tree. Often they are 
secondary infections following a viral infection. Most of these patients 
chronically produce sputum which differs in color and viscosity. Because of 
decreased local resistance, the bronchial tree can get colonised by organisms, 
such as Branhamella catarrhalis, Haemophilus influenzae. Staphylococcus 
aureus or Pseudomonas aeruginosa. In these cases the presence of bacteria 
alone does not differentiate between colonisation and infection. Other signs and 
symptoms such as fever, an exacerbation of the pulmonary complaints, and the 
presence of neutrophils found by microscopic examination of the sputum, can 
contribute to the diagnosis of an active infection. In general, it is less 
problematic to establish the diagnosis pneumonia, but in pneumonia it can be 
difficult to obtain adequate material in order to identify the causative organism. 
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To evaluate clinical and bacteriological effects of antimicrobial treatment in 
these infections in patients with bronchietasis and/or chronic obstructive 
pulmonary disease, one must realize that frequently used parameters such as the 
feeling of well being, coughing, dyspnea, the volume and color of the 
expectorated sputum and spirometrie lung function data, will be very 
significantly influenced by other therapeutic approaches, such as oxygen 
delivery, adequate bronchodilating therapy, the use of steroids, and 
physiotherapy. Conversely one must also realise that even in cases of succesful 
antibacterial treatment, the complaints will not disappear completely; the 
complaints must be compared with the patient's stable condition before the 
infectious episode. Often just restoring the state of locally decreased host 
defense by adequate bronchodilatory therapy, will successfully combat the 
infection (Anthonisen et al., 1987). The often reported favorable clinical results 
in spite of bacteriological outcome to the contrary are presumably unrelated to 
antimicrobial therapy. No randomised prospective data are available yet that 
compare the efficacy of the different quinolones. 
Favorable data have been reported from the treatment of infections, caused 
by Haemophilus influenzae, Klebsiella pneumoniae, and Branhamella 
catarrhalis (Shishido et al., 1983; Salvati et al., 1986; Hoogkamp-Korstanje & 
Klein, 1986; Davies et al., 1986). In some studies, a good effect on 
Streptococcus pneumoniae has been observed with ciprofloxacin (Vetter et al., 
1985; Bassaris et al., 1985; Hoogkamp-Korstanje & Klein, 1986) and ofloxacin 
(Taguchi et al., 1985; Kobayashi & Takamura, 1983; Grassi & Grassi, 1986). In 
several studies however Streptococcus pneumoniae was not eradicated in some 
of the patients (Klein et al., 1985; Mehtar et al., 1985; Campbell & du Bois, 
1985; Shishido et al., 1983; Davies et al., 1986). Overgrowth of Streptococcus 
pneumoniae during quinolone administration has been observed (Davies et al., 
1986). The reports on the effect on Pseudomonas aeruginosa in patients with 
cystic fibrosis or bronchiectasis of other origin are rather uniform: in a great 
number of patients a moderate to good clinical result has been obtained together 
with a reduced Pseudomonas growth; only in a minority of the cases the 
bacteria has been shown to be eradicated (Davies et al., 1986; Bender et al., 
1985; Hodson et al., 1985; Scully et al., 1984; Kobayashi & Takamura 1983; 
Yokota et al., 1983; Shishido et al., 1983; Grassi & Grassi, 1986; Nakamori et 
al., 1986). Sometimes MIC values increased in the persisting Pseudomonas 
strains (Davies et al., 1986; LeBel et ai, 1986; Scully et al., 1984; Salh & Webb, 
1987). 
In a comparative study with ciprofloxacin and cefalexin in respiratory tract 
infections, ciprofloxacin proved to be superior in eradicating Haemophilus 
influenzae and Escherichia coli (Vetter et al., 1985). The drug was found to be 
as effective as amoxicillin in lower respiratory tract infections, caused by 
Branhamella catarrhalis, Haemophilus influenzae and Streptococcus 
pneumoniae (Gleadhill et al., 1986). Ofloxacin has been reported bo be as 
effective as doxycycline (Harazim, 1985), cefazolin (Cristiano, 1985) and 
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amoxicillin (Lam et al., 1986) in lower respiratory tract infections. Enoxacin 
proved to be as effective as trimethoprim-sulfamethoxazole (Maasilta et al., 
1986) and amoxicillin (Glupczynski et al., 1986) in Haemophilus influenzae 
infections. Only casuistic clinical reports are available on the efficacy of 
ciprofloxacin and ofloxacin in infections caused by Legionella species (Winter 
et al., 1986). 
Unfortunately, in a number of the available comparative studies the efficacy 
has been judged only from the clinical outcome, with often only very limited 
data presented concerning the bacteriological results. Moreover, in most clinical 
studies, the bacteriological results were only assessed on the last day of 
treatment. Davies et al. (1986) found that in a significant number of patients, 
who had negative sputum cultures on the last day of quinolone treatment, the 
sputum showed growth of pathogens again one week after treatment. 
2.4. Adverse reactions 
Although the incidence of adverse reactions in the initial Japanese studies 
was considered to be low, 4 to 6 percent of the treated patients will suffer 
from side effects, related mainly to the digestive tract and to the central 
nervous system. Ciprofloxacin, ofloxacin, Pefloxacin and enoxacin do not 
show a clear difference in frequency and kind of adverse reactions (Janknegt, 
1986). Anorexia, nausea, vomiting, abdominal discomfort and diarrhoea are 
reported in 4.5% of European patients (Ball, 1986). Quinolones can cause 
neurotoxic effects; this has been reported for nalidixic acid (Islam & 
Sreedharan, 1965; Ronald et al., 1966), Cinoxacin (Buey, 1981), oxolinic acid 
(Shapera & Madsen, 1977), and acrosoxacin (Hunter Hands field et al., 1981). 
Restlessness, dizziness, insomnia, headache, or visual blurring can occur. The 
recently developed quinolone derivatives can cause the same adverse reactions; 
there is some evidence that the incidence is dose related (Tegelberg-Stassen et 
al., 1986). 
Photosensitivity of the skin can develop (Guibert & Boutelier, 1983). 
Infrequently haematological effects, such as trombocytosis, monocytosis or 
eosinophilia (Guibert et al., 1986) or biochemical changes, such as elevated 
transaminases (Baba, 1985) have been reported. 
Since Ingham (1977) described cartilage erosion in the limbs of juvenile dogs 
induced by nalidixic acid, lesions to the articular cartilage have been observed 
in all quinolones during toxicology studies, using high dosages of the drugs 
(Gough & De La Iglesia, 1979; Tatsumi, 1978). There are only scarce data con-
cerning adverse reactions of quinolones in children; to our knowledge there is 
a complete lack of data on the effect of the quinolones on articular cartilage 
in man. 
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3.1. Introduction 
Enoxacin [1 -ethyl-6-fluoro-1,4-dihydro-4-oxo-7-( 1 -piperazinyl)-1,8-naphthyrid-
ine-3-carboxylic acid; CI 919, AT 2266] is a new broad-spectrum antibacterial 
agent of the quinolone-azaquinolone class. Based on minimal inhibitory 
concentrations (MIC), enoxacin shows a high activity against Pseudomonas 
aeruginosa (Ozaki et ai, 1981). Enoxacin is metabolized by hydroxylation and 
oxidation to form 4-oxo-enoxacin. Another metabolic route is conjugation with 
formic and acetic acid, ring opening and deamination of the piperazine ring. 
The 4-oxo metabolite accounts for 10-15% of the ingested dose, and the four 
other metabolites each constitute less than 1% of the dose. This paper describes 
a reversed-phase liquid chromatographic determination of enoxacin and its 
4-oxo metabolite in human plasma, urine and saliva. Pharmacokinetic studies 
of enoxacin were carried out with two healthy volunteers in order to obtain a 
preliminary kinetic profile. 
3.2. Materials and methods 
Chromatography 
A Spectra-Physics 3500B liquid Chromatograph was used, equipped with a 
variable-wavelength spectrophotometer detector (Model SP 770). The detector 
was connected to a 10-mV recorder (BD7, Kipp & Zonen, The Netherlands): the 
chart speed was 1 cm/min. A stainless-steel column (15 cm χ 4.6 mm I.D.) was 
packed by a slurry technique with LiChrosorb RP-2, particle size 5 μΐη (Merck, 
Darmstadt, F.R.G.). In order to avoid contamination of the analytical column, 
a guard column (7.5 cm χ 2.1 mm I.D.) tap-filled with pellicular reversed-phase 
material (Chrompack, Middelburg, The Netherlands) was placed between the 
sampling valve and the analytical column. Detection of enoxacin was effected 
at 342 nm. The mobile phase was 7 лМ phosphoric acid-dimethylformamide-
ethanol (77:20:3). The chemicals were of analytical grade (Merck). The solvent 
flow-rate was 1.6 ml/min at a pressure of 23.5 mPa. The injection loop was 100 
μ\. Chromatographic analysis was carried out at room temperature. 
Drugs 
Enoxacin and its 4-oxo metabolite were obtained from Warner Lambert 
(Substantia, Іг. T. van Elzakker). 
Subjects 
One healthy male (subject A, 91 kg, 35 years) and one healthy female (subject 
B, 63 kg, 30 years) volunteered for this study. A dose of 400 mg and 600 mg 
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of enoxacin was administered to each volunteer in two different experiments 
after fasting. Blood and saliva were collected at г, 1, 1 Vi, 2, 3, 4, 6, 9, 12 and 
15 h after drug administration. Blood samples were prevented from clotting by 
0.5 mg of solid heparin. The plasma was separated immediately. Spontaneously 
voided urine was collected for 24 h. All samples were kept frozen at -20 oC 
until analysis. 
Sample preparation 
Plasma. To 0.1 ml of plasma was added 0.3 ml of 3% trichloroacetic acid and 
mixed thoroughly on a vortex mixer. The mixture was allowed to stand for 10 
min and centrifuged at 2600 g for 10 min. А 100-/Л volume of the clear 
supernatant was injected onto the column. 
Urine. Urine was diluted 50 times with the mobile phase. The solution was 
mixed and 100 μΐ were injected onto the column. 
Deglucuronidation of plasma and urine samples. To 0.1 ml of plasma was 
added 0.1 ml of a ^-glucuronidase solution (1000 U per 10 ml of phosphate 
buffer, pH 6.8; Sigma, St. Louis, MO, U.S.A.). The solution was incubated at 
370C. After 16 h of incubation, 0.2 ml of S^ o trichloroacetic acid was added, 
mixed thoroughly and centrifuged. Α 100-μ1 volume of the clear supernatant 
was injected onto the column. 
To 0.1 ml of urine was added 0.4 ml of 0.1 M acetate buffer (pH 5.0) and 
10 μ\ of a ^-glucuronidase solution (100 000 U/ml of water; Sigma). The 
solution was incubated at 370C for 16 h, then 0.1 ml of the mixture was diluted 
ten times with the mobile phase and 100 μ\ were injected onto the column. 
Saliva. After thawing, saliva samples were homogenised either on a vortex 
mixer or by ultrasonication and centrifugation at 2600 g for 15 min. A 100 μ\ 
volume of the sample was treated as described for plasma. 
Protein binding 
Plasma protein binding was estimated after ultrafiltration by using EMIT® 
Free Level™ filters (Syva, Palo Alto, CA, U.S.A.; Merck, Amsterdam, The 
Netherlands). To 100 μ\ of the ultrafiltrate, 200 μΐ of water were added, and 100 
μΙ of the mixture were injected onto the column. Filters were pre-tested with 
known amounts of enoxacin and the 4-oxo metabolite in phosphate buffer (pH 
7.4). Both compounds were filtered to 100%. 
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Figure 1 HPLC profiles of enoxacin and its 4-oxo metabolite (left) in plasma in 
concentrations of 4.7 /ig/ml enoxacin and 0.88 /¿g/ml in 4-oxo-enoxacin, and (right) in 
urine in concentrations of 282 ßg/ml enoxacin and 74 /ig/ml 4-oxo-enoxacin. 
3.3. Results 
Chromatography 
Enoxacin is well separated from its 4-oxo metabolite (Fig. 1). Absorption 
maxima of enoxacin in 0.1 M sodium hydroxide are at 345 and 265 nm, for the 
4-oxo metabolite at 342 and 265 nm. Sensitivity for both compounds is about 
two times higher at 265 nm. E\?k is 1300 for enoxacin and 900 for the 4-oxo 
metabolite. 
Owing to interfering peaks at 265 nm at the beginning of the chromatogram 
of plasma samples, enoxacin was measured at 342 nm, and once the enoxacin 
peak appeared, the detection wavelength was set at 265 nm to estimate the 4-oxo 
metabolite. Urine samples were measured at 342 nm. The minimum detectable 
concentrations of enoxacin and its metabolite in plasma and saliva were 0.05 
μg/ml, and in urine 0.5 and 1 μg/ml, respectively. 
The recovery of enoxacin added to human plasma in the concentration range 
0.8-12 pg/ml was 81.7±2.8%. The recovery of the 4-oxo metabolite was 
51.9±3.9% in the concentration range 0.1-2.5 /ig/ml. 
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Calibration curves of enoxacin and its 4-oxo metabolite were linear: г = 
0.9998 and г = 0.9990, respectively. The recovery for both compounds added 
to the urine and saliva was 100 ± 2 % . 
In order to estimate enoxacin and its metabolite in saliva it is necessary for 
the subject to abstain from drinking tea and coffee, to prevent interfering peaks 
appearing in the chromatogram. For this reason concentrations in saliva were 
not measurable in volunteer B. In subject A, the maximum saliva concentration 
1.0 h after a single 400 mg dose was 1.4 /ig/ml, after 600 mg enoxacin 1.8 /ig/ml. 
Pharmacokinetics 
Figure 2 shows the plasma concentration-time curves and renal excretion rate-
time profiles of enoxacin and its 4-oxo metabolite in a volunteer after an oral 
dose of 600 mg of enoxacin. The half-li ves of enoxacin and its metabolite are 
"n plasma cone ug/wi 
100 
Figure 2 Plasma concentration-time curves and renal excretion rate-time profiles of 
enoxacin and its metabolite 4-oxo-enoxacin in a volunteer after a single oral dose of 600 
mg of enoxacin. 
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identical (3 h in this subject) and vary between 3 and 7 h, depending on the 
subject and the dose. Approximately 55% of the ingested dose is excreted in 24 
h in the urine, 40% as parent drug and 15% as 4-oxo metabolite. Table I shows 
some pharmacokinetic parameters of enoxacin and its metabolite in the subjects 
A and B. 
Table I Some pharmacokinetic parameters of enoxacin in humans 
Subject 
A 
A 
В 
В 
Dose 
(mg) 
400 
600 
400 
600 
Maximum plasma concentration 
(/íg/ml) 
Enoxacin 
1.8(1.5)* 
2.3 (1.5) 
3.6(1.0) 
3.5 (1.0) 
4-Oxo 
0.24 (1.5) 
0.24 (1.5) 
0.53 (1.0) 
0.85 (1.0) 
Excreted in urine in 24 h 
(% of the dose) 
Enoxacin 
45.3 
38.1 
40.0 
30.2 
4-Oxo 
13.8 
10.0 
16.3 
18.0 
* The values between parentheses indicate the time (h) at which the maximum plasma 
concentration is reached. 
Protein binding 
Plasma protein binding for enoxacin and its 4-oxo metabolite was ca. 55% as 
shown in Table II. 
Table II 
Subject 
Half-life and protein binding of enoxacin and its metabolite in humans 
Dose Half-life (h) Protein binding (%) 
Enoxacin 4-Oxo Enoxacin 4-Oxo 
A 
A 
В 
В 
400 
600 
400 
600 
5.3 
7.0 
4.0 
3.0 
5.3 
7.0 
4.0 
3.0 
55.4±3.1 
58.4±6.3 
52.0±3.0 
55.1±5.3 
n.d.* 
54.2±3.8 
n.d.» 
55.2±8.1 
Not measurable, concentration too low. 
Urine 
Urinary concentrations ranged from 0.5 to 1500 /ig/ml for enoxacin and from 
1 to 500 /ig/ml for its metabolite. The renal clearance constant, the 
proportionality constant between the renal excretion rate (/ig/min) and the 
plasma concentration (¿ig/ml), was 214 ±21 ml/min for the parent drug and 
404 ±51 ml/min for the metabolite in the two volunteers. After 
37 
deglucuronidation of urine and plasma, no glucuronide of enoxacin or its 
metabolite could be detected. 
3.4. Discussion 
This HPLC method enables the measurement of plasma, urine and saliva 
concentrations of enoxacin and its 4-oxo metabolite in humans and can be used 
for the determination in patients. The HPLC method of Nakamura et al. (1983) 
requires a relatively large sample volume of 1 ml, but is able to detect four other 
metabolites. The presence of these metabolites seems of less clinical importance, 
as each of them accounts for 1 Ч/о or less of the administered dose. 
Similar HPLC methods and metabolic profiles have been reported for a 
structural analogue of enoxacin, i.e. norfloxacin (Eandi et al., 1983 ; Forchetti 
et al., 1984). 
Enoxacin is mainly eliminated by renal excretion with a high renal clearance 
(240 ml/min). The metabolite 4-oxo-enoxacin shows an even higher renal 
clearance of 400 ml/min. This means that both compounds are excreted by 
glomerular filtration and active tubular secretion. Approximately 50% of the 
dose is recovered from the urine, which corresponds to the low bioavailability 
of 50% reported by Eandi et al. (1983). The elimination of enoxacin depends 
totally on the renal clearance. Therefore, in patients with impaired renal 
function, the elimination will be slower and the half-life longer. 
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Summary 
Preliminary pharmacokinetic data were obtained from four healthy volunteers 
after oral administration of a single 400 mg or 600 mg dose of enoxacin. 
Enoxacin was absorbed quickly and absorption was increased when ingested 
after a meal. Renal clearance of enoxacin and 4-oxo-enoxacin decreased after 
simultaneous administration of probenecid. 
In addition, pharmacokinetic parameters of enoxacin and its 4-oxo 
metabolite were determined in plasma and sputum, obtained from 19 patients 
treated with enoxacin, 400 mg or 600 mg b.i.d., for a respiratory tract infection. 
The half-life of both enoxacin and 4-oxo-enoxacin was 5-6 hours; during 
treatment with 400 mg b.i.d. and 600 mg b.i.d., the plasma concentrations 
exceeded MIC values for most bacteria isolated in respiratory tract infections, 
including most Pseusomonas aeruginosa strains; Streptococcus pneumoniae is 
an exception. Diffusion from plasma to sputum was approximately 100%. Of 
the ingested dose, 60% to 65% was recovered in the urine in 24 hours. 
In a third study, a single 600 mg dose of enoxacin was given to 15 patients 
undergoing thoracotomy: Subsequent lung tissue concentrations of enoxacin 
were significantly higher than the plasma concentrations at the same time after 
ingestion. 
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4.1. Introduction 
Enoxacin, a recently developed antimicrobial agent belonging to the quinolone 
class, shows good in-vitro activity against Gram-positive and Gram-negative 
bacteria, including Pseudomonas species (Chin & Neu, 1983; Nakamura et al., 
1983a; Siporin & Towse, 1984). After oral administration, enoxacin is partly 
metabolized to 4-oxo enoxacin. Four other metabolites are formed, each 
constituting less than 1% of the ingested dose (Nakamura et al., 1983b). 
This study evaluated the presence of enoxacin and its 4-oxo metabolite in 
plasma, sputum, and of enoxacin in lung tissue after oral administration. 
4.2. Subjects, materials and methods 
This study consisted of three phases. In the first phase, preliminary 
pharmacokinetic profiles of the parent compound and its 4-oxo metabolite were 
obtained in four volunteers. In the second phase, 19 patients hospitalized for 
respiratory tract infections received enoxacin in an oral dose of 400 mg or 600 
mg b.i.d. In the third phase, 15 subjects undergoing thoracotomy received a 
single 600 mg dose of enoxacin before operation. Informed consent was 
obtained in all cases and the study had the approval of the hospital ethics 
committee. 
Phase I 
A single 400 mg and 600 mg oral dose of enoxacin was administered to two 
subjects on two separate occasions one week apart (Table 1, subjects A and B). 
In two other healthy volunteers (subjects С and D), a single oral dose of 600 
mg enoxacin was given two hours before breakfast; two weeks later the same 
dose was given after a standard breakfast. To one of these volunteers, 1.5 g of 
NaHC03 was given 12 hours before administration of 600 mg enoxacin. The 
NaHC03 was repeated three times (1 g every 3 h) after ingestion of enoxacin. 
In addition, 2.5 g of probenecid was administered to the other volunteer 
concomitantly with the 600 mg dose of enoxacin. 
Phase II 
Nineteen patients admitted to the hospital because of respiratory tract infections 
were treated with enoxacin, 600 mg b.i.d. or 400 mg b.i.d. The drug was 
administered two hours after a normal hospital breakfast. The group consisted 
of 12 men and 7 women. Their mean age was 60.0 ± 11.6 years (range 32 to 76 
years); mean weight was 66.6 ± 12.5 kg. All patients produced purulent sputum 
frequently. Blood samples were collected at г, 1, Wi, 2, 2Vi, 3, 4, 5, 7, 9 and 
11 Vi h after administration of the morning dose from an indwelling forearm 
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Table I Selected pharmacokinetic parameters of enoxacin and 4-oxo-enoxacin in 4 healthy volunteers after a single oral dose of 
400 mg or 600 mg. 
Subject 
A 
A 
В 
В 
С 
С 
С 
D 
D 
D 
Dose 
(mg) 
4001 
600' 
400' 
600' 
6001 
6002 
600' 
+ probenecid 
6001 
6002 
600' 
+ NaHCOj 
Maximum plasma concentration 
Enox 
1.8 (1.5) 
2.3 (1.5) 
3.6 (1.0) 
3.5 (1.0) 
4.0 (0.5) 
4.9 (1.5) 
3.9 (0.5) 
0.7 (0.5) 
4.3 (1.2) 
2.2 (1.0) 
(Mg/ml) 
4-oxo 
0.24 (1.5) 
0.24 (1.5) 
0.53 (1.0) 
0.85 (1.0) 
0.59(1.0) 
0.49 (1.5) 
0.25 (1.5) 
0.46 (1.5) 
0.92 (1.8) 
0.40(1.5) 
Elimination 
half-life (h) 
Enox 
5.3 
7.0 
4.0 
3.0 
3.5 
3.3 
4.5 
5.1 
4.5 
5.9 
4-oxo 
5.3 
7.0 
4.0 
3.0 
3.5 
3.3 
4.5 
5.1 
4.5 
5.9 
Protein-binding 
(4b) 
Enox 
55.4±3.1 
58.4 ±6.3 
52.0 ±3.0 
55.1±5.3 
40.6 ±5.0 
44.6 ±7.8 
24.7 ±2.5 
40.4 ±4.2 
47.9±4.3 
26.8 ±4.2 
4-oxo 
n.d. 
54.2±3.8 
n.d. 
55.2±8.1 
67.7 ±5.1 
58.2 ±6.3 
65.2 ±6.2 
86.4 ±7.0 
71.8±6.1 
73.3±6.9 
urinary excretion 
(% of dose) 
Enox 
45.3 
38.1 
40.0 
30.2 
43.1 
54.6 
39.6 
12.1 
46.1 
22.3 
4-oxo 
13.8 
10.0 
16.3 
18.0 
11.7 
15.1 
6.0 
8.8 
16.5 
8.5 
( ): time to C
max
; n.d.: not measurable; ': fasting; 2: after a standard breakfast 
1000. 
•"Plu 
plasma cone ug/ml 
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4= 
lb 
_ S 1 % 
4 3 % 
Figure 1 Plasma concentration-time curve and renal excretion rate-time profile of 
enoxacin in volunteer С after a 600 mg oral dose, after a standard breakfast ( ) and 
fasting ( ). 
catheter, on Day 1 and Day 3 of treatment. Clotting of blood samples was 
prevented by the addition of 0.5 mg of solid heparin. Each portion of 
spontaneously voided urine was collected separately and its volume measured. 
Each expectorated sputum sample was collected over a 12 h period on Day 1 
and Day 3. 
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Figure 2 Plasma concentration-time curve and renal excretion rate-time profile of 
enoxacin in volunteer D after a 600 mg oral dose, after a standard breakfast ( ), 
fasting ( ) and after administration of ІМаНСОз ( )• 
Phase IN 
Fifteen male patients with a mean age of 58.3 ± 11.1 years (range 39 to 77 years) 
and mean weight 69.8 ±9.7 kg, undergoing thoracotomy for a broncial 
malignancy, received enoxacin before surgery in a single oral dose of 600 mg, 
after fasting. At resection time, a blood sample was taken from an indwelling 
radial artery catheter. After pulmonary resection, a peripheral piece of 
macroscopically normal tissue (1-3 g) was taken and adherent blood was gently 
swapped off with a gauze. 
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Sample preparation 
Plasma was immediately separated from the blood samples. Plasma, sputum, 
lung tissue and urine were frozen at -20oC, pending analysis. To 0.1 ml 
of the plasma, 0.3 ml trichloroacetic acid (3%) was added and mixed thoroughly 
on a Vortex mixer. After 10 minutes the mixture was centrifuged at 2600 g for 
10 minutes and 0.1 ml of the clear supernatant was injected onto the high 
performance liquid chromatography (HPLC) column. Urine specimens were 
diluted 50-fold; the dilution was mixed and treated as described above for 
plasma. Sputum samples were thawed and homogenised ultrasonically for 20 
min. The homogenate was centrifuged at 2600 g for another 15 min; 0.1 ml 
samples were treated as described for plasma. Thawed lung tissue was weighed 
and 5 ml of 0.9% NaCl/g of tissue was added. The tissue was homogenised in 
an Ultra Turrax homogenizer (Labassco, Sweden). The homogenate was 
centrifuged at 2600 g for 10 minutes; 0.1 ml of the aqueous upper layer was 
treated as described for plasma. 
Assay method 
The concentrations of enoxacin and the 4-oxo metabolite were measured in 
plasma, sputum, lung tissue and urine by high performance liquid 
chromatography (HPLC), as previously described (Vree et al., 1985). Standards 
were made in plasma, sputum and lung tissue, obtained from untreated 
patients. 
Results are expressed as mean ± standard deviation. Statistical analysis was 
done by using Student's t-test for paired observations. Results were considered 
significantly different at the p<0.05 level. 
4.3. Results 
Phase I 
Selected pharmacokinetic parameters of enoxacin and 4-oxo-enoxacin are 
shown in Table I. Figures 1 and 2 show the individual plasma concentration-
time curves and renal excretion rate-time profiles of enoxacin in two volunteers 
after a single 600 mg dose ingested under fasting and postprandial conditions. 
When ingested after a standard breakfast, the area under the curve (AUC) 
values of enoxacin increased, in one from 14.68 to 23.02 mg.h/1 and in the other 
from 3.69 to 19.14 mg.h/1. In one volunteer, ingestion of 600 mg enoxacin after 
administration of НаНСОЗ resulted in a clear increase in plasma enoxacin 
concentrations. 
Figures 3a and 3b show the plasma concentration-time curves of enoxacin and 
the renal excretion rate of enoxacin in one volunteer, when administered alone 
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Figure 3 Plasma concentration-time curves and renal excretion rate-time profiles of enoxacin and 4-oxo-enoxacin in volunteer С 
after a 600 mg oral dose, taken alone or with probenecid. 
and in combination with 2.5 g probenecid. Renal clearance of enoxacin 
decreased from 374 ±56 ml/min to 171 ±72 ml/min after simultaneous 
administration of probenecid; renal clearance of the 4-oxo metabolite decreased 
from 532±127 ml/min to 202±30 ml/min. 
Phase II 
After a single 400 mg dose of enoxacin, the mean peak plasma concentration 
of enoxacin was 4.0 μg/mi and that of the 4-oxo metabolite was 0.7 /ig/ml. 
After a 600 mg dose, these concentrations were 5.6 ;tg/ml and 0.9 /tg/ml, 
respectively (table II). The half-life of enoxacin and the apparent elimination 
half-life of the 4-oxo metabolite in plasma were 5.0 ± 1.8 h after the 400 mg dose 
and 4.9 ±0.9 h after the 600 mg dose; this difference is not statistically 
significant. After 400 mg of enoxacin the mean peak concentration in the 
sputum was 3.0±1.4 /¿g/ml; after 600 mg, it was 5.6±11.4 /tg/ml. The 
maximum concentrations of enoxacin in sputum and plasma were not 
significantly different. 
The mean peak plasma concentration of enoxacin was reached 1.7 h after 
administration of enoxacin and that of the 4-oxo metabolite was reached 
approximately 2.0 h after either dose, an insignificant difference. The maximum 
concentration in the sputum was reached approximately 2.7 h after ingestion of 
either dose. The delay in reaching the maximum concentrations in sputum 
compared with plasma was significant (p<0.01). 
Table II Pharmacokinetic parameters of enoxacin and 4-oxo enoxacin after a single 
oral dose of 400 mg or 600 mg. 
SERUM 
Cmax (Mg/ml) 
Tma, (h) 
t* d (h) 
Protein-binding (%) 
SPUTUM 
Cmax Oig/ml) 
Tm„ (h) 
t./, d. (h) 
400 mg enoxacin (n = 8) 
enoxacin 
4.0 (0.8)* 
1.7 (0.7) 
5.0 (1.8) 
48.0(11.1) 
3.0 (1.4) 
2.6(1.2) 
4.8 (1.2) 
4-oxo-enoxacin 
0.7 (0.3) 
2.1 (0.8) 
5.0 (2.7) 
57.9 (6.9) 
600 mg enoxacin (n= 11) 
enoxacin 
5.6 (0.9) 
1.7 (0.2) 
4.9 (0.9) 
54.1 (12.3) 
5.6 (1.4) 
2.8 (0.7) 
5.0(1.1) 
4-oxo-enoxacin 
0.9 (0.3) 
1.9 (0.7) 
5.2(1.1) 
68.7 (14.4) 
* ( ) = standard deviation 
Table III shows that the steady-state peak plasma concentrations of enoxacin 
and its metabolite were 4.8 /¿g/ml and 0.7 /tg/ml, respectively, during treatment 
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with 400 mg enoxacin b.i.d., and 7.4 /tg/ml and 0.9 jig/ml with 600 mg b.i.d. 
The peak sputum concentration at steady-state was 2.7 μg/m\ for 400 mg b.i.d. 
and 6.9 /tg/ml for 600 mg b.i.d. The 4-oxo metabolite measurement in sputum 
was not possible because of interfering peaks. 
The protein binding of enoxacin was 51.2±10.6% and that of the 4-oxo 
metabolite was 65.4 ± 13.3% at Day 1; at Day 3, the protein binding of enoxacin 
and its 4-oxo metabolite were 52.6±10.5% and 62.6±10.4%, respectively. 
The renal clearance of enoxacin was 189 ±87 ml/min and that of the 4-oxo 
metabolite was 322 ±135 ml/min (Table IV). The recovery of the parent 
compound plus 4-oxo enoxacin from the urine after 24 h accounted for 60 to 
65% of the ingested dose. 
Table III Pharmacokinetic parameters of enoxacin and 4-oxo-enoxacin at Day 3 of 
treatment with 400 mg b.i.d. or 600 mg b.i.d. 
SERUM 
C
m a x
 Oig/ml) 
C
mi„ Oig/ml) 
Т
т а ж
 (h) 
Ι ν, a (h) 
SPUTUM 
C
m a x
 Oíg/ml) 
Cmin Oíg/ml) 
t/,el (h) 
400 mg enoxacin (η = 8) 
enoxacin 
4.8 (1.0)* 
2.1 (1.0) 
2.0 (0.5) 
4.5 (1.6) 
2.7 (1.2) 
0.7 (0.2) 
4.5 (1.9) 
4-oxo-enoxacin 
0.7 (0.2) 
0.3 (0.1) 
1.9(0.1) 
n.d. 
n.d. 
n.d. 
600 mg 
enoxacin 
7.4 (1.4) 
3.0(1.2) 
1.8 (0.3) 
6.0 (2.0) 
6.9 (2.3) 
2.9 (1.9) 
6.0 (2.2) 
enoxacin (n= 11) 
4-oxo-enoxacin 
0.9 (0.2) 
0.4 (0.2) 
2.0 (0.5) 
n.d. 
n.d. 
n.d. 
* ( ) = standard deviation 
n.d. = not measurable 
Table IV Renal clearance (CL
r
) and recovery of enoxacin and the 4-oxo metabolite 
in urine following oral administration (n= 16). 
enoxacin 4-oxo-enoxacin 
CL
r
 (ml/min) 189 (87)* 322(135) 
Recovery in urine 
(·% of ingested dose) 
after 12 h 37.2 ( 5.8) 9.8 (3.7) 
after 24 h 46.5 (11.5) 13.3 (4.9) 
whole treatment period' 55.7 ( 1.4) 10.1(0.4) 
1
 measured in 3 of these patients 
* ( ) = standard deviation 
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Figure 4 Individual plasma and lung tissue concentrations of enoxacin in IS patients 
undergoing thoracotomy 2.8 h after a single 600 mg dose. 
Phase III 
Figure 4 shows the individual plasma and lung tissue concentrations of enoxacin 
in 15 patients after administration of 600 mg enoxacin. The mean enoxacin 
concentration in the lung tissue was 7.0±3.6 /tg/g, after a mean time of 
2.8 ±0.6 h (range: 1.7 to 3.5 h); the mean plasma concentration was 1.8 ± 1.1 
/ig/ml, when measured at the same time after ingestion. 
4.4. Discussion 
It is important to study the diffusion of an antimicrobial agent into bronchial 
secretions during the treatment of lower respiratory tract infections as the 
49 
drug's ability to reach sufficient high concentrations at the infection site may 
be one of the factors that determines its efficacy (Bergogne-Bérézin, 1981). In 
this study, concentrations obtained in plasma, sputum, and lung tissue after the 
oral administration of 400 mg or 600 mg enoxacin were well above the MIC's 
for the most frequently isolated bacteria causing respiratory tract infections, 
including a proportion of the Pseudomonas aeruginosa strains. Against 
Streptococcus pneumoniae, however, the MIC of enoxacin is 8-16 /tg/ml; this 
bacteria must therefore be considered resistant in bronchitis as confirmed in 
several clinical studies (Davies et al., 1984; Wijnandseío/., 1986). Further study 
is required to determine whether enoxacin can be used succesfully in pneumonia 
caused by Streptococcus pneumoniae. 
Enoxacin was rapidly absorbed and absorption appeared to be increased 
when enoxacin was administered after a meal. In another study no influence of 
food intake on bioavailability of enoxacin was found (Somogyi et al., 1985). 
Because of the increased bioavailability observed in one volunteer after 
administration of NaHC03, it is possible that the absorption of enoxacin may 
be pH-dependent. At the time of the measurements, enoxacin was not available 
for i.v. administration. For that reason we have no data concerning the absolute 
bioavailability of enoxacin. 
Approximately 65% of the ingested dose was recovered in the urine. The 
extent of the biliary secretion of enoxacin is not yet known. Flowerdew et al. 
(1985) found that bile concentrations of enoxacin were 7 to 10 times those in 
plasma. 
Penetration of enoxacin into the sputum from blood was about 100%. This 
is in accordance with the findings of Dobbs (1985). The rate of penetration of 
enoxacin into the sputum may be influenced by the degree of inflammation of 
infected bronchi. The lower concentration in the sputum found at Day 3 for 400 
mg enoxacin b.i.d. may possibly be related to a decreased level of purulence in 
the sputum. Similar results were seen in the penetration of /Mactams into the 
respiratory tract (Bergogne-Bérézin et al., 1978). 
Wise et al. (1984) studied the penetration of enoxacin into chemically induced 
blister fluid, using this as a model for tissue penetration. After a single 600 mg 
dose of enoxacin, the peak blister fluid concentration was 2.9 /¿g/ml; the peak 
plasma concentration was 3.7 /¿g/ml. The lung tissue concentrations of enoxacin 
in the present study were clearly higher than the maximum plasma 
concentrations measured in the volunteers who received a single 600 mg oral 
dose 2 h before breakfast. The lung tissue specimens showed no signs of 
infection. Although an active mechanism may play a role in the penetration of 
enoxacin into lung tissue from the blood, resulting in the high concentrations 
we measured, the possibility remains that this result may have been produced 
by cell lysis during preparation of lung tissue. 
The 4-oxo metabolite of enoxacin has a bacteriological activity approximately 
20% that of enoxacin (Yamaguchi et al., 1983). Its half-life is similar to that 
of the parent compound. The plasma concentration of the metabolite depends 
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on the rate of hydroxylation and oxidation of enoxacin. Approximately 
lOVo-lS^o of an enoxacin dose is excreted in the urine as the 4-oxo metabolite. 
Renal clearance of enoxacin and its 4-oxo metabolite indicate that both 
compounds are excreted by glomerular filtration and active tubular secretion. 
This was demonstrated in a volunteer by probenecid, which is known to block 
the mechanism of active secretion. Since enoxacin is eliminated mainly by the 
kidneys, the elimination half-life can be expected to increase in patients with 
impaired renal function, resulting in higher plasma concentrations of the parent 
compound, the 4-oxo metabolite, or both. 
In conclusion, this study shows that enoxacin is absorbed rapidly, with good 
penetration into sputum and lung tissue. Its elimination half-life permits twice 
daily dosing to achieve concentrations above MIC values for an adequate period 
for most isolates, including most Pseudomonas aeruginosa strains, but 
excluding Streptococcus pneumoniae. Clinical efficacy studies are needed to 
further determine the value of this new antibacterial agent in respiratory tract 
infections. 
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Summary 
After a single oral 600 mg dose ofloxacin concentrations obtained in lung tissue 
and plasma were measured in 11 patients, undergoing thoracotomy for a 
bronchial malignancy. To correct for blood contamination in the tissue 
samples, the tissue hemoglobin content was measured using a specific method 
for hemoglobin determination based on the binding of hemoglobin by 
haptoglobin. 
The calculated blood content was 0.12 ±0.05 ml/g lung tissue. After 
correction for blood admixture, the mean lung tissue concentration 2.0 hours 
after administration of ofloxacin was 17.7 ±9.2 pg/g. At the same time the 
mean plasma concentration was 8.7 ±4.2 μg/ml. 
The ofloxacin concentrations in plasma and lung tissue reached after a single 
600 mg dose proved to exceed MIC values for most pathogens frequently 
involved in respiratory tract infections. 
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5.1. Introduction 
Ofloxacin is one of the new quinolone derivatives, broad-spectrum antibacterial 
agents, under clinical investigation for systemic infections, among which 
respiratory tract infections. The drug shows very low protein binding (Nakano 
et al., 1985; Wijnands et al., 1987a) and has a large volume of distribution 
(Nomura et al., 1986). After oral administration ofloxacin plasma and sputum 
concentrations are attained, which are well above MIC values for most bacteria 
involved in respiratory tract infections, including Pseudomonas aeruginosa 
(Davies et al., 1986; Wise, 1985). 
The objective of this study was to investigate the ofloxacin concentration 
attained in lung tissue after a single oral 600 mg dose, with a correction for the 
blood content in the tissue samples. 
5.2. Methods 
Patients 
Eleven patients, undergoing surgery for a bronchial malignancy, gave their 
informed consent to participate in this study. The group consisted of 6 males 
and 5 females ranging in age from 51 to 77 years (mean age: 62.7 + 6.8 year), 
ranging in weight from 59.0 to 88.8 kg (mean weight: 69.9 ±9.5 kg), and in 
height from 1.53 to 1.85 m (mean height: 1.68 ±0.10 m). Six of the patients had 
a chronic obstructive lung disease. A single ofloxacin dose of 600 mg was 
ingested as tablets, each containing 200 mg with a little water about 30 minutes 
before surgery. The time at which the tablets were ingested, and the time at 
which the arterial blood supply to the lung tissue was interrupted by the surgeon 
( = resection time) were recorded. 
Sample preparation 
Blood samples were obtained from an indwelling radial artery catheter at the 
time of resection. Dry heparin was added to the samples to prevent clotting. 
Part of the blood was immediately separated. After resection, a peripheral 
specimen macroscopically normal lung tissue was obtained; blood adhering to 
the tissue samples was gently swapped off with a gauze. Plasma, whole blood 
samples and lung tissue samples were stored immediately at -20° С pending 
analysis. After thawing out the tissue specimens, part of the tissue was isolated 
and weighted; 5 ml of 0.9% NaCl was added per gram tissue. The tissue was 
homogenised in an Ultra Turrax. The homogenised lung tissue was centrifuged 
at 2600 g for 10 minutes. To 0.1 ml of the aqueous upper layer 0.3 ml of 5% 
trichloroacetic acid was added, and thoroughly mixed. The mixture was allowed 
to stand for 10 minutes and centrifuged at 11000 g for 5 minutes. The whole 
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blood samples were ultrasoned for 10 minutes. Plasma and whole blood samples 
were treated according to the procedure used for the aqueous lung tissue upper 
layer; 0.1 ml of the clear supernatant was used. 
Assay methods 
The concentration of ofloxacin in plasma, ultrasoned whole blood, and 
homogenised lung tissue was measured by means of high performance liquid 
chromatography (HPLC). A Spectra Physics 3500 high performance liquid 
Chromatograph equipped with a spectrophotometer detector and connected to 
a 10 mV recorder was used. The column (25 cm x 4.6 mm ID) was packed with 
Spherisorb 5-ODS (Chrompack, Middelburg, The Netherlands). An injection 
loop of 100 /il was used. Detection of ofloxacin was effected at 294 nm. The 
mobile phase was 1 gram phosphoric acid and 0.25 gram 
tetramethylammoniumchloride dissolved in 580 ml water; 210 ml 
dimethylformamide and 210 ml acetonitrile were added. The solvent flow-rate 
was 1.6 ml/min. 
To assess the hemoglobin content in the lung tissue, a procedure was used 
based on the fact that the peroxidase activity of free hemoglobin is rapidly 
inactivated by the peroxidase chromogen 2,2'Azino-di(3-ethyl-
benzthiazolinsulfonate-6), whereas the peroxidase activity of the hemoglobin 
when bound to haptoglobin is unaffected. All hemoproteins possess peroxidase 
activity, but only hemoglobin is specifically protected by the presence of 
haptoglobin. Hemoglobin was incubated under denaturing conditions in serum 
(containing haptoglobin) and a haptoglobin-free, protein-rich fluid (egg white). 
It has been shown that the difference in peroxidase activity between samples 
incubated with and without haptoglobin is proportional to the content of 
hemoglobin (Marklund, 1979). Solutions were incubated at 30oC. The increase 
in absorbance was recorded at 418 nm. A calibration curve was obtained by 
diluting a Hb-control (Merz-Dade, Hb-control III), containing 160 g Hb/1, with 
0.9% NaCl. 
Results are presented as means ± standard deviation. Student's t-test was used 
for independent samples. Differences were considered significant at the p<0.05 
level. 
5.3. Results 
The hemoglobin content in the 11 lung tissue samples ranged from 0.38 x I O 3 
to 1.71 x l O - 3 μmol/g tissue (mean: 0.99 ± 0.40 x I O 3 jtmol/g tissue). Mean 
blood hemoglobin was 8.1 ±0.7 μτηοΙ/Ι, ranging from 6.7 to 9.6 μΐηοΙΑ. The 
calculated volume of blood admixture for each tissue sample ranging from 0.05 
to 0.22 ml/g tissue (mean: 0.12 ±0.05 ml/g tissue). After a single oral dose of 
600 mg ofloxacin, concentrations were measured in plasma, homogenised whole 
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Figure 1 Individual plasma and lung tissue concentrations of ofloxacin in 11 patients 
undergoing thoracotomy, measured 2.0 h after a single 600 mg dose. 
blood, and lung tissue at 120 ±50 minutes after ingestion (range: 54 to 210 
minutes). Mean plasma concentration was 8.7 ±4.2 /ig/ml. The mean whole 
blood ofloxacin concentration was 8.4 ±4.2 ¿tg/ml. The plasma and whole 
blood concentrations correlated closely (r = 0.926). The mean lung tissue 
concentration was significantly higher than the mean plasma concentration: 
16.3 ±8.1 /¿g/g (range 6.5 to 30.8 ¿ig/g) (<0.02). The ofloxacin tissue 
concentrations, after correction for blood contamination, ranged from 7.0 to 
35.5 /ig/g (mean: 17.7 ± 9.2 /ig/g). A correlation was found between lung tissue 
and plasma concentrations (Figure 1). There was no correlation between either 
plasma or tissue concentrations and the time after ingestion. 
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5.4. Discussion 
After ingestion of a single 600 mg dose, the ofloxacin lung tissue concentrations 
appeared to be significantly higher than the plasma concentrations which were 
obtained at the same time. Due to the design of the study, all tissue and plasma 
concentrations only represent individual points of the concentration-time 
curves. Nevertheless, since maximum concentrations after oral dosing can be 
expected about 1-1 Vi hours after ingestion and because the drug has a long 
elimination half-life, the differences in the lung tissue and plasma 
concentrations which were observed cannot be explained as resulting from and 
advanced elimination in the central compartiment. These findings are in 
accordance with those, reported by Couraud et al., (1986), who found an 
ofloxacin lung tissue to plasma ratio of 3.5 in steady-state, during 
administration of 200 mg ofloxacin twice daily. The same phenomenon of 
accumulation in lung tissue has been demonstrated for ciprofloxacin 
(Schlenkhoff et al., 1985) and enoxacin (Wijnands et al., 1987b). Ofloxacin 
concentrations in blood after lysis of all cells by ultrasonification, did not differ 
from plasma concentrations. This finding excludes the existence of an 
important difference between the intracellular concentration and the plasma 
concentration. Correcting the measured ofloxacin tissue concentrations for the 
blood content resulted in even higher lung tissue levels. 
The purpose of measurements of antibiotic concentrations in different body 
fluids and tissues is to determine whether the concentration attained at the site 
of the infection is sufficiently high, when compared to the in vitro susceptibility 
of a bacteria, as assessed by MIC values, thus allowing a prediction as to the 
therapeutic effect. In general, the concentrations are measured using an 
microbiological assay or HPLC procedure in tissue homogenates. The value of 
the drug concentrations obtained by these techniques in predicting therapeutic 
efficacy is limited, as the results only permit a rough judgment of total tissue 
uptake; they reflect contributions of the different compartments of the tissue 
such as extracellular and intracellular fluid, blood, and others, whereas the 
distribution within the tissue cannot be expected to be uniform. Such a 
measurement does not provide information about the unbound, i.e. 
bacteriologically active, fraction in the interstitial fluid. While correction for the 
blood concent does not solve this methodological problem, one can at least rule 
out one major disturbing compartment. 
The lung has to be considered not merely as an organ in which only passive 
diffusion processes occur (Wijnands, 1987c). On the contrary; this organ is 
unique in the sense that the total cardiac output passes through its capillary 
system. The different cells of the alveolar-capillary unit have a high enzymatic 
potential. These properties make the lung suitable as a controlling organ for a 
spectrum of hormonally active compounds. Few data are available concerning 
the involvement in the metabolism and clearance of drugs used in daily practice. 
For basic amines, it has been demonstrated that both carrier mediated and 
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passive uptake mechanisms play a role; the acumulation of these drugs in the 
lung has to be considered to be a result of uptake processes and clearance from 
the different tissue compartments, each with intrinsic elimination half-lives 
(Bakhle & Vane, 1974; Philpot et ai, 1977). 
Because of possible active uptake processes, which may be anticipated, the 
question arises, whether the chemically induced blister fluid model (Wise et al., 
1980), which may be of value in the study of exsudate concentrations in other 
tissues, is useful in predicting the behaviour of drugs in lung tissue. Indeed Wise 
et al. (1986) did not find a discrepancy between blister fluid and plasma concen­
trations. Whether the high concentrations of the new quinolones in lung tissue 
are of importance in pneumonia caused by only moderately susceptible bacteria, 
such as Streptococcus pneumoniae, needs further study. Persistence and even 
overgrowth of Streptococcus pneumoniae during treatment of acute bronchitis 
with a quinolone has been documented (Davies et al., 1986; Wijnands et al., 
1986). 
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Summary 
Steady-state pharmacokinetic parameters of Pefloxacin, ciprofloxacin, 
ofloxacin, and enoxacin were measured in 8 patients on maintenance treatment 
with theophylline. 
The quinolones were administered orally for 5.5 days, in an at random 
sequence: Pefloxacin 400 mg b.i.d., ciprofloxacin 500 mg b.i.d., ofloxacin 400 
mg b.i.d., and enoxacin 400 mg b.i.d. 
Mean maximum plasma concentrations of Pefloxacin (7.5 ± 1.9 μg/ml) and 
ofloxacin (5.9 ±0.9 ^g/ml) were significantly higher than those of enoxacin and 
ciprofloxacin. Pefloxacin was extensively metabolized. Elimination half-lives 
ranged from 3.9 hours for ciprofloxacin to 12.2 hours for Pefloxacin. The 
pharmacokinetic parameters and urinary recoveries of the 4 quinolones showed 
no notable differences when compared with the available data obtained from 
healthy volunteers. Thus it is improbable that theophylline greatly influences 
the metabolic clearance of these quinolones. 
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6.1. Introduction 
Recently, some new broad-spectrum antimicrobial agents of the quinolone class 
have been developed. These drugs show considerable differences in in vitro 
activity against respiratory tract pathogens (Auckenthaler et al. 1986; 
Hoogkamp-Korstanje, 1984). 
Extensive pharmacokinetic research has been carried out with these new drugs 
in both volunteers and patients. However, most of these studies cannot be used 
to compare the pharmacokinetic behaviour of the different quinolones tested in 
respiratory tract infections. Some studies used microbiological assay methods, 
measuring the total concentration of antibacterially active compounds, whereas 
others used high-performance liquid chromatography methods (HPLC), which 
measure only the parent drugs. To gain insight into the availability and 
clearance mechanisms, it is essential not only to measure the parent compound, 
but also the metabolites (Vree & Hekster, 1985a). In most of the 
pharmacokinetic studies performed in patients, co-medication at the time of 
quinolone treatment was insufficiently described, although interactions with 
theophylline (Wijnands et al., 1985; 1986a; 1986b) and with a coumarin (Toon 
et al., 1986) have been reported. 
In this study, comparative steady-state pharmacokinetic parameters of 
Pefloxacin, ciprofloxacin, enoxacin, ofloxacin and their major metabolites were 
measured in patients on maintenance treatment with a slow-release preparation 
of theophylline after oral administration of a quinolone. A review of the 
available literature was carried out to see whether the results of this study clearly 
differed from data obtained in healthy volunteers. 
6.2. Materials and Methods 
Patients 
Eight patients, 7 males and 1 female, gave their informed consent to participate 
in this study, which had the approval of the hospital's ethical committee. The 
mean age was 58.5 ±6.2 years (range 51 to 69 years), mean height was 
1.76 ± 0.05m (range 1.67 to 1.83 m) and mean weight was 76.4 ±8.7 kg (range 
65.0 to 88.4 kg). 
All 8 patients were on maintenance theophylline treatment with a slow-release 
preparation (Theolin retard®, Astra Pharmaceutics) because of chronic 
obstructive lung disease, which was stable for at least 4 weeks prior to the 
study period. The theophylline dose was 300 mg twice daily in five cases, 450 
mg twice daily in one case and 600 mg twice daily in two cases. The only 
co-medications were sympathomimetics and steriods taken by inhalation. 
Before the start of the study, a medical history, physical examination, complete 
blood count, blood chemistry, including liver and kidney function tests, and 
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a urinalysis were performed. For each subject, the results were within normal 
ranges. 
Study Design 
All 8 patients participated in 4 study periods, in which they ingested twice daily 
Pefloxacin 400 mg, ciprofloxacin 500 mg, enoxacin 400 mg, and ofloxacin 400 
mg. The quinolones were administered as a tablet at 9 a.m. en 9 p.m. for 5.5 
days. Consecutive study periods were separated by at least 9 days. 
Blood samples were taken at 8.30 a.m. on Days 2, 3, 4 and 5 of each period 
to determine minimum plasma quinolone concentrations. On Day 5, serial 
blood samples were obtained from an indwelling catheter in a forearm vein 
(kept open by a heparin solution) to establish quinolone plasma concentration-
time curves for each subject, up to 12 hours after ingestion of the quinolone. 
The plasma was separated immediately. All samples of spontaneously voided 
urine were collected for 12 hours. Plasma and urine samples were stored at 
- 2 0 o C pending analysis. 
Sampie Analyses 
Plasma and urine concentrations of the parent quinolones and the major 
metabolites (4-oxo-enoxacin, desmethyl-ofloxacin and ofloxacin W-oxide; 
4-oxo-pefloxacin, Pefloxacin N-oxide, the piperazinyl ring-opened metabolite, 
norfloxacin and 4-oxo-norfloxacin; 4-oxo-ciprofloxacin and the piperazine 
ring-opened metabolite (Bay o3964) were measured by a modified HPLC 
method (Vree et al., 1985b). A Spectra Physics 3500B liquid Chromatograph 
equipped with a stainless steel, reversed phase column (25 cm χ 4.6 mm ID), 
packed with Spherisorb 5-ODS (Chrompack, Middelburg, The Netherlands) 
and a variable wave length spectrophotometer detector (Model SP770) were 
used. The mobile phase consisted of a mixture of 0.75 g phosphoric acid, 0.25 
g tetramethyl-ammonium chloride, 155 ml N,N-dimethyl formamide and 155 ml 
acetonitrile, made up to 1.0 L with water. All chemicals were of analytical grade 
(Merck, Darmstadt). Solvent flow rate was 1.6 ml/minute at a pressure of 3800 
psi. Detection was measured at 265 nm for enoxacin, 278 nm for Pefloxacin and 
ciprofloxacin and 294 nm for ofloxacin. 
Protein binding of the different quinolones and their metabolites was mea­
sured using EMIT® free level filters (SYVA, Palo Alto USA; Merck, Amster­
dam) in 5 different plasma samples over the concentration range 1 to 10 mg/1. 
Calculations 
The following parameters were calculated for each study period: peak 
concentration (C
m M); trough concentration (Cm,n); area under the 
concentration-time curve after oral dosage (AUCQ.-) , obtained using the 
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linear trapezoidal rule; the apparent renal clearance values (CLr) of the 
quinolones and their metabolites, calculated from the average renal excretion 
rate in each urine sample divided by the plasma concentration at the midpoint 
of the measured time interval; and the elimination half-life (t,/,), deduced from 
linear least squares regression analysis of semilogarythmic experimental data 
points in the terminal part of the concentration-time curve. The total body 
clearance could not be assessed because of the incomplete absorption of these 
drugs. 
Results are expressed as mean values ± standard deviation. Differences were 
assessed using Student's t-test for paired observations and considered 
significant at the p<0.05 level. 
6.3. Results 
Figure 1 shows the trough plasma quinolone concentration-time curves. There 
was no accumulation in plasma concentrations of ciprofloxacin, enoxacin and 
ofloxacin. However, plasma Pefloxacin concentrations on Day 5 were 
significantly higher than on Day 1 (p<0.01). Some mean steady-state 
pharmacokinetic parameters of the investigated quinolones and their major 
metabolites are listed in table I. Figures 2 and 3 show the Pefloxacin and 
ciprofloxacin plasma concentration-time curves and the renal excretion rate 
time profiles of Pefloxacin and ciprofloxacin with the metabolites on Day 5 as 
examplified by 1 patient. 
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Figure 3 Plasma concentration-time curves and renal 
excretion rate-time profiles of ciprofloxacin and its metabolites 
on day S in 1 patient. 
Table I Some steady-state pharmacokinetic parameters of ofloxacin, Pefloxacin, ciprofloxacin, enoxacin and their major 
metabolites after oral administration during co-administration of theophylline (n = 8) 
Ofloxacin 400 mg b.i.d. 
Ofloxacin 
Ofloxacin-yV-oxide 
Desmethyl-ofloxacin 
Pefloxacin 400 mg b.i.d. 
Pefloxacin 
Norfloxacin 
4-охо-реПохасіп 
4-охо-погПохасіп 
Pefloxacin-ZV-oxide 
Ciprofloxacin 500 mg b.i 
Ciprofloxacin 
4-охо-сіргоПохасіп 
Bay 03964 
Enoxacin 400 mg b.i.d. 
Enoxacin 
4-oxo-enoxacin 
C
m
„ Wml) 
5.9±0.9 
nd 
0.13 ±0.05 
7.5±1.9 
0.57 ±0.07 
0.07 ±0.04 
nd 
nd 
i.d. 
2.0±0.6 
0.20 ±0.07 
0.04 ±0.01 
3.2±1.1 
0.6±0.2 
C
m
,„ fog/ml) 
1.9±0.8 
nd 
0.06 ±0.02 
3.8±1.8 
0.45 ±0.12 
nd 
nd 
nd 
0.4 ±0.2 
0.05 ±0.05 
nd 
1.1±0.5 
0.3±0.1 
T
max
 (h) 
1.7±0.7 
nd 
1.8 ±0.8 
1.4±0.6 
3.2±2.6 
nd 
nd 
nd 
1.6±0.8 
2.0±1.1 
2.1 ±1.0 
1.2±0.1 
1.7±0.7 
t., (h) 
7.0 ±2.0 
12.2±4.2 
3.9±0.8 
6.7 ±2.4 
AUC^ 
(mg-h/1) 
59.0 ±24.2 
139.2±67.5 
11.4±5.1 
34.0±13.0 
Protein-
binding (%) 
1.1±1.9 
nd 
« 0 
13.7±5.6 
16.8±4.3 
28.3 ±4.0 
21.1±3.0 
32.6 ±8.0 
16.6 ±6.4 
50.5 ±14.0 
Abbreviation: nd = not detectable. 
Ofloxacin and its metabolites were only minimally protein-bound, whereas 
Pefloxacin, enoxacin and ciprofloxacin were 13.7, 16.6 and 28.3% protein-
bound, respectively. 
The high renal clearances of ofloxacin, ciprofloxacin and enoxacin indicate 
an important tubular secretion (table II). The renal clearance of Pefloxacin 
appeared to be significantly lower at 36 ± 11 ml/min. The urinary elimination 
within 12 hours accounted for 68% of the dose for ofloxacin, 32% for 
ciprofloxacin, 71% for enoxacin and 60% for Pefloxacin. Pefloxacin was 
extensively metabolised, the parent drug accounting for only 21.2% of the total 
urinary excretion. 
Table II Renal clearance (CLr, ml/min) and urinary recovery (% of ingested dose in 
12h) of ofloxacin, Pefloxacin, ciprofloxacin, enoxacin and some metabolites after oral 
administration (Day 5) during co-administration of theophylline (n = 8) 
Clr (ml/min) Urinary recovery (%) 
62.9 ±9.6 
0.8 ±0.2 
4.6±1.1 
12.7±3.8 
22.1 ±2.4 
6.4±1.3 
1.3±0.5 
17.7±2.7 
Ofloxacin 400 mg b.i.d. 
Ofloxacin 
Ofloxacin-/V-oxide 
Desmethyl-ofloxacin 
Pefloxacin 400 mg b.i.d. 
Pefloxacin 
Norfloxacin 
4-oxo-pefloxacin 
4-oxo-norfloxacin 
Pefloxacin-N-oxide 
Ciprofloxacin 500 mg b.i.d. 
Ciprofloxacin 
4-oxo-ciprofloxacin 
Bay 03964 
Enoxacin 400 mg b.i.d. 
Enoxacin 
4-oxo-enoxacm 
119±29 
nd 
28.4 ±58 
36±11 
257 ± 57 
nd 
nd 
nd 
227 ±49 
413 ±90 
297 ±116 
223 ± 56 
253 ±45 
27.2±8.2 
4.3±0.9 
0.8±0.3 
56.3±13.5 
14.7±3.6 
Abbreviation: nd = not measurable, because of very low plasma concentrations 
6.4. Discussion 
After oral dosing, the quinolones were quickly absorbed, reaching maximum 
concentrations in plasma and urine within 1.2 to 1.7 hours. 
When ciprofloxacin, Pefloxacin or ofloxacin are ingested after breakfast, the 
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lime elapsed before maximum plasma concentrations will be reached is greater 
and the maximum concentrations are lower, than the values obtained during a 
fasting state (Borner et al., 1986; Verho et al., 1985a; Sörgel et ai, 1986). 
However, fasting reduces the absorption of Cinoxacin (Black et al., 1979); the 
same phenomenon was observed for enoxacin in healthy volunteers (Wijnands 
et al., 1987). Bioavailability of Pefloxacin is complete (Frydman et al., 1986; 
Barré et al., 1984), whereas 47 to 55% of the ciprofloxacin dose is absorbed 
(Borner et al., 1986), 87 to 9147o of enoxacin (Dunkey & Seiler, 1985), and 92% 
of ofloxacin (Dagrosa et al., 1984). Bioavailability will fall if antacids are co-
administered, probably resulting from the formation of magnesium or 
aluminium chelates (Höffken et al., 1985). 
The protein-binding of ofloxacin was very low although this agrees with the 
findings of Nakano et al. (1985). 
CK 
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Figure 4 The chemical structure of Pefloxacin, 4-oxo-pefloxacin, norfloxacin, 4-oxo-
norfloxacin, pefloxacin-N-oxide and the piperazine ring-opened metabolite. 
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The piperazine ring is the main site of metabolism of the quinolones. The ring 
is hydroxylated, N-oxidized, demethylated, formylated and acetylated. 
Pefloxacin appeared to be extensively metabolized; this is essential for total 
body elimination because of the low renal clearance of the drug. Figure 4 shows 
the chemical structures of Pefloxacin, norfloxacin ( = desmethyl-pefloxacin), 
4-oxo-norfloxacin, 4-oxo-pefloxacin, pefloxacin-TV-oxide and the piperazinyl 
ring-opened metabolite. Similar metabolites have been identified or can be 
anticipated for the other quinolones studied. Demethylation of Pefloxacin to 
norfloxacin was accompanied by an increase in the renal clearance rate from 36 
to 257 ml/min. The plasma concentrations of 4-oxo-pefloxacin, 4-oxo-
norfloxacin and pefloxacin-N-oxide barely exceeded the lower detection limit of 
the HPLC procedure, although they were recovered from the urine up to 6.4%, 
1.3% and 17.7% respectively of the ingested dose of Pefloxacin. Up to the fifth 
day of administration Pefloxacin showed an increase in plasma concentrations. 
This phenomenon has been explained by a decreasing non-renal clearance due 
to repeated dosages (Frydman et al., 1986). The importance of the non-renal 
clearance of Pefloxacin was demonstrated by Danan et al. (1985) who found a 
significant decrease in the total body clearance with an increased urinary 
excretion of unchanged Pefloxacin in patients with hepatic cirrhosis. No 
influence on the total body clearance of Pefloxacin was measured in patients 
with renal insufficiency (Montay et al., 1984). Wether the metabolites of 
Pefloxacin will accumulate is not known. Renal clearances of ciprofloxacin, 
enoxacin and ofloxacin are significantly higher than the creatinine clearances, 
which indicate that tubular secretion contributes to renal clearance as has been 
demonstrated for enoxacin and ciprofloxacin during co-administration of 
probenecid (Vree et al., 1986; Wingender et al., 1985). The major proportion 
of ofloxacin was excreted unchanged by the kidney after oral administration. 
Renal insufficiency will decrease excretion, resulting in plasma accumulation of 
ofloxacin (Arosio et al., 1985; Tsugaya et al., 1985). The same phenomenon has 
been reported for ciprofloxacin (Dirksen & Vree, 1986; Singlas et al., 1985). 
There is evidence that the incidence of adverse reactions increases with high 
quinolone plasma concentrations; therefore the quinolone dose has to be 
adapted in cases of severe renal insufficiency. 
After oral administration of the quinolones only 30 to 80% of the dose is 
recovered either as the parent drug or as a known metabolite. As a considerable 
part of the mass balance is still missing, even when the compound is 
administered by the i.v. route (Borner et al., 1986), a major as yet unidentified 
metabolic pathway may be predicted, possibly by the removal of the piperazinyl 
ring; another explanation could be binding on tissue components. 
In the present study, steady-state maximum plasma quinolone 
concentrations, well above minimal inhibitory concentration (MIC) for most 
bacteria, frequently involved in respiratory tract infections, such as 
Haemophilus influenzae, Branhamella catarrhalis, Legionella Pneumophilia 
and Mycoplasma pneumoniae, were attained during twice daily oral 
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administration. Trough plasma concentrations were also above MIC values for 
most susceptible organisms. However, borderline activity can be expected 
against Pseudomonas aeruginosa. Administration of enoxacin or Pefloxacin 400 
mg twice daily will result in plasma concentrations below MIC values for most 
Pseudomonas strains, necessitating a higher dose for these infections. 
Streptococcus pneumoniae is less susceptible (Hoogkamp-Korstanje, 1984; 
Wise, 1985). 
Comparing the pharmacokinetic parameters and urinary recoveries of the 
parent drugs obtained in this study with the available data obtained from 
healthy volunteers in other studies (Table III) shows that there are no clear and 
consistent differences. In human volunteers, Montay et ai. (1984) found urinary 
elimination of Pefloxacin and its metabolites comparable with the findings in 
the present study. Thus an important influence of theophylline on the metabolic 
clearance of these quinolones is improbable. In contrast to ciprofloxacin, 
Pefloxacin, and enoxacin, it has been shown that ofloxacin does not influence 
theophylline metabolism. However, ofloxacin displays the same spectrum of 
adverse reactions related to the central nervous system as the other quinolones 
(Janknecht, 1986) and these are similar to those known to occur during 
administration of nalidixic acid (Hoigné et ai., 1980). 
Table III Some pharmacokinetic parameters of ciprofloxacin, Pefloxacin, enoxacin 
and ofloxacin obtained in healthy volunteers after oral dosing 
Ciprofloxacin 
Pefloxacin 
Enoxacin 
Ofloxacin 
Wise et al., 1986 
LeBele/fl/., 1985 
Wingerder et al., 1985 
Singlas et al., 1985 
Gonzalez et al., 1984 
Frydman et al., 1986 
Sörgel et al., 1985 
Wolf et al., 1984 
Wise et al., 1986 
Dunkey & Seiler, 1985 
Arosio et al., 1985 
Lockley et al., 1984 
Vulterini et al., 1985 
Borner et al., 1986 
Fior et al., 1985 
Verhoe/e/. , 1985b 
Wise et al., 1986 
Dose 
(mg) 
500 
500 
500 
500 
500 
400 
400 
400 
600 
800 
300 
400 
400 
400 
600 
600 
600 
^-max 
(mg/1) 
2.3 
3.51 
1.79 
2.0 
2.89 
7.86 
2.8-4.1 
4.53 
3.7 
3.8 
3.68 
5.64 
4.0 
6.75 
6.9 
10.7 
1 max 
(h) 
1.25 
1.33 
0.82 
1.8 
1.0 
1.25 
1.05 
1.9 
1.38 
0.99 
0.7 
1.3 
1.4 
1.18 
1.0 
1.2 
t./, 
(h) 
3.9 
4.7 
4.5 
7.3 
4.7 
12.0-14.8 
6.2-10.5 
4.90 
6.2 
4.9 
4.12 
7.4 
6.0 
5.0 
5.9 
6.4 
7.0 
Urine 
recovery (%) 
30.6 (24h) 
36.6 (24h) 
42.6 (24h) 
30.7 (24h) 
30-50 (72h) 
61.2 (24h) 
61-65 
69.6 (24h) 
80.8 
72.0 (24h) 
73 (24h) 
75 (48h) 
72.9 (24h) 
71 
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Summary 
In this open, non-comparative study 45 lower respiratory tract infections were 
treated with the new 4-quinolone enoxacin. Special attention was paid to 
infections caused by Pseudomonas aeruginosa. Pseudomonas infections were 
treated with 600 mg b.i.d., whereas infections caused by other bacteria were 
treated with 400 mg enoxacin b.i.d. In 43 cases efficacy could be assessed. In 
six out of 23 cases Pseudomonas spp. were eradicated from the sputum. In 12 
of the remaining 17 cases a clear reduction in bacterial numbers and a decrease 
of sputum volume and purulence were obtained. Clinical improvement or cure 
was obtained in 20 out of the 23 cases. 
Most of the causative microorganisms in the other infections were eradicated. 
In two patients Staphylococcus aureus persisted. Overgrowth with streptococci 
occurred in three patients. Adverse reactions were frequent and occurred in 29 
out of 45 treatment periods. These reactions were mainly related to the 
gastrointestinal tract and the central nervous system. In 25 out of 30 patients 
on concomitant treatment with theophylline an elevation of plasma theophylline 
concentrations occurred. Twelve of these patients developed signs and 
symptoms possibly related to theophylline toxicity. After treatment with 
enoxacin the MIC of most persisting Pseudomonas strains was two to four times 
higher than pre-treatment values. 
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7.1. Introduction 
Enoxacin is a newly developed 4-quinolone derivative for oral administration. 
The drug is effective against a wide spectrum of Gram-positive and Gram-
negative bacteria, including Pseudomonas aeruginosa (Nakamura et al., 1980; 
Carlson et al., 1983; Charbrand et al., 1983). Streptococci are less susceptible 
(Siporin & Towse, 1984). The antimicrobial effect is achieved by inhibition of 
the bacterial DNA-gyrase. 
The only drugs available for the treatment of Pseudomonas infections of the 
lower respiratory tract must be administered parenterally. A study with oral 
enoxacin was conducted to assess its efficacy in lower respiratory tract 
infections, with particular attention to those caused by Pseudomonas 
aeruginosa. 
7.2. Patients and methods 
Hospitalized patients, aged above 18 years, with a respiratory tract infection 
were eligible to enter the open, non-comparative study. Infection was 
established by a history of cough, production of purulent sputum and a positive 
sputum culture. No concomitant treatment with other antibiotics was allowed. 
Terminally ill patients, pregnant or lactating women and patients with 
hepatic or renal function disturbances, a history of hypersensitivity to 
quinolones, and primary or acquired immunodeficiency were excluded from the 
study. 
Enoxacin was administered every 12 h as capsules, containing 200 mg of the 
drug. Infections caused by Pseudomonas strains, were treated with 600 mg 
enoxacin twice daily, whereas infections caused by other bacteria were treated 
with 400 mg enoxacin twice daily. 
Sputum for culture was obtained before and daily during treatment with 
enoxacin. Disc-diffusion susceptibility tests were performed on each sample 
according to the principles of Ericsson & Sherris (1971), using discs containing 
10 /ig of enoxacin. Minimum inhibitory concentrations (MICs) and the 
minimum bactericidal concentrations (MBCs) of enoxacin were determined in 
microdilution trays (Gowan & Barry, 1980) for all pre-treatment isolates. Post-
treatment isolates of pseudomonads were also tested, in parallel with the pre-
treatment strains. 
Patients receiving concomitant treatment with the bronchodilator 
theophylline had repeated plasma theophylline trough concentrations measured 
by an enzyme immuno-assay described by Gushaw, Hu et al. (1977) (EMIT® , 
Syva Diagnostics, Palo Alto). 
A complete history and a physical examination were obtained before 
treatment. Thereafter a clinical assessment was made on Days 3, S, 7, 10 and, 
in pseudomonal infections, Days 14 and 18. This included a patients' diary card 
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recording general well being, coughing and dyspnoea, rated on scale of 0 to 3 
and frequency of sputum production/24h scored from 0 to 4 (0 = absent, 
1 = <twice, 2 = 2-5 times, 3 = 5-10 times and 4=10 times or more). Body 
temperature was measured twice daily and the highest value was recorded. 
The volume of sputum expectorated in 24 h was also measured and nature 
of sputum scored from 0 to 4 (0 = absent, l=mucoid, 2 = mucopurulent, 
3 = purulent, 4 = blood-stained). Chest X-rays were obtained before treatment 
and were repeated only if infiltrates were present. 
Blood samples were taken for routine haematology, renal and liver function 
tests, and a urine-analysis was performed on the days of assessment. 
At the end of the treatment period clinical response was classified as: cure: 
disappearance of baseline signs and symptoms relevant to the acute episode; 
improvement: remission of signs and symptoms but no complete disappearance; 
failure: no significant remission of baseline signs and symptoms. 
Bacteriological response was evaluated as eradication of initial pathogen(s); 
persistence of initial pathogen(s); marked reduction in the number of causative 
microorganisms to clinically insignificant levels, and superinfection with a 
pathogen not cultured before the start of treatment. 
The study was approved by the Hospital Ethics Committee. The patients gave 
informed consent before treatment with enoxacin. Statistical analysis was 
performed using the sign-test. Differences were considered significant at the 
/?<0.01 level. Results are given as mean ± standard deviation. 
7.3. Results 
Forty-five courses of treatment were given to 41 patients (26 males and 15 
females) with a mean age of 62.2 ± 12.8 years (range 31 to 87 years) admitted 
to hospital because of an exacerbation of their underlying pulmonary disease. 
In all patients a respiratory tract infection of bacterial origin could be proven 
by a positive sputum culture. Fifteen of the patients had been unsuccessfully 
treated with other antibiotics: six with co-trimoxazole, five with amoxicillin, 
two with clavulanate-potentiated amoxicillin and two patients with doxycycline. 
Forty patients had chronic obstructive pulmonary disease; 22 of them had 
emphysema and 20 had proven bronchiectasis, often extensive. Seventeen 
patients with bronchiectasis were chronic Pseudomonas carriers. One patient 
had a destroyed lung after tuberculosis, and another had developed acute 
purulent bronchitis during treatment for a pneumothorax. 
Before treatment with enoxacin one major pathogen was cultured in 25 cases, 
two different bacteria were found in 20 cases and three bacterial species in one 
patient. The MICs of enoxacin for the isolates are listed in Table I. The clinical 
state of the patients after physical examination was graded by the treating 
physician as severely ill in 19 cases, as moderately ill in 21 cases and as mildly 
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ill in five cases. Twenty-nine of the patients had purulent bronchitis, whereas 
12 patients had bronchopneumonia. 
7.3.1. Clinical results 
The efficiacy of enoxacin was évaluable for 43 courses of treatment. In the two 
non-evaluable patients enoxacin had to be discontinued within three days 
because of adverse reactions. 
Nineteen patients were treated for Pseudomonas infection; four of them 
twice. The mean duration of treatment in this group was 14.3 ±3.5 days. 
Twenty patients with respiratory tract infections caused by other bacteria were 
treated with 400 mg enoxacin twice daily for 9.8 ± 1.9 days. Changes in the 
clinical parameters during administration of enoxacin in the Pseudomonas and 
the non-pseudomonas groups are shown in Figure 1. Comparing the scores at 
the pre-treatment assessment with those on the last day of treatment, all 
parameters improved significantly (p<0.01). As shown in Table II an overall 
clinical improvement or cure was obtained in 20 out of 23 Pseudomonas 
infections. In one patient treated because of a Pseudomonas infection, enoxacin 
had to be discontinued on Day 14 because of fever and recurrence of purulent 
sputum, which grew Streptococcus pneumoniae. All four patients treated twice 
with enoxacin had an inferior result the second time. An overall moderate to 
good clinical response was achieved in 19 of the 20 patients treated for a non-
pseudomonas infection. In one of the two patients treated for a Staphylococcus 
aureus infection, no improvement occurred. 
In the 27 patients who had an elevated ESR (38.4±20.2 mm) before 
treatment, a significant decrease was registered on the last day of therapy 
(p<0.01). No significant decrease of polymorphonuclear leucocytes occurred 
during treatment. 
7.3.2. Bacteriological results 
The in-vitro sensitivity of the isolated strains is listed in Table I. In only six out 
of 23 episodes were Pseudomonas spp. eradicated from the sputum (Table II). 
The MICs for these six strains were ^ 0.5 mg/1. In four patients no relapses 
with Pseudomonas spp. have occurred during follow-up periods of 6, 7, 12 and 
20 months. The remaining two patients had Pseudomonas spp. again isolated 
from the sputum after three and five months respectively. In 12 other patients 
a significant decrease in bacterial numbers was obtained, combined with 
reduced sputum purulence and volume. In five patients, after an initial 
decrease, a slight increase in bacterial numbers was observed during the last 
days of treatment. Because of this phenomenon the MICs were measured for 
14 Pseudomonas strains persisting on the last day of treatment in parallel with 
the pre-treatment strains (Table III). Two- to four-fold increase in MIC 
compared to pre-treatment values was usually observed. Some of these strains 
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Table I Minimal inhibitory concentrations of enoxacin for 67 bacteria isolated from 45 episodes of infection 
Number of 
strains 
tested 
Number of strains with the following MIC (mg/1) 
0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 > 1 6 N.D. 
P. aeruginosa 25 
Pseudomonas spp. 3 
P. vesicularis 1 
P. stützen 1 
Haemophilus influenzae 18 
Branhamella catarrhalis 6 
Neisseria subflava 1 
N. meningitidis 2 
N. mucosae 1 
Str. pneumoniae 4 
K. ozaenae 1 
K. pneumoniae 1 
A leal ¡genes odorans 1 
Staph, aureus 2 
I 2 
— 
4 
2 
6 
2 
2 
2 
8 
1 
3 
1 
2t 
1 
N.D., Not measured, t One patient previously treated with enoxacin, one patient with ciprofloxacin. 
4 -
3 5 7 IO 14 18 
Day of treatment 
Figure 1 Changes in clinical parameters during treatment with enoxacin in 
Pseudomonas (л = 23, ) and non-pseudomonas (я = 20, ) infections of the 
lower respiratory tract, (a) General well being; (b) cough; (c) dyspnoea; (d) frequency 
of sputum production; (e) sputum volume in ml/24h; (0 nature of sputum. 
(For grading see text). 
were also less susceptible to ureidopenicillins (five strains), aminoglycosides 
(three strains) and ceftazidime (three strains). No further decrease in 
susceptibility to enoxacin occurred after the second period of treatment in four 
patients. These increased MICs of enoxacin persisted in eight out of nine tested 
patients for more than 15.9 weeks after treatment (range: 2-34 weeks). 
In 18 out of 20 infections caused by other bacteria the microorganism was 
eradicated from the sputum. Both patients treated because of Staph, aureus 
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infections were bacteriological failures. Despite the high MIC values for Str. 
pneumoniae, this bacterium was eradicated from the sputum in three patients. 
Superinfections with Sir. pneumoniae occurred in two patients and with Str. 
agalactiae in one. 
Table II Clinical and microbiological evaluation of 43 treatments with enoxacin (600 
or 400 mg twice daily) for lower respiratory tract infections in 39 patients 
Clinical evaluation Microbiological evaluation 
Cure Improvement Failure Eradication Persistence Decreased Over­
growth growth 
Pseudomonas 
infections 9 11 
(л = 23) 
Other 
infections 17 2 
(и = 20) 
All 
infections 26 13 
(и = 43) 
* Staph, aureus; "f Str. agalactiae; f Str. pneumoniae. 
Table III MIC/MBC values of enoxacin for Pseudomonas aeruginosa strains isolated 
before and after treatment from 14 patients (17 episodes) 
MIC/MBC (mg/1) of enoxacin 
Patient no. 
2 
3 
4 
4a 
9 
14 
14a 
15 
15a 
20 
22 
28 
30 
32 
33 
34 
35 
before treatment 
0.5/1 
0.5/1 
0.5/0.5 
0.5/0.5 
0.015/0.015 
0.06/0.06 
2/4 
0.5/0.5 
4/8 
0.125/0.125 
0.5/0.5 
0.25/0.25 
0.125/0.25 
1/1 
2/2 
1/1 
4/4 
after treatment 
2/4 
eradicated 
4/4 
8/8 
eradicated 
4/4 
4/8 
2/4 
4/8 
1/2 
8/8 
4/8 
eradicated 
8/8 
8/8 
4/4 
16/16 
3 6 17 12 If 
1 18 2* 1 2tf 
4 24 19 13 3 
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7.4. Adverse reactions 
The only significant abnormality in haematological parameters, renal and liver 
function tests, was an eosinophilia in one patient. 
The adverse effects which occurred in 29 of the 45 treatment courses, are 
shown in Table IV. In two patients enoxacin treatment had to be discontinued 
within 3 days: in one because of severe agitation, and in the other because of 
visual hallucinations and a short period of apnoea. 
In 25 of the 30 patients who were receiving concomitant treatment with 
theophylline, a significant and clinically important rise in plasma theophylline 
concentration occurred. Twelve of these patients developed nausea, vomiting or 
tachycardia; in nine cases these complaints disappeared rapidly and completely 
after decreasing the dose of theophylline. Six patients complained of a bitter 
taste after ingestion of the enoxacin capsules. One patient developed 
photosensitivity; another patient complained of a burning sensation of the skin 
but had no objective skin abnormalities. 
Table IV Adverse effects after 45 courses of enoxacin treatment 
Number of patients 
Gastro-in tesi ¡nal 
Nausea, vomiting 12* 
Abdominal pain 1 
Central nervous system 
Agitation 3 | 
Tremor, myoclonus 1 
Visual hallucination, apnoea 1 
Others 
Increased theophylline concentration 25 
Bitter taste 6 
Photosensitivity 1 
Burning sensation of skin 1 
* Disappeared in nine patients after lowering theophylline dose, t In two cases 
disappeared after lowering theophylline dose. 
7.5 Discussion 
In the present study enoxacin proved to be effective bacteriologically in 37/43 
treated cases of lower respiratory tract infections. Although it has to be kept 
in mind that several of the clinical parameters are influenced by other 
medications such as bronchodilators and corticosteroids, the overall clinical 
effect is in accordance with the bacteriological results. In three patients 
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overgrowth with streptococci occurred and in two patients Staph, aureus could 
not be eradicated from the sputum. 
Pseudomonas infections of the lower respiratory tract are difficult to treat. 
Frequently there is a Pseudomonas carrier state in patients with anatomical 
abnormalities in the bronchial tree, such as bronchiectasis. At the moment the 
only antimicrobial agents available to these patients are for parenteral 
administration e.g. the aminoglycosides, ureidopenicillins and some 
cephalosporins. Exacerbations of pulmonary disease with evidence of 
Pseudomonas infection, are usually treated with a combination of an 
aminoglycoside and a broad-spectum penicillin given for two to three weeks. 
Such prolonged parenteral treatment is very unpleasant for the patient. In this 
respect most patients judged the oral administration of enoxacin a great 
advantage. The clinical and bacteriological results of enoxacin treatment in 
Pseudomonas infections seem to be comparable to those after treatment with 
aminoglycosides (Wientzen et al., 1980; Hoff et al., 1974), ureidopenicillins or 
combinations (Hoogkamp-Korstanje & Van der Laag, 1983). In five patients an 
increase in Pseudomonas growth numbers occurred during treatment, despite 
an initial decrease in growth. In four patients treated twice because of 
pseudomonal infection the result of the second treatment was poor. Recently 
Roberts and colleagues (1985) reported the development of resistance to 
ciprofloxacin in patients with cystic fibrosis; in 11 of 21 patients resistance was 
transient. In the present study a diminished sensitivity to quinolones and also 
to unrelated drug classes like /3-lactams and aminoglycosides was observed in 
all but one Pseudomonas strain persisting after treatment with enoxacin. In 
eight strains the decreased susceptibility was still present after a mean time of 
four months. An increase of MIC values during treatment with quinolones was 
also reported by Neu & Scully (1985). It is still unknown whether the drug selects 
resistant strains of a mixed infection, or selects less susceptible mutants in vivo. 
Decreased susceptibility to unrelated drugs was also observed in Klebsiella 
pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa by Sanders et 
al. (1984); the effect may be associated with changes in outer membrane 
proteins of the bacteria. 
Adverse reactions occurred in 64% of the treatment periods. Enoxacin exerts 
a strong effect on plasma theophylline concentrations. This effect is possibly 
due to a decreased metabolic clearance of theophylline (Wijnands et al., 1984; 
Wijnand et al., 1985). If simultaneous treatment with enoxacin and theophylline 
is indicated, plasma theophylline concentrations must be measured in order to 
adjust the theophylline dose and avoid toxicity. 
Adverse effects related to the central nervous system were also observed in 
patients not concomitantly treated with theophylline. These effects resemble the 
unwanted effects seen during treatment with the chemically related agents 
nalidixic acid and oxoline acid (Hoigné et al., 1980). Davies et al. (1984) 
reported epileptiform attacks in one patient and hallucinations in another 
patient during treatment with enoxacin. Theophylline toxicity was not excluded 
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in that study. Simpson & Brodie (198S) observed convulsions in an 18-year old 
man after the third dose of 400 mg enoxacin. In the present study one patient 
developed visual hallucinations on the third day of treatment with 600 mg 
enoxacin bid. This 83-year old man was receiving numerous other medications, 
including theophylline. The plasma theophylline concentrations on Day 3 was 
15.6 /¿g/ml. One week after enoxacin had been stopped, the hallucinations 
recurred; the consulting neurologist judged the relation to enoxacin treatment 
doubtful. 
In conclusion enoxacin proved to be an effective treatment for lower 
respiratory tract infections except in those caused by Gram-positive bacteria. In 
Pseudomonas infections most patients showed a sufficient clinical response, but 
Pseudomonas spp. were eradicated from the sputum in only six out of 23 
patients, even though in most other patients a clear decrease in numbers was 
observed. 
To what extent the observed interaction with theophylline metabolism and the 
adverse reactions of the central nervous system occurs with other quinolones 
used for respiratory tract infections, is unknown, and needs further 
investigation. The rapid development of resistance during monotherapy with 
enoxacin, persisting in the absence of any selective pressure, is of real concern. 
Clinical studies using for example combinations with a ureidopenicillin should 
be undertaken in an attempt to prevent the selection of resistant mutants. 
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Summary 
After treatment with enoxacin, persisting Pseudomonas aeruginosa strains 
showed a diminished susceptibility to quinolones and in several cases also to 
unrelated antibiotics, such as beta-lactams and aminoglycosides. Further 
investigations were performed on these strains to study if pre- and post-
treatment isolates were isogenic, and to study the mechanism and duration of 
the observed decreased susceptiblity to quinolones and unrelated drugs. 
The data obtained by 4 different typing procedures indicated that the pairs 
of strains, isolated from the sputum of individual patients before and after 
treatment with enoxacin, were very closely related and can be concluded to be 
isogenic. 
The susceptibility to Pefloxacin, ofloxacin, and ciprofloxacin was also found 
to be decreased. In 2 of 4 measured strains this decreased susceptibility was still 
present after 16 and 257 days, respectively. 
In 4 cases a concurrent increase of MIC values of beta-lactams, and in 2 cases 
of aminoglycosides was measured. In one post-treatment isolate a decreased 
uptake of C14 enoxacin was demonstrated. This isolate appeared to lack outer 
membrane protein F. In one strain a GyrA mutation was concluded to be 
responsible for the diminished quinolone susceptibility. In another strain 
decreased susceptibility to beta-lactams could be related to different 
concentrations of the same beta-lactamase. No aminoglycoside modifying 
enzymes were detected. 
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8.1. Introduction 
Infections of the respiratory tract frequently occur in patients with cystic 
fibrosis, bronchiectasis of other origin, leucopenic patients, and in patients in 
intensive care units with Pseudomonas species the causative organism. The only 
therapeutic options are antimicrobial agents for parenteral administration, such 
as ureidopenicillins, aminoglycosides and some cephalosporins. In these 
infections, multiresistant Pseudomonas strains are often isolated. The lengthy 
parenteral treatment can only be administered to hospitalized patients. A 
possibility for oral treatment would benefit these patients because of the 
discomfort of parenteral treatment. 
Recently some new fluorinated quinolone derivatives for oral use have been 
developed, which show good to moderate in vitro activity against Pseudomonas 
aeruginosa, like ciprofloxacin, ofloxacin, Pefloxacin, and enoxacin 
(Hoogkamp-Korstanje 1984; Auckenthaler et al., 1986). 
In an open study aimed at evaluating the efficacy of enoxacin in respiratory 
tract infections with special attention to infections caused by Pseudomonas 
aeruginosa (Wijnands et ai., 1986), a moderate to good clinical effect was 
observed during enoxacin treatment in 20 out of 23 Pseudomonas infections. 
A significant number of Pseudomonas strains developed a decreased 
susceptibility to enoxacin during treatment. Several strains showed a diminished 
susceptibility to unrelated drug classes. Due to these findings, a further study 
with some of these Pseudomonas strains has been carried out to answer the 
following questions: 
1. Is the decreased susceptibility, found after treatment with enoxacin, the 
result of a selection of resistant strains in a mixed infection, or of less 
susceptible mutants of the parent strain selected by the drug in v/'vo? 
2. Is the development of decreased susceptibility reversible after the suppressive 
agent has been stopped or stable? 
3. What is the mechanism of this observed resistance? 
4. Is there evidence that the decreased activity of unrelated antibiotics, in 
particular beta-lactams, is associated with changes in outer membrane 
proteins of the bacteria? 
8.2. Materials and methods 
Patients 
The Pseudomonas aeruginosa strains were obtained from 8 patients, suffering 
from chronic bronchitis with chronic pulmonary function impairment. Seven 
patients had proven, usually extensive bronchiectasis colonised by 
Pseudomonas aeruginosa for several years which were treated in the past with 
antipseudomonal drugs, mostly a combination of an ureidopenicillin and an 
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aminoglycoside. They were admitted because of an exacerbation of the 
underlying pulmonary disease, with signs and symptoms of a Pseudomonas 
aeruginosa infections. Patient 6, also admitted because of a Pseudomonas 
infection of the respiratory tract, had never previously had positive sputum 
cultures for Pseudomonas aeruginosa. 
Selection of isolates 
From 9 treatment periods in 8 patients, Pseudomonas aeruginosa strains were 
isolated from sputum before the start of enoxacin treatment, after completion 
of the course and also in 4 episodes, at a mean time of 131 days afterwards 
(range: 34 to 275 days). The strains were stored in Iso-Sensitest agar (Oxoid, 
UK) at room temperature. 
Susceptibility tests 
Disc diffusion susceptibility tests were performed according to the principles of 
the ICS (Ericsson & Sherris 1971). 
Minimum inhibitory concentrations (MIC) were determined in microdilution 
trays (Gowan & Barry, 1980) and the agar dilution method according to the 
recommendations of the Dutch Working Party on the Standardisation of 
Susceptibility Testing (1985). Each well contained 100 μΐ of 11 concentrations 
of the antibiotics tested, at doubling dilutions in Mueller Hinton broth, 
standardised for Mg + + and C a + + content. The plates were inoculated with 3 
|tl of an overnight culture diluted to yield a final inoculum of 10M06 cfu/ml. 
After overnight growth the MIC's were determined. The stability of post 
treatment MIC's was investigated in five Pseudomonas strains by repeated, 4 
times transfer in drug free Iso-Sensitest broth. 
Typing procedures 
The Pseudomonas strains were typed by 4 different techniques: 
Serological typing was performed using monospecific antisera, prepared in 
rabbits, to Pseudomonas strains. Typing was carried out in microliter plates, 
under different temperature and titer conditions. Sixteen serotypes were 
recognised. 
Active pyocin typing was performed according to Gillies & Govan (1966). 
Passive pyocin typing was carried out according to Osman (1965). 
Bacteriophage typing was performed according to Suter et al. (1965) using 20 
bacteriophages from the Central Public Health Laboratory, Colindale, 
England. 
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Beta-lactamase detection 
The presence of beta-lactamase was detected using the chromogenic 
cephalosporin, nitrocefin (O'Callaghan et al., 1972). Beta-lactamases were 
tentatively identified using a disc sensitivity antibiogram of cefoxitin (30 /xg), 
cefamandole (30 /ig), cefotaxime (30 ¿¿g), mezlocillin (30 /ig), and ceftazidime 
(30 /ig). All classifications were confirmed using iso-electric focussing (LKB 
Multiphor, LKB, UK), according to Matthew et at. (1975). 
Aminoglycoside modifying enzymes 
Aminoglycoside modifying enzymes (AME) were detected using a disc 
sensitivity antibiogram of gentamicin (10 /tg), kanamycin (30 /tg), netilmicin (30 
/ig), sisomicin (10 /ig), tobramycin (10 /tg), and amikacin (30 /ig) as described 
by Van de Klundert et al. (1984). 
Outer membrane protein profile 
To study the outer membrane protein profile (Omp), the Pseudomonas strains 
were grown in Iso-Sensitest broth until the late logarithmic phase. The culture 
was harvested at 10000 g at 4° С and the cells washed in 50 mM sodium 
phosphate buffer pH 7 at 4 0 C. An outer membrane preparation was made by 
sonicating the washed cell suspension for 6 minutes at 4 0 C. The remaining 
unbroken cells were removed by centrifugation. The supernatant was incubated 
in a final concentration of 1% sarkosyl (Sigma, UK) for 20 minutes at 25 0C. 
The outer membranes were pelleted by ultracentrifugation at 100000 g at 10oC 
for 30 minutes. Electrophoresis of the outer membrane preparations was 
performed, according to Lugtenberg et al. (1975). 
Examination of the uptake of C'4enoxacin 
From an overnight broth, a 2% inoculum was made to 20 ml fresh Iso-Sensitest 
broth and grown until the mid-logarithmic phase. Three aliquots of 2.5 ml were 
withdrawn to three tubes, the control (no antibiotic), the test (containing 16 
/ig/ml C14enoxacin) and another control containing 16 /tg/ml unlabelled 
enoxacin, and incubated with stirring at 370C. Until 30 minutes, repeated 500 
/tl samples were withdrawn from the tube containing Cinoxacin, added to 20 
ml phosphate buffered saline (PBS) at 4 0 C, mixed and filtered through a 
vacuum filtration manifold. The filters were then washed with 20 ml PBS at 
4 0 C. The filters were dried and the radioactivity measured by scintillation 
counting. Parallel viable counts were performed for all three tubes before, and 
at 30 minutes. Each assay was performed in duplicate, and the results expressed 
graphically as cpm per 107 cfu against time. 
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Table I Typing characteristics of 9 sets of Pseudomonas aeruginosa strains isolated 
from the sputum of 8 patients before and after treatment with enoxacin. 
Pat. no Day serol pyocine type phage 
0 
18 
0 
18 
111 
0 
1? 
0 
18 
34 
0 
18 
102 
0 
18 
0 
18 
275 
0 
18 
0 
18 
6 
6 
9 
9 
9 
9 
9 
6 
6 
6 
3 
3 
3 
9 
9 
9 
9 
9 
3 
3 
9 
9 
active 
73 c 
73 c 
nt 
45 c 
55 с 
55 с 
55 с 
72 d 
82 d 
82d 
45 с 
45 с 
45 с 
15 b 
15 b 
12 c 
12 c 
12 c 
64c 
74 c 
83 a 
83 a 
passive 
57 с 
57 с 
28 b 
28 b 
28 b 
28 b 
28 b 
34 d 
34 d 
34d 
24 c 
24 c 
24 c 
74 c 
74 c 
24 c 
24c 
54 c 
63 a 
63 d 
83 a 
33 a 
nt 
3/13 
nt 
nt 
nt 
nt 
nt 
3/8/13 
3/8/13 
3/8/13 
3 
nt 
3 
3 
3 
nt 
15 
15 
2/7 
2/7 
6/8/14/18 
6/8/14/18 
(nt = not typable) 
8.3. Results 
As can be seen in Table I the typing data indicate that pairs of Pseudomonas 
aeruginosa strains isolated from the sputum of individual patients before and 
after treatment with enoxacin, seem to be very closely related, and can be 
concluded to be isogenic. 
The post-treatment isolates showed a two- to six-fold increase in the MIC 
values of enoxacin, compared to the pre-treatment values (Table II). The 
susceptibility to Pefloxacin, ofloxacin, and ciprofloxacin was also found to be 
decreased (Table III). After a mean period of 131 days, the increased MIC 
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Table II MIC values of enoxacin, piperacillin, tobramycin, and ceftazidime for 
Pseudomonas aeruginosa strains isolated before and at day 18 of with enoxacin 
treatment (Broth dilution method). 
Pat. no Day MIC (mg/1) of: 
0 
18 
0 
18 
111 
0 
18 
0 
18 
34 
0 
18 
102 
0 
18 
0 
18 
275 
0 
18 
0 
18 
enoxacin 
0,5 
2 
0.5 
4 
0.5 
0.5 
8 
0.06 
4 
2 
0.125 
1 
0.06 
0.5 
8 
0.25 
4 
1 
1 
4 
4 
16 
piperacillin 
4 
4 
0,125 
1 
0.06 
0.06 
0.25 
0.25 
4 
8 
0.06 
2 
0.06 
0.25 
0.25 
0.25 
0.06 
0.06 
1 
32 
0.5 
0.125 
tobramycin 
2 
2 
0.125 
0.25 
0.125 
0.125 
2 
0.125 
4 
4 
0.125 
0.125 
0.125 
2 
4 
1 
1 
0.5 
2 
1 
0.5 
0.125 
ceftazidime 
2 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2 
4 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
8 
0.5 
0.5 
values of enoxacin were still present in 2 of the 4 measured strains. The MIC's 
of norfloxacin, measured in 4 post-treatment strains, appeared to be stable, as 
they did not change after repeated passages in Iso-Sensitest broth. These strains 
also grew slowly and produced minimal green pigment. The MIC value of the 
post-treatment strain obtained from patient 4, which showed a normal growth 
and produced a normal quantity of pigment, returned to pre-treatment value 
after only one passage. 
As indicated in Table II, post-treatment strains showed a decreased 
susceptibility for unrelated drugs: a two- to five-fold increase of the MIC value 
of piperacillin was measured in 4 cases, a four-, resp. five-fold increase of the 
MIC of tobramycin in 2 cases, and in 2 cases a two- and four-fold increase of 
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Table HI MIC values of enoxacin, Pefloxacin, ofloxacin and ciprofloxacin for 
Pseudomonas aeruginosa strains obtained from 5 patients before and at day 18 of 
enoxacin treatment. (Agar dilution method, RIVM) 
Pat. no 
3 
4 
5 
6 
7 
Day 
0 
18 
0 
18 
0 
18 
0 
18 
0 
18 
MIC (mg/I) of: 
enoxacin 
0.06 
4 
0.03 
0.5 
0.5 
4 
0.12 
2 
0.12 
1 
Pefloxacin 
0.03 
8 
0.015 
1 
0.25 
2 
0.25 
8 
0.25 
1 
ofloxacin 
0.03 
2 
0.015 
0.5 
0.5 
2 
0.25 
4 
0.25 
0.5 
ciprofloxacin 
0.015 
0.5 
0.008 
0.25 
0.06 
0.5 
0.008 
0.5 
0.25 
0.5 
Corrected CPM per I07CFU 
Figure 1 The uptake of C14enoxacin in Pseudomonas aeruginosa, isolated from the 
sputum of patient 3 before and after treatment with enoxacin. 
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the MIC of ceftazidime. In 2 patients a decreased susceptibility to piperacillin 
could still be detected after a longer period (16 and 257 days, respectively). 
As shown in Table IV, the set of Pseudomonas strains cultured from the 
sputum of patient 1 appeared to be identical with respect to the Omp profile, 
the absence of aminoglycoside modifying enzymes and beta-lactamase 
production, but the susceptibility for enoxacin was decreased. This may be due 
to an altered DNA gyrase, the target enzyme. The isolates of patient 2 showed 
a concurrent decrease in susceptibility to piperacillin. This appeared to be due 
to different concentrations of the same Richmond & Sykes group 1 beta-
lactamase (20 nmoles nitrocefin hydrolysed per minute per mg dryweight 
bacteria in the pre-treatment isolate compared to 800 nmoles in the post-
treatment isolate), possibly indicating that these isolates are not isogenic, as was 
concluded from the typing data, but probably derived in parallel from a 
common ancestor. The strains of patient 3 appeared identical. However, the 
post-treatment isolate with decreased enoxacin susceptibility also showed 
decreased susceptibility to beta-lactams and aminoglycosides. This isolate 
appeared to lack outer membrane protein F. The uptake of C'Mabeled 
enoxacin in the post-treatment isolate was lower than in the pre-treatment 
isolate (figure 1). 
Table IV Characteristics of pre- and post-treatment Pseudomonas aeruginosa strains 
isolated from 3 patients before and after treatment with enoxacin. 
Pat. no 
1 
2 
2a 
3 
Day 
0 
18 
0 
18 
111 
0 
18 
0 
18 
8.4. Discussion 
Omp profile 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
OMP F 
missing 
A.M.E. 
none 
none 
none 
none 
none 
none 
none 
none 
none 
/3-lactamase 
identification 
partially derepressed 
partially derepressed 
inducible 
inducible 
inducible 
inducible 
inducible 
inducible 
partially derepressed 
/3-lactamase 
IEF 
8.45 
8.0 
8.15 
8.2 
8.15 
8.15 
8.15 
8.8 
8.8 
Based on in vitro data, resistance to the new quinolones is not expected to occur 
quickly. This assumption is based on the fact that no single step highly resistant 
mutants have been reported so far (Nakamura et al. 1983). A stepwise, slight 
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decrease in susceptibility will result from serial passages on subinhibitory 
concentrations of the quinolone (Smith, 1984). Transfer of resistance to 
quinolones by means of plasmids will not occur, due to the action mechanism 
of this class of drugs. Cross-resistance between nalidixic acid and the fluoro-
quinolones is incomplete (Nakamura et al., 1983; Tenney et al. (1983). 
Due to the very slow growth and the special growth requirements of 
quinolone resistant mutants, it has been assumed that mutants are not of great 
clinical significance, because they should be counterselected in ecosystems such 
as the intestinal tract (Crumplin, 1986; Courvalin et al., 1986). Despite these 
observations, an increase in the quinolone MIC values for Pseudomonas 
aeruginosa after treatment with these agents has been reported (Davies et al., 
1986a; Giamarellou et al., 1984; Lebel et al., 1986; Salh & Webb, 1987). 
Increasing MIC values also have been observed for Staphylococcus aureus 
(Desplaces et al., 1986), Klebsiella pneumoniae (Desplaces et al., 1986), 
Branhameila catarrhalis (Davies et al., 1986b), and Streptococcus pneumoniae 
(Maesen et al., 1985). Due to the borderline susceptibility of Pseudomonas 
aeruginosa to enoxacin and Pefloxacin, a further diminished susceptibility will 
result in clinical resistance. As the activity of ciprofloxacin on Pseudomonas 
aeruginosa is good, most strains which show only a two- to four-fold increase 
in the MIC values can still be considered susceptible. 
As observed in the present study, the susceptibility to quinolones will not 
always return to pre-treatment values. Moreover, the slowly growing post-treat-
ment Pseudomonas strains still proved to be capable of causing infection in 
patients with seriously decreased local resistance in the bronchial tree. The 
clinical and bacteriological result of repeated treatment with enoxacin was 
disappointing. 
Some of the investigated post-treatment strains showed not only a decreased 
susceptibility to quinolones, but also to unrelated drugs, particularly beta-
lactams. This apparent cross-resistance of quinolones and unrelated classes of 
antibiotics has been thought to be associated with decreased permeability of the 
outer bacterial membrane, caused by a change in outer membrane proteins 
(Sanders et al., 1984). However, in nalidixic acid resistant enterobactereaceae, 
which show a simultaneous resistance to new quinolones and unrelated 
antimicrobials, conventional mechanisms such as beta-lactamases and 
aminoglycoside modifying enzymes to those unrelated drugs were shown to be 
responsible for the resistance. No decreased permeability through the outer 
membrane was detected (Piddock et al., 1986). 
In the present study, the altered susceptibility to beta-lactams, detected in 
patient 2, could be related to different concentrations of the same Richmond 
& Sykes group ID-lactamase, possibly indicating that these isolates were not 
isogenic, despite the very close characteristics, found during the typing 
procedures. One pair of isogenic Pseudomonas strains (obtained from patient 
1) appeared identical for ail measured characteristics except for the enoxacin 
susceptibility; the decreased susceptibility is probably due to an altered DNA 
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gyrase by a gyrA mutation. From another patient (no. 3), an isogenic, post-
treatment Pseudomonas strain was isolated with a decreased susceptibility not 
only to quinolones, but also to beta-lactams and aminoglycosides. This isolate 
lacked outer membrane protein F. The uptake of enoxacin in this isolate proved 
to be decreased compared to the pre-treatment strain. It has been shown by 
Jaffe et al. (1982) that membrane protein F facilitates the beta-lactams 
penetration through the outer membrane of Escherichia coli. 
Although the new quinolones are not expected to cause a higher incidence of 
resistance than some of the older classes of antibiotics, when used as a single 
agent in Pseudomonas aeruginosa infections (Sanders et al., 1984), the rapid 
emergence of resistance of Pseudomonas aeruginosa in patients treated with one 
of the new quinolones, which results in decreased susceptibility to this whole 
group of antibiotics, has given rise to concern. Thabaut et al. (1984) observed 
no decreased susceptibility when Pefloxacin was combined with low 
concentrations of an aminoglycoside. Clinical studies have to be performed to 
assess whether the emergence of resistance can be reduced or prevented, when 
the quinolone is combined with an unrelated antipseudomonal agent. 
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Summary 
1 In patients treated concurrently with theophylline and enoxacin, a new broad-
spectrum antibacterial agent of the quinolone class, unexpectedly high plasma 
theophylline concentrations were measured. 
2 In part I of this study, daily plasma theophylline concentrations were 
measured in 14 patients. The mean theophylline concentrations increased from 
8.5 + 2.8 ¿tg ml-1 prior to enoxacin to a maximum of 21.7±7.8 /ig ml - ' during 
co-administration. 
3 In part II, six of these patients received aminophylline intravenously at a 
constant infusion rate and under controlled conditions. Plasma theophylline 
concentrations rose from 8.4 ±2.4 μg ml - 1 prior to enoxacin treatment to 
15.0±5.1 /ig ml"' at Day 3 of co-administration (p < 0.005). 
4 Plasma protein-binding and renal clearance of theophylline remained 
unchanged, whereas total body clearance of theophylline significantly decreased 
(p < 0.005). 
5 From these observations it is concluded that the rise of plasma theophylline 
concentrations is caused by a reduced metabolic clearance of theophylline. 
6 If concomitant use of both drugs is necessary, monitoring of plasma 
theophylline concentration and adjustment of the theophylline dose is 
recommended. 
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9.1. Introduction 
Theophylline is a potent bronchodilator and is frequently prescribed for the 
treatment of patients with obstructive lung disease. The bronchodilatory effect 
of theophylline is related to its plasma concentration with an optimal 
therapeutic effect occurring at plasma concentrations of 10 to 20 ¿ig ml"1 
(Mitenko & Ogilvie, 1973). Because of this narrow therapeutic range a change 
in theophylline clearance will have consequences for adequate treatment. At 
higher plasma concentrations adverse reactions are mainly associated with the 
digestive, circulatory and nervous systems. 
Many factors are known to influence theophylline clearance (Hendeles & 
Weinberger, 1983). Simultaneous treatment with drugs such as allopurinol 
(Manfredi & Vesell, 1981), Cimetidine (Jackson et al., 1981; Reitberg et al., 
1981), erythromycin (Prince et al., 1981), troleandomycin (Weinberger et al., 
1977), can cause decreased theophylline clearance, whereas co-administration of 
phénobarbital (Landay et al., 1978), Phenytoin (Marquis et al., 1982) and 
isoprenaline (Hemstreet et al., 1982) can produce an increased clearance. 
Recently a number of new quinolone carboxylic acid derivatives have been 
developed. Enoxacin, one of these new compounds, has shown a good in vitro 
activity against Gram-positive and Gram-negative bacteria, including 
Pseudomonas aeruginosa. 
In a previous study with enoxacin in respiratory tract infections by Davies et 
al. (1984), the drug had to be discontinued in 9 of 15 patients because of side 
effects mainly related to the digestive system; seven of these patients used 
concomitant theophylline medication. In a clinical study with oral enoxacin in 
patients with a respiratory tract infection we observed unexpectedly high plasma 
theophylline concentrations causing complaints and symptoms of theophylline 
toxicity such as nausea and vomiting (Wijnands et al., 1984). Since theophylline 
and antibiotics are frequently used concomitantly in the treatment of patients 
with obstructive lung disease, this study was designed to elucidate the 
mechanism of interaction between these two compounds. 
9.2. Methods 
Patients with chronic obstructive pulmonary disease, who were admitted to the 
hospital for treatment of a respiratory tract infection, participated in the study, 
which had received the approval of the Hospital Ethics Committee. All patients 
were on maintenance treatment with a slow release theophylline administered 
twice daily. Drugs known to influence theophylline clearance were avoided prior 
to the study and during administration of enoxacin (Hendeles & Weinberger, 
1983; Jonkman & Upton, 1984). Infections caused by Pseudomonas aeruginosa 
were treated with oral enoxacin, 600 mg twice daily, whereas other infections 
were treated with 400 mg enoxacin, twice daily. Patient characteristics and 
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comedication are listed in Table I. None of the patients had signs of congestive 
heart failure, nor did they smoke cigarettes or drink coffee. Hepatic and kidney 
functions were within normal ranges. 
In part I of the study daily through plasma theophylline concentrations were 
measured before the start of and during treatment with enoxacin. Plasma 
samples were taken at the same time of the day (09.00 h). In part II 
aminophylline (theophylline content 85%) was administered intravenously via 
an infusion pump, to obtain a constant infusion rate. After steady-state plasma 
theophylline concentrations were attained, i.e. difference between through 
concentration on 2 consecutive days less than 2 μg m l ' , oral enoxacin was 
started at a dose of 400 or 600 mg twice daily. Complaints occurring during 
enoxacin treatment were recorded in a diary. 
On the day before the start of enoxacin treatment and on Day 3 of co­
administration serial blood samples were collected from a vein in the arm 
opposite that of the aminophylline infusion. Plasma was separated 
immediately. Specimens of spontaneously voided urine were collected over a 24 
h period to assess renal clearance. Urine and plasma samples were stored at 
- 180C until analysis. Theophylline concentrations in plasma and urine were 
determined by means of an enzyme immunoassay (EMIT® , Syva Diagnostics, 
Palo Alto, California) (Gushaw et al., 1977), which is known to correlate 
significantly with high pressure liquid chromatography (Koup & Brodsky, 
1978). Protein binding was measured by ultrafiltration (EMIT® , Free Level 
System I, Syva Diagnostics, Palo Alto). Total body clearance of theophylline 
was calculated as Оозе/т.С^. 
Results are presented as means ± s.d. Statistical analysis was performed 
using Student's Mest for paired observations; differences were considered 
significant at the ρ < 0.05 level. 
9.3. Results 
Fourteen patients (nine men and five women) with a mean age of 63.2 years 
(range 41-86 years) entered the study. 
Part I 
Mean plasma theophylline concentrations were 8.5 ±2.8 /tg m l - 1 prior to 
administration of enoxacin and increased to a highest value of 21.7 ±7.8 /ig 
ml - 1 , following 3-5 days of concomitant oral enoxacin. In eight patients 
treated with a daily dose of 800 mg enoxacin plasma theophylline 
concentrations increased from 8.3±3.5 /ig m l - 1 to 21.3±9.5 /tg ml" 1 during 
treatment with enoxacin (p < 0.01). In six patients treated with a daily dose of 
1200 mg enoxacin, plasma theophylline concentrations increased from 8.8 ± 1.6 
/tg ml" 1 to 22.2±5.5 /tg m l - 1 during enoxacin treatment {p < 0.001). The 
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Table I Patient characteristics 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
Mean: 
s.d.: 
9 
10 
11 
12 
13 
14 
Mean: 
s.d.: 
Age 
(years) 
64 
41 
69 
66 
56 
75 
86 
76 
66.6 
13.7 
61 
69 
41 
54 
75 
52 
58.7 
12.3 
Weight 
(kg) 
67.7 
51.6 
62.5 
41.8 
59.0 
69.6 
56.8 
49.0 
77.6 
81.5 
60.1 
61.0 
51.7 
77.5 
Theophylline 
dose (mg 24 h1) 
600 
816 
1200 
612 
612 
400 
400 
408 
612 
816 
612 
612 
612 
600 
Enoxacin 
dose (mg 24 h'1) 
800 
800 
800 
800 
800 
800 
800 
800 
1200 
1200 
1200 
1200 
1200 
1200 
Theophylline concentration fog ml'1) 
before 
enoxacin 
7.0 
12.3 
9.0 
12.8 
6.5 
2.5 
10.5 
6.1 
*8.3 
3.5 
8.6 
11.5 
8.5 
7.8 
9.4 
6.7 
•8.8 
1.6 
during 
enoxacin 
26.6 
20.0 
17.2 
21.0 
13.6 
10.2 
20.6 
41.3 
021.3 
9.5 
15.0 
31.0 
20.3 
25.2 
22.9 
18.9 
022.2 
5.5 
Further 
comedication 
S Ρ Pr 
S Ρ С Pr 
S P F D 
S P I R 
S P 
S T P 
S B F D 
S P 
S P 
S T P F 
S P D F 
S Ρ I Pm 
S P 
S = salbutamol, inhalation; Τ = terbutaline, oral; Ρ = prednisolone, i.v./oral; В = beclomethasone, inhalation; I = ipratropium, 
inhalation; С = cromolyn sodium, inhalation; F = frusemide, oral; D = digoxin, oral; Pr = prochlorperazine, oral. 
Pm = promethazine, oral R = ranitidine, oral (* and 0 : not significant) 
E 20 
σ> 
¿ I O 
β 
с 
= Οί­
ο. 
о 
φ 
<л 
• · • · 
2 х 300 mg 2 χ 200 mg theophylline 
enoxacin 2 χ 400 mg] 
5 10 
Day of treatment 
15 
Figure 1 Plasma theophylline concentrations in a single patient before, during and 
after co-administration of enoxacin. 
increase of plasma theophylline concentrations during 800 mg and 1200 mg 
enoxacin did not differ significantly (p > 0.05). An example of the course of 
plasma theophylline concentrations is given in Figure 1 for a single patient 
(number 4) before, during and after co-administration of enoxacin. Similar 
trends were observed in the other patients. In one patient (number 12) 
theophylline was discontinued on two occasions. On the first occasion the 
patient received concomitant enoxacin and on the second occasion theophylline 
alone. As illustrated in Figure 2 the theophylline half-life increased to 16.5 h 
with co-administration of enoxacin, compared to a 5.5 h half-life of 
theophylline when given alone. 
Part II 
In this part of the study five patients (number 4, 5, 9, 11, 12) received 720 mg 
aminophylline 24 h - 1 intravenously (equivalent to 612 mg theophylline) and 
one patient (number 8) 480 mg aminophylline 24 h - 1 (equivalent to 408 mg 
theophylline) (Table I). The mean steady-state plasma theophylline 
concentration of 8.4±2.4 /tg ml - 1 , measured before starting enoxacin, 
increased to 15.0±5.1 /ig m l - 1 at Day 3 of enoxacin treatment (p < 0.005, 
Figure 3a). Plasma protein binding of theophylline was 61.8 ± 9 . 0 % before and 
63.2±4.9% following enoxacin therapy (p >0.05, Figure 3b). 
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Elimination of theophylline in a single patient during enoxacin treatment (О) and 1 week 
after enoxacin had been stopped ( · ) . 
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Figure 3 (a) Plasma concentration, (b) protein binding, (с) total body clearance and (d) 
renal clearance of theophylline before and at Day 3 of concomitant treatment with 
enoxacin (---- mean) (NS = ρ > 0.05). 
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Total plasma theophylline clearance decreased from 50.2 ±10.6 ml 
min"1 to 28.9±7.8 ml min"1 (ρ < 0.005, Figure 3c). Renal clearance of 
theophylline was 7.2 ±4.3 ml min - 1 before and 7.0±3.8 ml min - 1 at Day 3 of 
concomitant treatment (p > 0.05, Figure 3d). Enoxacin did not interfere with 
the theophylline EMIT® assay. Concentrations of selected samples measured 
by HPLC were equivalent to those determined by EMIT® . 
9.4 Discussion 
Enoxacin markedly inhibits the total body clearance of theophylline. Mean 
plasma theophylline concentration increased by a factor 2.6, following 
concomitant enoxacin administration in this study. The increase in plasma 
theophylline concentration appeared to be independent of enoxacin dose 
(800-1200 mg d a y 1 ) · 
Davies et al. (1984) used oral enoxacin 600 mg twice daily to treat 15 patients 
with a lower respiratory tract infection. In nine cases enoxacin had to be 
discontinued because of adverse reactions. Of these nine patients, seven who 
developed severe nausea, were on concomitant theophylline therapy. Plasma 
theophylline concentrations were not measured in that study. In the present 
study nine patients simultaneously treated with theophylline and enoxacin, 
complained of nausea and vomiting. These complaints disappeared completely 
and quickly after the theophylline dose was lowered, while enoxacin adminis­
tration continued. Thus, the symptoms appeared to be related primarily to high 
plasma theophylline concentrations, rather than to any direct effect of enoxacin. 
To investigate the mechanism by which enoxacin decreases theophylline 
clearance, aminophylline was administered by constant i.v. infusion to six 
patients. A clear and consistent rise in the plasma theophylline concentrations 
was observed in all patients following concomitant administration of enoxacin. 
Since the plasma protein binding and renal clearance of theophylline did not 
change, the decrease in theophylline clearance probably relates to effects on the 
liver enzymes or a change in volume of distribution. The prolonged half-life of 
theophylline measured in a single patient during co-administration of enoxacin 
(Figure 2) suggests that a metabolic inhibition is more likely than an effect on 
volume of distribution. 
Theophylline is primarily eliminated by hepatic metabolism (Ogilvie, 1978; 
Pfeifer et al., 1979). Few studies have investigated the effects of drugs on the 
individual pathways of theophylline metabolism, N-demethylation and 
8-oxidation. Lohmann & Miech (1976) showed that the /V-demethylation in rats 
is related to the hepatic cytochrome P-448, which can be stimulated by 
phénobarbital (Landay et al., 1978). Grygiel et al. (1984) showed that 
theophylline clearance diminished during co-administration of Cimetidine 
largely due to reduced TV-demethylation. Cimetidine did not influence 
theophylline oxidation. 
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The mean age of the patients in this study was 63.2 years. All but one of the 
patients necessarily received other co-medication as indicated in Table 1. 
Although no influence is known from the co-medication used on theophylline 
clearance, the interaction studied between enoxacin and theophylline needs 
confirmation in subjects, without further co-medication. In our opinion other 
antibacterial agents of the quinolone class have to be investigated with respect 
to this interaction because of the close chemical structure similarities to 
enoxacin. 
Our preliminary clinical experience indicates that enoxacin may be of value 
in respiratory medicine as an antibacterial agent for selected indications, 
including Gram-negative infections. If simultaneous treatment with 
theophylline is necessary, we recommend lowering the theophylline dosage by 
approximately 40170 before the start of enoxacin. Any further modification of 
the theophylline dosage during enoxacin treatment has to be based on 
measurements of plasma theophylline concentrations in order to avoid toxicity. 
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Summary 
1 Enoxacin decreases the metabolic clearance of the bronchodilator 
theophylline not only in severely ill patients, but also in patients with stable 
chronic obstructive pulmonary disease. 
2 In this comparative study, significantly increased plasma theophylline 
concentrations were measured during co-administration of enoxacin (110.9%) 
and, to a lesser degree, also during co-administration of Pefloxacin (19.6%) and 
ciprofloxacin (22.8%). 
3 Total body clearance of theophylline was significantly decreased by enoxacin 
(63.6%), ciprofloxacin (30.4%) and Pefloxacin (29.4%). The pharmacokinetic 
parameters of theophylline did not change during co-administration of 
ofloxacin and nalidixic acid. 
4 There is growing evidence that the observed interaction is caused not by the 
parent drugs, but by the 4-oxo metabolite of enoxacin, Pefloxacin and 
ciprofloxacin. 
112 
10.1. Introduction 
During two different clinical studies in patients with chronic obstructive 
pulmonary disease, testing the efficacy and safety of enoxacin (CI 919), a new 
antibacterial agent of the quinolone class, unexpectedly high plasma 
theophylline concentrations were measured in patients who were on 
concomitant theophylline therapy. These high theophylline concentrations 
resulted in severe complaints of nausea, vomiting, tachycardia or agitation for 
some of the patients (Davies et al., 1984; Wijnands et al., 1984). Further 
investigation into this increase in plasma theophylline concentrations showed 
that neither theophylline protein binding nor theophylline renal clearance were 
influenced by the enoxacin co-medication; it was therefore concluded that the 
interaction mechanism might be a decreased theophylline metabolic clearance 
(Wijnands et al., 1985a). 
Due to the clinical importance of this observed interaction between enoxacin 
and theophylline, other new quinolones which are currently being tested 
clinically to treat respiratory tract infections were studied to see if they produced 
a similar interaction. 
10.2. Methods 
Subjects an materials 
Eight subjects, seven males and one female, aged 51 to 69 years (mean age: 
58.5 ± 6.2 years) gave their informed consent to be included in this study, which 
had the approval of the Hospital Ethics Committee. All eight patients were on 
maintenance theophylline treatment (Theolin retard® , Astra Pharmaceutics) 
due to a chronic obstructive pulmonary disease which was stable for at least 4 
weeks prior to the measurement period. The theophylline dose was 300 mg twice 
daily in five cases, 450 mg twice daily in one case and 600 mg twice daily in two 
cases. In all cases, for safety reasons, through plasma theophylline 
concentrations were kept below 10 /ig ml - 1 . At the time of the study the 
patients used only sympathomimetics and corticosteroids by inhalation as co-
medication, drugs which are known not to influence theophylline clearance. 
None of the patients showed signs of congestive heart failure. Seven subjects did 
not smoke. One smoked approximately five cigarettes a day; he was asked not 
to change his smoking habit during the study period. Before the start of the 
study a medical history, physical examination, complete blood count, blood 
chemistry and a urinalysis were performed; the results were within normal 
ranges for each subject. 
All subjects participated in five study periods, each separated by at least 9 
days, in which they ingested: theophylline alone ( = blank period), theophylline 
with ciprofloxacin 500 mg twice daily, theophylline with Pefloxacin 400 mg 
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twice daily, theophylline with ofloxacin 400 mg twice daily, and theophylline 
with enoxacin 400 mg twice daily. After completion of these measurements 
a sixth period of theophylline and nalidixic acid 500 mg twice daily was 
added in four of these subjects. After steady-state theophylline plasma 
concentrations (Css) were confirmed (difference of 2 /tg ml"1 or less 
between two measurements on 2 consecutive days), the quinolone 
administration was started for a 5.5 day period (last quinolone administration: 
Day 6 at 09.00 h). Both the quinolone and theophylline were ingested at 
09.00 h and 21.00 h. On Day 5 of the quinolone administration after 
themorning dose or when plasma theophylline concentrations exceeded 20 ¿tg 
ml - 1 , theophylline was stopped for at least 32 h, until the plasma theophylline 
concentration was less than 1 μ$ m l ' . Adverse reactions were registered by 
the volunteers. 
Sampling procedure 
Blood samples were taken at 08.30 h on Day 2, 3, 4 and 5 of each period to 
determine trough plasma theophylline concentrations. On Day 5 and 6 serial 
blood samples were taken from an indwelling catheter in a forearm vein, which 
was kept open by a heparin solution, to establish theophylline plasma 
concentration-time curves for each subject, up to 32 h after the last theophylline 
dose or until plasma theophylline concentration was less than 1 ¿ig m l ' . 
Plasma was separated immediately. All samples of spontaneously voided urine 
were collected for a 24 h period. Plasma and urine samples were kept at — 20°С 
pending analysis. 
Sample analysis 
Theophylline plasma and urine concentrations were determined by a 
homogenous enzyme immunoassay technique (EMIT® ; Syva Diagnostics, Palo 
Alto, California) (Gushaw et al., 1977), using a Gilford Stasar III 
spectrophotometer, wave length 340 nm. A lyophilized assayed human control 
serum was used (Lyphochek, Boi Rad, California). This technique is known to 
correlate significantly with high pressure liquid chromatography analysis (Koup 
& Brodsky, 1978). Urine samples were diluted six times. 
Quinolone plasma concentrations and the 4-oxo metabolite (formed with 
ciprofloxacin, Pefloxacin and enoxacin) were determined by a HPLC method 
(Vree et al., 1985): A Spectra Physics 3500B high performance liquid 
Chromatograph equipped with a stainless steel, reversed phase column 15 cm, 
4 mm i.d., packed with Spherisorb 5 ODS (Chrompack, Middelburg, The 
Netherlands) and a variable wave length spectrophotometer detector (model SP 
770) were used. The mobile phase consisted of a mixture of 0.75 g phosphoric 
acid, 0.25 g tetramethylammoniumchloride, 155 ml JV,/V-dimethylformamide 
and 155 ml acetonitrile, adjusted with water to 1 I. The chemicals were of 
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analytical grade (Merck, Darmstadt, F.R.G.)· Solvent flow rate was 1.6 ml 
min-1 at a pressure of 3800 psi. 
The folowing parameters of theophylline were recorded i.e. calculated for 
each study period: C
max
, С,,,, area under the plasma concentration-time curve 
after oral administration (AUC o-oo), total body clearance after oral 
administration (CL), renal clearance (CL
r
) and the apparent half-life of 
elimination (tM). AUC (o-oo) was calculated by the linear trapezoidal rule. CL 
of theophylline was obtained by dividing the dose by the AUC in the 12 h 
period. The half-life of theophylline was deduced from linear least squares 
regression analysis of semilogarathmic experimental data points in the terminal 
part of the concentration-time curve. These calculations assumed that the dose 
of theophylline was completely absorbed, as has been shown in several studies 
(Hendelese/a/., 1977). 
Results are expressed as mean values ± standard deviation. Differences in the 
parameters between the periods in which theophylline with one of the 
quinolones was administered and the blank period were assessed using Student's 
/-test for paired observations; differences were considered significant at the ρ 
< 0,05 level. 
10.3. Results 
Mean trough theophylline concentrations prior to the five different study 
periods did not differ significantly (Table I). Mean trough theophylline 
concentrations on Day 2, 3, 4 and 5 of the measurement periods are shown in 
Figure 1. 
A significant raise of theophylline plasma concentrations occurred on the 
second day of enoxacin administration in all subjects compared to the blank 
period (j> < 0.001). In two subjects on enoxacin, theophylline had to be 
discontinued on Day 3 and Day 4 respectively because theophylline plasma 
concentrations exceeded 20 /*g ml - 1, and there where moderately severe 
complaints of agitation, restlessness and nausea. After the third day of admin­
istration, no further increase in the theophylline concentration was observed. 
During co-administration with ciprofloxacin and Pefloxacin, a significant 
increase of theophylline plasma concentrations occurred on Day 3 of 
administration (p < 0.001). On the contrary, no change in theophylline plasma 
concentrations was observed during co-administration with ofloxacin. 
A highly significant rise of maximum theophylline plasma concentrations 
occurred during co-administration of enoxacin (p < 0.001), ciprofloxacin and 
Pefloxacin (ρ < 0.05); trough theophylline plasma concentrations were raised 
during co-administration of enoxacin (p < 0.001), and to a lesser degree, during 
Pefloxacin and ciprofloxacin co-administration (p < 0.05). Mean AUC values 
increased during enoxacin (p < 0.001) and Pefloxacin and ciprofloxacin 
administration (p < 0.01). No change in these parameters was measured during 
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Table I Selected pharmacokinetic parameters of theophylline when ingested alone (blank), or during co-medication with enoxacin, 
Pefloxacin, ciprofloxacin, ofloxacin (я = 8) or nalidixic acid (n = 4) (mean ± s.d.). 
Blank 
Enoxacin 
Pefloxacin 
Ciprofloxacin 
Ofloxacin 
Nalidixic acid 
enigmi-') 
6.1 (2.1) 
6.3 (2.0) 
5.7 (1.8) 
5.3 (1.7) 
6.2(1.9) 
6.3 (1.9) 
C^fßgmr1) 
9.2 (1.8) 
19.4 (2.8)*** 
11.0(1.8)* 
11.3 (2.6)* 
8.5 (2.1) 
9.1 (1.8) 
Cmmfrgml-') 
6.3 (2.4) 
16.6 (2.5)*** 
8.6 (2.6)*** 
8.8 (3.1)*** 
6.3 (2.3) 
6.6 (1.6) 
AUCg* (mgl'h) 
146 (67) 
537 (125)*** 
224 (79)** 
222 (100)** 
147 (60) 
138 (48) 
tyjh) 
5.9 (2.5) 
15.3 (5.3)*** 
8.6 (3.6)** 
8.4 (2.4)** 
6.0(2.1) 
5.7 (2.3) 
CL (ml min-') 
85.9 (33.4) 
31.3 (7.8)** 
60.6 (23.8)* 
59.8 (27.4)* 
81.5 (31.1) 
82.4 (15.9) 
CLr (ml min 
7.6(1.5) 
7.2 (1.8) 
7.5 (1.7) 
7.0 (1.6) 
6.6(1.0) 
8.0 (2.7) 
Css = trough theophylline plasma concentration before the administration of the quinolone; Cmax = maximum theophylline plasma 
concentration; Cm,n = trough theophylline plasma concentration; AUCg0 = area under the concentration-time curve of 
theophylline; /./, = observed half-life of theophylline; CL = total body clearance; CLr = renal clearance. 
*p < 0.05, **p < 0.01, ***p < 0.001 
Theophylline plasma cone 
(jjg/ml) 
20 
I S -
IO 
5 -
\ Ι Ι Ι Ι Ι г 
0 2 A 6 
Day of administration 
Figure 1 Mean trough plasma theophylline concentrations in subjects when given alone 
(= blank, O), or during co-administration with ofloxacin (D), Pefloxacin (V), 
ciprofloxacin (A) and enoxacin (•) (+ ρ < 0.001). 
ofloxacin administration. A significant increase in the theophylline half-life was 
seen during the co-administration of enoxacin (p < 0.001), Pefloxacin (ρ < 
0.01) and ciprofloxacin (p < 0.01). Total body clearance of theophylline 
decreased 63.6% during enoxacin co-administration (p < 0.01), 29.4% during 
Pefloxacin co-administration and 30.4% during ciprofloxacin co-administration 
(both ρ < 0.05). No change in the renal clearance occurred during co­
administration of the different quinolones when compared to the blank period. 
During ofloxacin co-medication no change in the theophylline half-life or total 
body clearance was measured. 
After completion of these five study periods, a sixth period was added in four 
of these subjects following the same study design, in which nalidixic acid, 500 
mg twice daily was co-administered. The theophylline parameters did not 
change when compared to the blank period (Table I). 
No correlation could be found between the change in the theophylline AUC 
values or the apparent elimination half-life and the AUC values of the parent 
quinolone. Of the enoxacin dose, 14.7±3.6% was recovered in the urine as 
4-oxo metabolite; of ciprofloxacin and Pefloxacin the urinary recoveries of the 
4-oxo metabolite were 4.3 ±0.9%, and 6.4±1.3% respectively. There was a 
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Figure 2 The increase of the AUC value for theophylline during co-medication with 
enoxacin ( · ) , ciprofloxacin (*) or Pefloxacin (О) compared to the blank AUC, vs the 
urinary excretion in 24 h of 4-oxo quinolone, expressed as % of the ingested dose. 
correlation between the urine recovery of the 4-oxo metabolite (% dose) and the 
increase of theophylline AUC values (r = 0.90) (Figure 2). No 4-oxo metabolite 
could be found in the urine after administration of nalidixic acid and only traces 
after ofloxacin. 
Adverse reactions 
One subject developed complaints of sleeplessness during administration of 
both ofloxacin and ciprofloxacin. Another subject felt depressed and had 
complaints of nausea and diarrhea during ofloxacin, ciprofloxacin and 
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enoxacin administration. One subject had moderate upper abdominal 
complaints on Day 4 and 5 of enoxacin ingestion. One other subject felt languid 
during the whole period of Pefloxacin administration. As stated above, two 
subjects developed complaints during the co-administration of enoxacin and 
theophylline, probably related to the high theophylline plasma concentrations. 
10.4 Discussion 
Infections of the lower respiratory tract occur frequently in patients with 
chronic obstructive pulmonary disease. Recently a group of new antibacterial 
agents of the quinolone class has been developed. Some of these agents, such 
as ciprofloxacin, ofloxacin, Pefloxacin and enoxacin share a good in vitro 
activity on both Gram-positive and Gram-negative bacteria, including 
multiresistant Pseudomonas aeruginosa strains, and show a good penetration 
into bronchial secretions and lung tissue after oral dosing (Bergogne-Bérézin, 
1985). 
A large elevation of theophylline plasma concentrations was reported during 
concomitant treatment with enoxacin in patients, who were hospitalized due to 
an exacerbation in their pulmonary disease. In some of these patients, this 
interaction gave rise to signs and symptoms of theophylline toxicity (Davies et 
al., 1984; Wijnands et al., 1985a). The present study confirms this interaction 
in subjects with stable pulmonary disease, whose only simultaneous treatment 
is with sympathomimetics and corticosteroids, by inhalation. 
In spite of the fact that during concomitant treatment of theophylline with 
ciprofloxacin, Pefloxacin or ofloxacin no clinical signs of theophylline toxicity 
were reported in earlier clinical reports (Davies et al., 1986), this study 
demonstrates that ciprofloxacin and Pefloxacin also influence theophylline 
clearance. The magnitude of this interaction is significantly smaller than the 
effect of enoxacin. Nevertheless, because of the considerable interindividual 
difference in the size of the effect on theophylline clearance, the influence of 
ciprofloxacin and Pefloxacin can be expected to be of clinical importance in a 
proportion of the patients. Recently, Raoof and co-workers (1985) reported in 
60% of patients on concomitant treatment with theophylline and ciprofloxacin 
750 mg twice daily, a significant increase of theophylline plasma concentrations 
from 7.9±4.8 /tg ml - 1 to 18.4±6.5 ¿ig ml"1. A possible interaction between 
ciprofloxacin and theophylline was also reported by Scully & Neu (1985). In 
both studies the ciprofloxacin dose was higher dan the dose used in this study. 
The similarities in chemical structure between enoxacin, ciprofloxacin and the 
yV-methylsubstituted analogues Pefloxacin and ofloxacin (Figure 3) preclude the 
structure of the parent drug being the cause of the interference with the 
theophylline clearance. However, there are differences in the metabolic 
clearance of these four quinolones, especially in the formation of 4-oxo 
quinolone: ofloxacin showed only traces of a 4-oxo metabolite. Nalidixic acid, 
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the oldest quinolone, is metabolized into 7-hydroxy- and 7-carboxynalidixic 
acid without forming a 4-oxo metabolite: the pharmacokinetic parameters of 
theophylline in four subjects on nalidixic acid did not differ from those of the 
blank period. 
A correlation was found between the extent of the interaction and the urinary 
recovery of the 4-oxo metabolite. The 4-oxo group seems therefore to be 
responsible for the interaction with the theophylline clearance. The 4-oxo 
piperazine group shows a chemical structure similar to the N1-N3 part of the 
dimethylxanthine structure. 
Cimetidine, a drug known to inhibit the demethylation processes and which 
has also a strong effect on theophylline clearance has a similar structure in the 
imidazole group. Grygiel et al. (1984) showed that during co-administration 
with Cimetidine, theophylline clearance diminished largely due to reduced N-
demethylation. It is possible that the above mentioned part of the molecule, 
found in Cimetidine and in 4-oxo quinolone, competes with theophylline for 
liver enzymes (Figure 4). 
If simultaneous administration of theophylline and enoxacin is necessary, it 
is recommended to halve the theophylline dose before starting enoxacin and to 
monitor theophylline plasma concentrations daily during the treatment to avoid 
toxicity. In the case of ciprofloxacin and Pefloxacin co-medication, the 
theophylline dose needs no pretreatment adjustment but measurements of 
H'N J 1 
Enoxacin 
H j c - O с
Л 
Pefloxacin 
О А 
Ciprofloxacin 
р с< 
Ofloxacin 
Figure 3 Chemical structures of enoxacin, Pefloxacin, ciprofloxacin, and ofloxacin. 
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Figure 4 Proposed mechanism of the influence of 4-oxo quinolone on the metabolic 
degradation of theophylline. 
theophylline plasma concentrations during treatment are essential, especially in 
patients who develop adverse reactions. In the present study no effect was 
measured during ofloxacin administration. 
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Summary 
Nalidixic acid is metabolized by hydroxylation into 7-hydroxynalidixic acid and 
subsequently by oxidation into 7-carboxynalidixic acid. The half-lives of 
nalidixic acid and its metabolites are 0.7S, 2.5 and S.5 h respectively for each 
of the three phases in the plasma elimination-time curves. 
Plasma protein binding of nalidixic acid is 95% and that of 
7-hydroxynalidixic acid 65*70. The renal clearance of nalidixic acid varies 
between 2 and 25 ml/min and that of 7-hydroxynalidixic acid between 37 and 
162 ml/min. 
Nalidixic acid is for 42% glucuronidated and for 40% hydroxylated. The 
hydroxy metabolite is for 57% glucuronidated, for 11% oxidized and for 32% 
excreted unchanged. 7-Carboxynalidixic acid is excreted in the urine and not 
glucuronidated. The balance between glucuronidation and hydroxylation of 
nalidixic acid depends on the enzymic composition of the individual, not on a 
hydroxylator or glucuronidator phenotype. The variation in this balance 
belongs to a normal distribution. The variation in the ratio 
glucuronidation/renal excretion of the 7-hydroxy metabolite also is part of a 
normal distribution. 
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11.1. Introduction 
Nalidixic acid is the first clinically applied quinolone derivative. The drug is 
metabolized into 7-hydroxynalidixic acid, which has equal antibacterial potency 
and further into 7-carboxynalidixic acid, which has lost its activity (McChesney 
et al., 1964) (figure 1). The carboxy group in nalidixic acid and the 7-hydroxy 
metabolite is partly glucuronidated, and the glucuronide is then excreted by the 
kidney (McChesney et al., 1964; Portmann et al., 1966a; Ferry et al., 1981; 
Männistö et al., 1976). 
Members of the quinolone group show a strong and clinically relevant 
interaction with the metabolism of theophylline (Wijnands et al., 1985). There 
is evidence that this interaction depends on the presence of a 4-oxo group in the 
piperazinyl substituent at the 7-position, as found for example in enoxacin, 
ciprofloxacin and Pefloxacin. Nalidixic acid itself does not interfere with 
theophylline metabolism (Wijnands et al., 1986). In these interaction 
experiments, it was observed that the yield of 7-hydroxynalidixic acid in blood 
and urine varied considerably among the patients, and it was questioned 
whether this variation might be due to a hydroxylator or a glucuronidator 
phenotype. 
The aims of this investigation were: 
a) to assess pharmacokinetic properties of nalidixic acid, 
b) to detect a possible hydroxylator or glucuronidator phenotype in the 
metabolism of nalidixic acid, 
c) to quantify the ratio between hydroxylation and glucuronidation of nalidixic 
acid, 
d) to quantify the ratio between oxidation and glucuronidation of 
7-hydroxynalidixic acid. 
CH 
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Figure 1 Molecular structures of nalidixic acid and its 7-hydroxy and 7-carboxy 
metabolites. 
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11.2. Materials and methods 
Subjects 
Fourteen healthy Caucasian subjects (5 females and 9 males) with ages ranging 
from 20 to 55 years, gave their informed consent to volunteer in the study. A 
single oral dose of one gram nalidixic acid was administered as a tablet. 
Sampling procedures 
Blood. 2 ml blood samples were collected at regular time intervals by means of 
fingertip puncture with Monolet® lancets (Monoject, St. Louis, USA). After 
centri fugat ion plasma samples were stored at -20 oC pending analysis. 
Urine. Urine was collected on spontaneous voiding for a 72 h period. Urinary 
pH was measured immediately after collection. Measurements were made with 
a Radiometer (Copenhagen PMH61) instrument. Urine samples of 5 ml were 
stored at -20°С pending analysis. 
Drugs 
Nalidixic acid, 7-hydroxynalidixic acid and 7-carboxynalidixic acid were 
obtained from Sterling Winthrop (Newcastle upon Tyne, UK). 
Drug analysis 
The concentration of nalidixic acid and its metabolites in plasma and urine was 
measured by means of HPLC. A Spectra Physics 3500B high performance 
liquid Chromatograph was used equipped with a spectrophotometric detector 
(Spectroflow 757, Kratos, USA) connected to a 10 mV recorder. The column 
(25 cm χ 4.6 mm ID) was packed with Spherisorb 5-ODS (Chrompack, 
Middelburg, The Netherlands). An injection loop of 100 μ\ was used. The 
mobile phase consisted of 1 gram of phosphoric acid and 0.25 gram of 
tetramethylammoniumchloride dissolved in 580 ml of water, 210 ml of 
dimethylformamide and 210 ml of acetonitrile. All reagents were of analytical 
grade. The solvent flow rate was 1.6 ml/min. Detection of the nalidixic acid 
derivatives was effected at 334 nm. The assay was carried out at room 
temperature. Retention times was 7.4 min for nalidixic acid, 3.2 min for 
7-hydroxynalidixic acid and 3.5 min for 7-carboxynalidixic acid. Calibration 
curves were made by adding known quantities of nalidixic acid and its 
metabolites to blank human plasma and urine (correlation coefficients of 
0.999). 
The recovery from plasma for nalidixic acid (concentration range 0.3-30 
/¿g/ml; η = 6)) was 45.6 ±1.7%; for 7-hydroxynalidixic acid (concentration 
range 0.13-13 /¿g/ml, η = 6) 78.4 ±2.4% and for 7-carboxynalidixic acid 
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(concentration range 0.1-10 pg/ml; η = 6) 72.1 ± 1.2%. The recovery from urine 
for nalidixic acid (range 3-1000 /ig/ml; n = 6) was 100±1.8%; for 
7-hydroxynalidixic acid (range 1.3-1300 /ig/ml; n = 6) 100±1.507'о; for 
7-carboxynalidixic acid (range 1-50 /tg/ml; n = 6) 100±3.4%. 
The precision is 100± 1.647ο for nalidixic acid, 100±1.1% for 
7-hydroxynalidixic acid and 100±3.4% for 7-carboxynalidixic acid (n = 6). 
Deglucuronidation 
To 0.1 ml of plasma was added 25 μΐ of a /3-glucuronidase solution (from 
Escherichia coli), 1000 U per 10 ml of phosphate buffer at pH 6.8 (Sigma, St. 
Louis, MO, USA). The solution was incubated at 37CC. After 16 h of 
incubation 0.3 ml of 5% trichloroacetic acid was added, mixed thoroughly and 
centrifugated at 2600 g. A 100 μΐ volume of the clear supernatant was injected 
onto the column. 
To 10 μΐ of urine was added 50 μΐ of the /3-glucuronidase solution. The 
solution was incubated at 370C for 16 h, then 0.4 ml of trichloroacetic acid 5% 
was added, mixed and centrifuged. A 100 μΐ volume of the clear supernatant was 
injected onto the column. 
Protein binding 
Protein binding of nalidixic acid and its metabolites, 7-hydroxy- and 
7-carboxynalidixic acid, was measured by means of EMIT® Free level filters 
(SYVA, Palo Alto, USA; Merck, Amsterdam) in six different plasma samples 
over the concentration range 10-100 /ig/ml. The average protein binding (± 
S.D.) for nalidixic acid and 7-hydroxynalidixic acid was calculated. 
Renal clearance fCl
r
) 
The apparent renal clearance values of nalidixic acid and its metabolites were 
calculated from the average renal excretion rate in each urine sample, divided 
by the plasma concentration at the midpoint of the measured time interval. For 
the calculation of the apparent renal clearance values, the total plasma 
concentration was used. 
Statistics 
The basic statistical calculations were performed with the Statistical Analysis 
System (SAS) (SAS User's Guide, 1982). Test of Normality was performed with 
Shapiro-Wilk statistics (Shapiro & Wilk, 1965). 
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11.3. Results 
Figure 2 shows the plasma concentration-time curves and renal excretion rate-
time profiles of nalidixic acid (N), its glucuronide (Ngluc) the metabolite 
7-hydroxynalidixic acid (NOH), its glucuronide (NOHgluc) and the metabolite 
7-carboxynalidixic acid (N-COOH) in a volunteer after an oral dose of 1 gram 
of nalidixic acid. In the plasma elimination curve three phases can be 
distinguished, characterized by the half-lives of respectively 1.1, 2.2 and 7 h. 
The metabolite 7-hydroxynalidixic acid shows two phases with the half-lives of 
resp. 2.2 and 7 h. No glucuronides of nalidixic acid and 7-hydroxynalidixic acid 
are found in the plasma. Table I summarizes the half-lives, renal clearances and 
protein binding values of nalidixic acid and its metabolite 7-hydroxynalidixic 
acid in the 14 volunteers. 
Figure 2 Plasma concentration-time curves and renal excretion rate-time profiles of 
nalidixic acid (N), its glucuronide (Ngluc), the metabolite 7-hydroxynalidixic acid 
(NOH), its glucuronide (NOHgluc), and the metabolite 7-carboxynalidixic acid (N-
COOH) in a volunteer after an oral dose of 1 gram nalidixic acid. 
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Table I. Half-life, renal clearance and protein binding of nalidixic acid and 
7-hydroxynalidixic acid (mean ± S.D.) 
Subj. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
half-life (h) 
N 
0.75 + 2.1 
0.75 + 1.5 
1.5 
1.0 
0.75 + 2.5 
0.75 + 2.0 
1.0 +2.2 
0.75 + 5.5 
0.75+1.5 
1.0 
1.5 
1.2 +2.5 
0.75 
1.0 +4.5 
NOH 
1.5 + 2.5 
2.0 
2.0 
1.5 
2.5 
2.5 
2.2 
1.0 + 6.0 
1.5 
2.5 
2.5 
1.5 + 2.5 
1.0 
2.0 + 4.5 
renal clearance ml/min 
N 
11.2( 2.9) 
25.1(17.8) 
22.5( 8.6) 
18.0( 3.1) 
2.1( 2.3) 
18.0(15.0) 
4.0( 2.2) 
3.5( 2.0) 
5.1( 3.5) 
— 
-
9.5( 4.5) 
3.0( 1.7) 
5.5( 2.9) 
NOH 
37.9( 8.7) 
50.1(51.1) 
86.2(35.7) 
121 (31.0) 
55.7(30.0) 
93.1(40.0) 
51.5(35.9) 
98.4(53.1) 
86.0(25.2) 
-
-
108 (23.1) 
162(51) 
60.6(43) 
protein binding Ψο 
N 
— 
-
-
-
94.1(5.14) 
-
95.0(2.0) 
-
95.9(0.14) 
-
-
93.8(1.60) 
91.2(0.14) 
94.0(2.0) 
NOH 
— 
-
-
-
62.4(8.62) 
-
63.0(3.47) 
-
68.9(4.46) 
-
-
65.9(4.20) 
52.5(4.91) 
48.9(2.92) 
N = nalidixic acid, NOH = 7-hydroxynalidixic acid 
Table II Percentage of the nalidixic acid dose (1000 mg) excreted in the urine (mean 
± S.D.). 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
N 
3.7 
5.2 
5.0 
3.9 
0.3 
0.7 
0.6 
0.6 
0.1 
0.2 
1.3 
0.1 
0.4 
0.8 
1.6(1.9) 
Ngluc 
31.5 
42.3 
62.3 
42.9 
43.1 
45.5 
73.3 
51.3 
28.4 
27.5 
25.6 
43.5 
42.3 
45.1 
42.2(14.8) 
NOH 
9.3 
15.4 
8.1 
12.7 
10.9 
15.8 
5.5 
13.9 
22.5 
19.3 
30.9 
22.2 
19.2 
11.3 
14.7(6.6) 
NOHgluc 
49.4 
32.5 
21.0 
28.8 
30.1 
27.5 
17.3 
20.7 
21.8 
20.5 
33.2 
30.8 
25.5 
33.1 
27.2(9.2) 
N-COOH 
9.0 
4.6 
3.7 
11.6 
4.3 
5.9 
2.3 
2.7 
5.6 
5.1 
8.4 
2.9 
3.9 
4.8 
5.1(2.7) 
Total 
102.9 
100.1 
100.1 
99.9 
88.7 
95.4 
99.1 
89.2 
80.2 
72.6 
99.4 
99.5 
99.5 
95.1 
94.4(8.8) 
N = nalidixic acid, Ngluc = nalidixic acid glucuronide, NOH = 7-hydroxynalidixic 
acid, NOHgluc = 7-hydroxynalidixic acid glucuronide, NCOOH = 7-carboxynalidixic 
acid 
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The renal excretion rate-time profiles of the parent drug and the metabolites 
show two phases with half-lives of 2 and 7 h respectively. Table II summarizes 
the percentage of the dose excreted in the urine as unchanged parent drug and 
the metabolites. Approximately the complete administered dose is excreted in 
the urine, predominantly as nalidixic acid glucuronide (42,Уо) and as 
7-hydroxynalidixic acid and its glucuronide (42%). 1.63 ± 1.92% of the dose is 
excreted unchanged and nalidixic acid is partly glucuronidated and thereafter 
excreted (42.2 ± 14.8%; range 28.4%-73.3%). Approximately 40% of the dose 
is hydroxylated to 7-hydroxynalidixic acid (14.7 ±6.6%) and its glucuronide 
(27.2 ±9.2%). Only a small percentage of the dose (5.1 ±2.7%) is further 
oxidized to 7-carboxynalidixic acid which is excreted in the urine without 
further conjugation. There was a wide interindividual variation of the 
hydroxylation (phase I) and glucuronidation (phase II) pathway of nalidixic 
acid (Figure 3). This variation belongs to a normal distribution (Shapiro-Wilk 
test) which is also reflected in the correlation coefficient of the linear regression 
(r = 0.935). 
100% hydroxylation 1 
glucuronidation 
Figure 3 The yield of hydroxylation plotted versus the glucuronidation of nalidixic 
acid. The solid dots represent the sum of 7-hydroxynalidixic acid (OH) and its 
glucuronide (OHgluc) while the open dots represent all metabolic pathways following the 
hydroxylation. 
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100% glucuromdation 
60 
¿.О 
20 
Hydroxy na l id ix ic acid 
10 Ί 1 1
 — 
20 30% 
oxidation 
Figure 4 The yield of glucuromdation plotted versus the oxidation of 
7-hydroxynalidixic acid. 
Figure 4 shows the competition between the two metabolic elimination 
pathways of 7-hydroxynalidixic acid, i.e., glucuromdation (conjugation) and 
oxidation to 7-carboxynalidixic acid. There is a variation between the two 
metabolic pathways of 7-hydroxynalidixic acid. This variation belongs to a 
normal distribution (Shapiro-Wilk test) which is also reflected in the correlation 
coefficient of the linear regression (r = 1.00). Fig 5 shows that glucuromdation 
of 7-hydroxynalidixic acid is the predominant pathway of elimination. 
The mass balance of nalidixic acid and the normalized (set at 100%) mass 
balance of the metabolite 7-hydroxynalidixic acid are shown in figure 6. The 
yield of glucuronidation of both nalidixic acid and its 7-hydroxy metabolite are 
similar. The yield of the formation of 7-hydroxynalidixic acid is approximately 
5 times higher than that of the oxidation to 7-carboxynalidixic acid. 
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Figure 5 The yield of glucuronidation plotted versus the renal excretion of the 
unchanged metabolite 7-hydroxynalidixic acid. (Solid dots represent 7-hydroxynalidixic 
acid itself and the open dots the sum of 7-hydroxy and 7-carboxynalidixic acid). 
A 2 % 
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Nalidixic acid 
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100%* 
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Figure 6 Mass balance of nalidixic acid and its metabolite 7-hydroxynalidixic acid 
(small printed figures). 
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11.4. Discussion 
Nalidixic acid was measured initially by spectrophotometric methods 
(McChesney et al., 1964; Männistö et al., 1976; Brühl et al., 1973) which lacks 
sufficient product specificity to establish the kinetics of the parent drug and the 
metabolites. Portmann et al. (1966a; 1966b) studied the kinetics of nalidixic acid 
and metabolites by separate administration of parent drug and 
7-hydroxynalidixic acid. A thin-layer chromatographic method was reported 
(Hundt & Barlow, 1981), but HPLC analysis of nalidixic acid and its 
metabolites is now the method of choice (Cuisinaud et al., 1980; Sorel et al., 
1980). 
Nalidixic acid is rapidly metabolized by a phase I hydroxylation in 7-hydroxy-
nalidixic acid and by a phase II glucuronidation in its glucuronide. Both 
reactions have similar yields and rates as was reported earlier (McChesney et al., 
1964; Portmann, 1966a). 
The plasma concentration-time curve shows sometimes three phases, 
characterized by a half-life of respectively 0.75 h, 2 h and 7 h. The renal 
excretion rate-time profile only shows the half-lives of 2 and 7 h. The terminal 
half-life in plasma is observed in one patient, and in all patients in the renal 
excretion rate-time profiles. The short half-life of 0.75 h must be due to the high 
rates of glucuronidation and hydroxylation. 
The renal excretion of nalidixic acid is negligible (1.6%) and its renal 
clearance is low, 2-10 ml/min (McChesney et al., 1964; Ferry et al., 1981). The 
metabolite 7-hydroxynalidixic acid is mainly glucuronidated (54%), excreted 
unchanged (30%) and only for a minor part (10%) further oxidized in 
7-carboxynalidixic acid. The latter compound is excreted as such, it is not 
glucuronidated (McChesney et al., 1964). The rate of formation of 
7-hydroxynalidixic acid is approximately 5 times higher than its rate of 
elimination by oxidation of the 7-hydroxy group. Glucuronidation of both 
nalidixic acid and its 7-hydroxy metabolite takes place with comparable rates 
and yields at the carboxy group at the 3 position (Portmann, 1966a; Portmann, 
1966b). The second carboxy group at the 7 position prevents glucuronidation. 
When a piperazine group is substituted at the 7 position, as is found with the 
quinolones ciprofloxacin, enoxacin, Pefloxacin, and ofloxacin, glucuronidation 
of the carboxy group is also prevented. Hydroxylation of nalidixic acid 
increases the renal clearance by a factor 10 (Vree et al., 1986). The renal 
clearance of the glucuronides and of 7-carboxynalidixic acid could not be 
measured as these compounds were not present in the plasma of the volunteers. 
7-Hydroxynalidixic acid is partly excreted by active tubular secretion because it 
was reported that probenecid reduces its renal clearance from 40 ml/min to 17 
ml/min (Cuisinaud et al., 1982). Old age and reduced kidney function reduce 
the renal clearance of nalidixic acid glucuronide, of 7-hydroxynalidixic acid 
with its glucuronide and of 7-carboxynalidixic acid and increases the half-life 
of all compounds (Barbeau & Belanger, 1982; Vree et al., 1986). 
133 
The yields of the metabolic pathways of glucuronidation and hydroxylation 
of nalidixic acid showed a large variation. The ratio between these pathways 
belongs to a normal distribution and seems therefore to depend on the 
individual. A similar distribution is found for the yield of the glucuronidation 
and oxidation of 7-hydroxynalidixic acid. Part of this variation may be caused 
by variation in the urine pH (McChesney et al., 1964; Ferry et al., 1982). 
Although in the present study the average urine pH values varied between 5.83 
and 6.64, this variation is too small to be reflected in the percentage of the dose 
excreted in the urine. It is concluded that the differences in hydroxylation and 
glucuronidation are not caused by a difference in phenotype between the 
patients. The main elimination pathways for nalidixic acid was assesed being 
hydroxylation and glucuronidation. The specific rates and yields depend on the 
enzymic composition of the subject. The metabolite 7-hydroxynalidixic acid is 
more glucuronidated and excreted (57%) than excreted unchanged (32%) and 
oxidized into the 7-carboxy metabolite (11%). This last metabolite is rapidly 
excreted unchanged and therefore not detectable in subjects with a normal 
kidney function (Barbeau & Belanger, 1982; Cuisinaud et al., 1982; Ferry et al., 
1981; McChesney et al., 1964). 
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Summary 
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CHAPTER 1 describes the development of the fluorinated quinolones, 
analogues of nalidixic acid. The objectives of the studies performed are 
outlined. 
In CHAPTER 2, a short introduction to the quinolones' mechanism of action, 
their in vitro activity on respiratory pathogens, and the early clinical experience 
with respiratory tract infections is presented. 
In CHAPTER 3, a high performance liquid chromatographic (HPLC) method 
is described for the analysis of enoxacin and its major metabolite 4-oxo 
enoxacin in human plasma, urine and saliva. 
Pharmacokinetic data obtained from 2 healthy volunteers after single oral 
doses of 400 mg and 600 mg enoxacin are presented. Approximately fifty 
percent of the ingested enoxacin dose was recovered from the urine. 
In CHAPTER 4, pharmacokinetic data for orally administered enoxacin are 
presented. Absorption and clearance processes were first studied in 4 healthy 
volunteers after administration of single 400 mg and 600 mg doses. Enoxacin 
proved to be quickly absorbed. The absorption rate decreased when enoxacin 
was ingested after fasting. Probenecid decreased the renal clearance of enoxacin 
and the 4-oxo metabolite, indicating a renal clearance by glomerular filtration 
and active tubular secretion. 
In 19 patients with respiratory tract infections, plasma- and sputum 
concentration-time curves for enoxacin and 4-oxo enoxacin were made both 
after a single dose and in steady-state, at the third day of administration. 
Enoxacin was administered in a dose of 400 mg, twice daily in 8 patients and 
in a dose of 600 mg, twice daily in 11 patients. The penetration from blood into 
sputum appeared to be approximately 100%. The plasma and sputum 
concentrations obtained were above MIC values for most respiratory 
pathogens, including most Pseudomonas aeruginosa strains, but not for 
Streptococcus pneumoniae. 
Finally, the enoxacin concentration in lung tissue was measured in 15 
patients. The mean tissue concentration 2.8 ±0.6 hours after administration of 
a single 600 mg dose was 7.0±3.6 /ig/g tissue, while the mean plasma 
concentration at the same time was 1.8 ± 1.1 /¿g/ml. Lung tissue concentrations 
of enoxacin appeared to be significantly higher than the corresponding plasma 
concentrations. 
In CHAPTER 5, measurements of ofloxacin concentrations in lung tissue in 11 
patients after a single oral 600 mg dose are presented. Using a specific enzymatic 
method which measures the peroxidase activity of hemoglobin bound to 
haptoglobin, the blood content in lung tissue samples was assessed. The mean 
volume of blood admixture was 0.12 ± 0.05 ml/g tissue. After correction for the 
blood content, the mean ofloxacin tissue concentration 2.0±0.8 hours after 
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ingestion was 17.7 ± 9.2 jtg/g, while the mean plasma concentration at the same 
time was 8.7 ±4.2 /tg/ml. 
After a single 600 mg dose ofloxacin lung tissue concentrations were 
concluded to be significantly higher than the plasma concentrations and well 
above MIC values for most respiratory pathogens. 
CHAPTER 6 describes the results of a comparative pharmacokinetic study with 
the quinolones ciprofloxacin, ofloxacin, Pefloxacin, and enoxacin in steady-
state. The quinolones were administered orally for 5.5 days in a random 
sequence to 8 volunteer patients, who were on maintenance treatment with the 
bronchodilator theophylline: Pefloxacin 400 mg b.i.d., ciprofloxacin 500 mg 
b.i.d., ofloxacin 400 mg b.i.d., and enoxacin 400 mg b.i.d. 
The mean maximum plasma concentrations of Pefloxacin (7.5 ±1.9 /ig/ml) 
and ofloxacin (5.9±0.9 /ig/ml) were significantly greater than the maximum 
concentrations of enoxacin and ciprofloxacin. Pefloxacin was extensively 
metabolized. Elimination half-lives ranged from 3.9 hours for ciprofloxacin to 
12.2 hours for Pefloxacin. 
The plasma parameters and recovery from urine of the 4 quinolones showed 
no notable differences when compared with the available data obtained from 
healthy volunteers. 
It is improbable that theophylline greatly influences the metabolic clearance 
of these quinolones. 
CHAPTER 7 gives the results of an open, noncomparative study aimed at 
assessing the efficacy and safety of enoxacin in lower respiratory tract 
infections. Forty-one patients suffering from chronic bronchitis with a chronic 
pulmonary function impairment were studied; 22 of them had also signs of 
emphysema and 20 had proven bronchiectasis, often extensive. Special attention 
was paid to infections caused by Pseudomonas aeruginosa. Pseudomonas 
infections were treated with enoxacin 600 mg twice daily, whereas infections 
caused by other bacteria were treated with 400 mg twice daily. In 43 of the 45 
treatment periods efficacy could be evaluated. An overall clinical improvement 
or cure was obtained in 20 of the 23 Pseudomonas infections. However, after 
a mean treatment duration of 14.3 days, in only 6 cases was Pseudomonas 
eradicated from the sputum. 
The bacteriological results of infections caused by other bacteria was good, 
as in 18 of the 20 cases the causative bacteria was eradicated. Staphylococcus 
aureus was not eradicated in 2 patients. Superinfections with streptococci were 
observed in 3 patients. Almost all persisting Pseudomonas strains had increased 
enoxacin MIC values, in comparison with the pre-treatment MIC values. In 29 
of the 45 treatment periods, adverse effects occurred. They were mainly related 
to the gastro-intestinal tract. In several cases, severe reactions developed related 
to the central nervous system, such as a state of agitation, tremor, and visual 
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hallucinations in one patient. Theophylline plasma concentrations rose in 25 of 
the 30 patients on concomitant theophylline treatment. 
Enoxacin proved to be an effective agent for lower repiratory tract infections, 
except for those caused by Gram-positive bacteria. 
CHAPTER 8 reports the results of further bacteriological investigations on 
selected Pseudomonas strains, which persisted during treatment with enoxacin 
and showed diminished susceptibility to the fluorinated quinolones. The 
objectives were to study if pre- and post-treatment isolates were isogenic, and 
to study the mechanism and duration of the observed decreased susceptibility 
to quinolones and unrelated drugs, such as beta-lactams and aminoglycosides. 
The data obtained by 4 different typing procedures indicated that the pairs 
of strains, isolated from the sputum of individual patients before and after 
treatment with enoxacin, were very closely related and can be concluded to be 
isogenic. 
The susceptibility to Pefloxacin, ofloxacin, and ciprofloxacin was also found 
to be decreased. In 2 of the 4 measured strains this decreased susceptibility was 
still present after 16 and 257 days, respectively. 
In 4 cases a concurrent increase of MIC values of beta-lactams, and in 2 cases 
of aminoglycosides was measured. In one post-treatment strain, in which a 
decreased susceptibility to quinolones, beta-lactams, and aminoglycosides 
occurred, a decreased uptake of C'Mabeled enoxacin was demonstrated. This 
isolate appeared to lack outer membrane protein F. In another post-treatment 
strain an isolated decreased susceptibility to quinolones occurred, probably due 
to an altered DNA gyrase by a GyrA mutation. In one strain, the decreased 
susceptibility to beta-lactams could be related to different concentrations of the 
same beta-Iactamase. No aminoglycoside modifying enzymes were detected. 
CHAPTER 9 describes the clinical experience of unexpectedly high plasma 
theophylline concentrations documented by daily measurements in 14 patients, 
treated concurrently with theophylline and enoxacin. In 6 of these patients, an 
analysis of the mechanism for this observation has been carried out under more 
controlled conditions. 
Mean plasma theophylline concentrations rose significantly from 8.4 ¿tg/ml 
prior to administration of enoxacin to 15.0 /ig/ml at day 3 of enoxacin 
treatment. Plasma protein-binding and renal clearance of theophylline 
remained unchanged, whereas the total body clearance of theophylline 
decreased significantly. 
From these observations it was concluded that the elevation of plasma 
theophylline concentrations was caused by a reduced metabolic clearance of 
theophylline. 
CHAPTER 10. Due to both the clinical importance of this interaction between 
enoxacin and theophylline, and the close chemical structure resemblance of 
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Ciprofloxacin, ofloxacin, and peñoxacin to enoxacin, a comparative study with 
these drugs was started to see if they produced a similar effect on theophylline 
clearance. Eight patients volunteered in 5 study periods, in which the 
pharmacokinetic parameters of theophylline were assessed when taken alone, 
and during co-administration with ciprofloxacin, ofloxacin, Pefloxacin, and 
enoxacin. In 4 patients a sixth period was added, in which nalidixic acid was 
co-administered. 
Compared to the control period, in which only theophylline was 
administered, the total body clearance of theophylline decreased significantly 
during enoxacin (63.3%), ciprofloxacin (30.4%), and Pefloxacin (29.4%) co-
administration. The pharmacokinetic parameters of theophylline were not 
influenced by ofloxacin or by nalidixic acid. There was a correlation found 
between the urinary recovery of the 4-oxo metabolite, formed in enoxacin, 
ciprofloxacin, and Pefloxacin and the increase of the theophylline AUC values. 
Thus there is evidence, that this metabolic interaction is mediated not by the 
parent drugs, but by their 4-oxo metabolite. 
CHAPTER 11. During the measurements of nalidixic acid and its metabolites, 
it was observed that the yield of 7-hydroxynalidixic acid in blood and urine 
varied considerably among the patients. For this reason, a study was started in 
fourteen volunteers, aimed at detecting a possible hydroxylator or 
glucuronidator phenotype in the metabolism of nalidixic acid. 
The variation in hydroxylation and glucuronidation, the main elimination 
pathways for nalidixic acid, were found not to be the result of a phenotype 
difference among the patients. The specific rates and yields will depend on the 
enzymic composition of the patient. 
In conclusion, due to the limited activity on Gram-positive bacteria, in 
particular streptococci, the new quinolone derivatives cannot be recommended 
as first choice antibacterial agents in respiratory tract infections. Highly potent 
compounds such as ciprofloxacin and ofloxacin may be of value in cases in 
which multiresistant bacteria are involved, for example in infections caused by 
Pseudomonas aeruginosa. 
Until more data have become available about the mechanism and the 
frequency of the severe adverse reactions related to the central nervous system 
and about the incidence of highly resistant mutants, the application of these 
products has to be limited to clinically supervised use. 
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Samenvatting 
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In dit laatste hoofdstuk wordt een beknopte samenvatting gegeven van de in dit 
proefschrift gepresenteerde onderzoeken. 
Quinolonen zijn synthetische antibiotica, chemisch verwant aan 
nahdixinezuur, dat sinds 1963 wordt toegepast bij urineweginfecties. De 
antibacteriële activiteit komt tot stand door beïnvloeding van het bacteriële 
DNA, via remming van het DNA-gyrase. In tegenstelling tot nahdixinezuur, dat 
slechts actief is tegen een beperkt spectrum van Gram-negatieve bacteriën, 
bezitten de recent ontwikkelde, gefluoreerde quinolonen, zoals ciprofloxacin, 
ofloxacin, Pefloxacin en enoxacin, activiteit tegen een breed spectrum van zowel 
Gram-negatieve als Gram-positieve micro-organismen. 
De quinolonen worden na orale toediening snel geabsorbeerd en in 
vergelijking met nahdixinezuur beduidend langzamer via de nieren 
uitgescheiden. Door deze eigenschappen worden in het bloed en de weefsels 
gedurende meerdere uren concentraties bereikt die hoog genoeg zijn om een 
bactericide werking mogelijk te maken. 
Patiënten met een CARA hebben een verhoogd risico op het ontwikkelen van 
luchtweginfecties. Door herhaalde toepassing van antibiotica kunnen bacteriën 
ongevoelig worden voor de beschikbare middelen; de ontwikkeling van nieuwe 
middelen blijft dan ook noodzakelijk. Onze interesse in deze nieuwe groep 
quinolonen ging echter op de eerste plaats uit naar de mogelijkheid van orale 
toediening bij infecties veroorzaakt door Gram-negatieve bacteriën zoals 
Pseudomonas aeruginosa. Voor de behandeling van deze infecties zijn tot op dit 
moment slechts antibiotica voorhanden voor parenterale toediening. Een lan-
gerdurende behandeling hiermee betekent voor de patiënt een grote belasting. 
In HOOFDSTUK 1 wordt een overzicht gegeven van de ontwikkeling van de 
gefluoreerde quinolonen. De doelstellingen van de verschillende studies waren 
de volgende: 
- De farmacokinetische eigenschappen van de 4 genoemde quinolonen en hun 
belangrijkste metabolieten werden bestudeerd. 
- Er werd een niet-vergelijkend onderzoek verricht met enoxacin bij lagere 
luchtweginfecties. 
- Pseudomonas aeruginosa stammen, geïsoleerd uit het sputum voor en na 
behandeling met enoxacin, werden verder onderzocht i.v.m. het ontwikkelen 
van een verminderde gevoeligheid voor quinolonen. 
- Onderzoek werd verricht naar een mogelijke invloed van enoxacin op de 
klaring van theofylline, n.a.v. de klinisch waargenomen stijging van theofylline-
spiegels tijdens gelijktijdige toediening van enoxacin. In een latere fase werden 
bij dit onderzoek tevens ciprofloxacin, ofloxacin, Pefloxacin en nahdixinezuur 
betrokken. 
- Omdat bij de onderzoeken met nahdixinezuur een grote interindividuele 
variatie bleek te bestaan in de mate van hydroxylering werd een nader 
onderzoek verricht naar de aanwezigheid van verschillende fenotypen van de 
hydroxylering of glucuronidering. 
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In HOOFDSTUK 2 wordt ingegaan op het werkingsmechanisme van de 
quinolonen en de in vitro activiteit tegen pathogenen die frequent betrokken zijn 
bij luchtweginfecties. De beschikbare literatuur omtrent de effectiviteit van de 
gefluoreerde quinolonen bij deze infecties wordt besproken, alsmede de 
opgetreden bijwerkingen. 
HOOFDSTUK 3 beschrijft een gevoelige en specifieke HPLC-methode voor de 
bepaling van enoxacin en 4-oxo enoxacin in bloed, urine en speeksel. De 
resultaten van de metingen bij 2 gezonde vrijwilligers na een eenmalige dosering 
van 400 mg en 600 mg enoxacin worden gepresenteerd. Vijftig percent van de 
ingenomen hoeveelheid enoxacin werd teruggevonden in de urine. Enoxacin 
wordt voornamelijk renaal geklaard. 
In HOOFDSTUK 4 wordt een pharmacokinetisch onderzoek met enoxacin 
beschreven. 
De plasma-concentratie en -klaring van enoxacin en de 4-oxo metaboliet 
werden eerst gemeten bij 4 gezonde vrijwilligers na orale toediening van 400 mg 
of 600 mg enoxacin. De stof werd snel in het bloed opgenomen; bij 2 
proefpersonen bleek de absorptie lager wanneer enoxacin nuchter werd 
ingenomen, dan bij opname na een ontbijt. Behoudens glomerulaire filtratie 
speelt bij de renale klaring actieve tubulaire excretie een rol. Dit kon worden 
aangetoond middels gelijktijdige toediening van probenecid. 
Vervolgens werden bij 19 patiënten op de eerste en derde dag van behandeling 
met enoxacin, 2 x daags 400 mg of 600 mg, de concentraties van enoxacin en 
4-oxo enoxacin gemeten in plasma, sputum en urine. De concentraties in het 
sputum bleken vergelijkbaar met de plasmaconcentraties en hoger dan de 
minimum remmende concentraties (MIC's) voor een aantal bacteriën, die 
frequent betrokken zijn bij lagere luchtweginfecties, inclusief Pseudomonas 
aeruginoisa. De MIC-waarden voor Streptococcus pneumoniae werden echter 
niet bereikt. 
De enoxacin-concentratie in longweefsel werd gemeten bij 15 patiënten na een 
eenmalige toediening van 600 mg enoxacin. Na gemiddeld 2,8 uur bedroeg de 
longweefselconcentratie 7,0/tg/gram weefsel bij een gelijktijdige concentratie in 
het plasma van 1,8 ^g/ml. 
In HOOFDSTUK 5 worden de resultaten beschreven van de meting van 
ofloxacin-concentraties in longweefsel bij 11 patiënten na een eenmalige orale 
dosis van 600 mg. 
Om een indruk te krijgen van de hoeveelheid bloed die in de longweefsel-
monsters aanwezig was, werd het hemoglobinegehalte gemeten met een 
specifieke enzymatische methode. Gemiddeld bedroeg het volume bijgemengd 
bloed 0,12 ml/gram weefsel. Twee uur na inname was de ofloxacin-concentratie 
in het weefsel, na correctie voor de bloedbijmenging, 17,7 /¿g/gram, bij een 
gelijktijdige waarde in het plasma van 8,7 /tg/ml. De MIC-waarden voor de 
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meeste respiratoire pathogenen liggen belangrijk lager dan de gemeten 
concentraties in longweefsel en plasma. 
HOOFDSTUK 6 beschrijft de resultaten van een vergelijkend farmaco kinetisch 
onderzoek met ciprofloxacin, enoxacin, ofloxacin en Pefloxacin bij 8 patiënten 
met een chronische bronchitis, tijdens onderhoudsbehandeling met de 
bronchusverwijder theofylline. In opeenvolgende meetperioden werden 
enoxacin (2x400 mg), ofloxacin (2x400 mg), Pefloxacin (2x400 mg) en 
ciprofloxacin (2 x 500 mg) ingenomen. De meting van de kinetische parameters 
werd verricht op de vijfde dag van toediening. 
De hoogste plasma concentraties werd bereikt met Pefloxacin (7,5 /tg/ml) en 
ofloxacin (5,9 ¿ig/ml). Voor enoxacin (3,2 /ig/ml) en ciprofloxacin (2,0 /¿g/ml) 
werden lagere waarden gemeten. 
De halfwaardetijd van Pefloxacin was het langste met 12,2 uur. Vergelijkbare 
waarden werden gemeten bij ofloxacin en enoxacin: respectievelijk 7,0 en 6,7 
uur. Ciprofloxacin werd belangrijk sneller geklaard gezien de halfwaardetijd 
van 3,9 uur. De uitscheiding in de urine toonde eveneens een grote variatie: van 
de ingenomen hoeveelheid ofloxacin werd in totaal 68,3% teruggevonden, 
grotendeels onveranderd. Van de Pefloxacin werd 60,2% met de urine 
uitgescheiden in 12 uur, grotendeels in de vorm van metabolieten. 
De resultaten van deze metingen bij patiënten die gelijktijdig werden 
behandeld met theofylline, werden vergeleken met de beschikbare 
literatuurgegevens van onderzoek, verricht bij gezonde vrijwilligers. Duidelijke 
verschillen werden hierbij niet vastgesteld. Dit maakt een belangrijke invloed 
van theofylline op de eliminatie van de onderzochte quinolonen 
onwaarschijnli j к. 
In HOOFDSTUK 7 worden de resultaten gepresenteerd van een open, niet-
vergelijkend onderzoek naar de effectiviteit van enoxacin bij de behandeling van 
lagere luchtweginfecties. De belangstelling ging vooral uit naar het effect bij 
infecties, veroorzaakt door Pseudomonas aeruginosa. 
Aan de studie namen 41 patiënten lijdend aan een chronische bronchitis met 
een obstructief gestoorde longfunctie deel. 22 patiënten toonden tekenen van 
een longemfyseem; bij 20 patiënten was sprake van aangetoonde, soms 
uitgebreide, bronchiëctasieën. Pseudomonas-infecües werden behandeld met 
600 mg, 2 χ daags; infecties veroorzaakt door andere pathogenen met 400 mg, 
2x daags. Van de 45 behandelingsperioden konden er 43 worden geëvalueerd 
wat betreft effectiviteit. 
Het klinische en bacteriologische effect bij niet-pseudomonas infecties was 
goed bij 18 van de 20 patiënten. In de beide gevallen waarin Staphylococcus 
aereus werd geïsoleerd, bleven de kweken positief. In 3 gevallen werd een 
superinfectie door Streptococcen waargenomen. Alhoewel bij de patiënten met 
een Pseudomonas-mfectie in 20 van de 23 gevallen een matige tot goede 
klinische verbetering werd bereikt, werden de sputumkweken slechts in 6 
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gevallen steriel. In de meerderheid van de resterende gevallen werd een 
duidelijke afname van de groei van Pseudomonas in het sputum waargenomen 
tijdens de eerste dagen van de behandeling. Het feit, dat bij enkele patiënten na 
ongeveer 10 dagen de purulentiegraad van het sputum weer toenam was reden 
de in vitro gevoeligheid van de persisterende Pseudomonas stammen te testen, 
gelijktijdig met de stammen geïsoleerd voorafgaande aan de behandeling. De 
MIC-waarden van de persisterende Pseudomonas stammen bleken in alle 
gevallen gestegen te zijn t.o.v. de MIC-waarden van de oorspronkelijk 
aanwezige stammen. 
Tijdens 29 van de 45 behandelingen werden bijwerkingen geregistreerd, 
voornamelijk gastro-intestinale en neurologische. Bij 25 patiënten, die 
gelijktijdig werden behandeld met theofylline, trad een stijging op van de 
plasma theofylline-spiegels. Alhoewel waarschijnlijk een deel van de genoemde 
bijwerkingen samenhing met verhoogde plasma theofylline-concentraties, leken 
in een belangrijk aantal waarnemingen т . п . de neurologische bijwerkingen 
gerelateerd te zijn aan de toediening van enoxacin. 
HOOFDSTUK 8 beschrijft het verdere onderzoek dat werd verricht met de 
Pseudomonas aeruginosa stammen, geïsoleerd uit het sputum van 8 patiënten 
voor en na behandeling met enoxacin. 
De onderzochte sets van Pseudomonas aeruginosa bleken alle isogeen. Niet 
alleen de gevoeligheid voor enoxacin, maar ook voor Pefloxacin, ciprofloxacin 
en ofloxacin bleek afgenomen te zijn. Deze verminderde gevoeligheid was in 2 
van de 4 gevallen nog aantoonbaar respectievelijk 16 en 257 dagen na het 
stoppen van de behandeling met enoxacin. In 4 gevallen werd tevens een afname 
waargenomen van de gevoeligheid voor beta-lactam antibiotica en in 2 gevallen 
voor aminoglycosiden. Verder onderzoek toonde aan, dat dit bij 1 stam berustte 
op een verminderde penetratie van antibiotica door de bacteriële membraan. Bij 
een andere stam was zeer waarschijnlijk sprake van een veranderd DNA-gyrase 
op basis van een mutatie. 
Deze snelle afname van gevoeligheid van Pseudomonas aeruginosa is 
verontrustend. Onderzoek, waarbij een combinatie van een quinolon en een 
niet-gerelateerd antipseudomonas-middel wordt toegediend zal moeten 
uitwijzen, of op deze wijze een afname in de frequentie van resistentievorming 
kan worden verkregen. 
HOOFDSTUK 9 beschrijft de stijging van de plasma theofylline-concentraties 
bij patiënten tijdens behandeling met enoxacin. Bij 14 patiënten werd deze 
stijging gedocumenteerd middels dagelijkse metingen. Een nadere analyse bij 6 
patiënten toonde aan dat deze stijging werd veroorzaakt door een afgenomen 
metabole klaring van theofylline. 
In HOOFDSTUK 10 wordt de uitbreiding van het onderzoek naar de interactie 
met het theofylline-metabolisme gepresenteerd. Het onderzoek werd verricht bij 
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8 patiënten met een chronische bronchitis, die behoudens een theofylline-
preparaat met vertraagde afgifte, als verdere medicatie slechts beta-
sympaticomimetica en Steroiden per inhalatie gebruikten. Omdat de chemische 
structuur van ciprofloxacin, ofloxacin en Pefloxacin een sterke gelijkenis 
vertoont met de structuur van enoxacin werden ook deze quinolonen bij dit 
vergelijkende onderzoek betrokken. De farmacokinetische parameters van 
theofylline werden gemeten wanneer dit middel alleen werd ingenomen en 
tijdens gelijktijdige toediening van de vier quinolonen. Na afloop hiervan werd 
bij 4 patiënten nog een zesde periode toegevoegd, tijdens welke nalidixinezuur 
werd ingenomen. 
In vergelijking met de controle-periode, waarin alleen theofylline werd 
ingenomen, daalde de totale lichaamsklaring van theofylline tijdens enoxacin 
(63,3%), ciprofloxacin (30,4%) en Pefloxacin (29,4%). De klaring van 
theofylline werd niet beïnvloed door gelijktijdige toediening van ofloxacin of 
nalidixinezuur. Er werd een correlatie gevonden tussen de grootte van de 
interactie en de uitscheiding in de urine van de 4-oxo metaboliet, die wordt 
gevormd bij enoxacin, ciprofloxacin en Pefloxacin. Er zijn aanwijzingen, dat de 
demethylering van theophylline wordt geremd door deze 4-oxo metaboliet. 
HOOFDSTUK 11. Bij het onderzoek dat werd verricht met nalidixinezuur bleek 
de uitscheiding van de 7-hydroxy metaboliet in de urine sterk te variëren. Om 
mogelijk verschillende fenotypen voor de hydroxylering of glucuronidering aan 
het licht te brengen werd door 14 vrijwilligers 1 gram nalidixinezuur ingenomen. 
De variaties in hydroxylering en glucuronidering behoorden tot een normale 
verdeling en bleken niet te berusten op een verschillend fenotype. De verschillen 
worden veroorzaakt door de individuele enzymatische opbouw. 
De recent ontwikkelde quinolonen bezitten een goede in vitro gevoeligheid te 
voor een breed spectrum van vooral Gram-negatieve, maar ook Gram-positieve 
bacteriën. Van de onderzochte groep tonen ciprofloxacin en ofloxacin de beste 
gevoeligheid. Naast deze antibacteriële werking onderscheiden de onderzochte 
stoffen zich van vroeger ontwikkelde quinolonen, zoals nalidixinezuur, door 
hun langzamere eliminatie, resulterend in plasma- en weefselspiegels die 
gedurende meerdere uren hoger blijven dan de MIC waarden van een groot 
aantal pathogenen. 
Of de hooggespannen verwachtingen wat betreft de toepassing van deze groep 
antibiotica bij systeeminfecties worden waargemaakt, is op dit moment nog 
onvoldoende te beoordelen. Bij indicaties, waarvoor andere voorkeursmiddelen 
voorhanden zijn, zal terughoudendheid moeten worden betracht in het 
toepassen van deze nieuwe, zeer potente antibiotica, ter voorkoming van 
resistentievorming. 
Wat betreft de behandeling van luchtweginfecties kan worden gesteld dat deze 
quinolonen effectief zijn, ook tegen Pseudomonas aeruginosa. De matige tot 
slechte gevoeligheid van Streptococcus pneumoniae, vaak verwekker van 
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luchtweginfecties, maakt deze quinolonen ongeschikt als eerste keus 
antibioticum voor deze indicatie. De waargenomen bijwerkingen en de snelle 
afname van gevoeligheid van Pseudomonas verdienen nadere en voortgezette 
aandacht. Om deze redenen is toepassing van deze middelen in een klinische 
setting bij strikte indicatiestelling op dit moment aan te bevelen. 
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Allen, die een bijdrage hebben geleverd aan de verschillende studies, wil ik 
gaarne bedanken. In het bijzonder ben ik dank verschuldigd aan de patiënten 
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belastende protocollen, dit onderzoek onmogelijk zou zijn geweest. 
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De talloze quinolonbepalingen in bloed, plasma, sputum, speeksel, 
longweefsel en urine werden op het laboratorium van de sectie Onderzoek & 
Ontwikkeling van de afdeling Klinische Farmacie van het Sint 
Radboudziekenhuis (hoofd: Dr T.B. Vree) met grote inzet bepaald door Ita 
Baars. De hierbij toegepaste HPLC procedure werd door haar zelf ontwikkeld. 
De medewerkers van het klinisch-chemisch laboratorium van het Medisch 
Centrum Dekkerswald (hoofd: Mevrouw E. Labout) assisteerden waar nodig bij 
de afname van bloedmonsters en verrichtten de theofylline bepalingen. 
Emiel Termond (sectie Onderzoek & Ontwikkeling, afdeling Klinische 
Farmacie) was behulpzaam bij het berekenen van de verschillende 
farmacokinetische parameters en bij de statistische bewerking. 
Het hemoglobinegehalte in de longweefselmonsters werd bepaald door Bea 
Kohler op het Laboratorium voor Klinische Chemie van het Sint 
Radboudziekenhuis. 
Het bacteriologisch onderzoek van het sputum werd verricht door het bac-
teriologisch laboratorium van het Medisch Centrum Dekkerswald en het bacte-
riologisch laboratorium van het Canisius-Wilhelmina Ziekenhuis in Nijmegen. 
De Pseudomonas aeruginosa-stammen werden verder onderzocht in het 
laboratorium voor Pseudomonas-onderzoek (hoofd: Dr. J. Borst) en het 
laboratorium voor Chemotherapie (hoofd: Dr. B. van Klingeren) van het Rijks 
Instituut voor de Volksgezondheid en Milieuhygiëne te Bilthoven en Utrecht. Ik 
ben Dr. Bert van Klingeren en Dr. Han de Neeling zeer erkentelijk voor hun 
bijdrage aan en hun commentaar op het onderzoek. Hun bereidheid mij ten alle 
tijde van advies te dienen heb ik zeer gewaardeerd. 
Dr. Laura Piddock, als research scientific officer verbonden aan de afdeling 
Microbiologie (hoofd: Dr. R. Wise) van het Dudley Road Hospital in 
Birmingham heeft enthousiast en op creatieve wijze geparticipeerd aan het 
onderzoek dat werd verricht met de Pseudomonas stammen. 
De medewerkers van de Medische Bibliotheek (hoofd: Mevrouw Drs. S. 
Bakker) zijn behulpzaam geweest bij het verzamelen van de literatuurgegevens. 
De tekeningen werden gedeeltelijk vervaardigd door Dr. T.B. Vree van de 
afdeling Klinische Farmacie en door de heer C. Nicolasen van de afdeling 
Medische Illustratie. De figuren werden gefotografeerd op de afdeling 
Fotografi? van de Stichting Deventer Ziekenhuizen. 
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Tenslotte hecht ik eraan mijn erkentelijkheid uit te spreken voor het feit, dat 
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STELLINGEN 
behorende bij het proefschrift van 
W.J.A. Wijnands 
I 
De recent ontwikkelde fluoroquinolon derivaten zijn effectief bij de 
behandeling van infecties van de lagere luchtwegen. De slechte gevoeligheid van 
Streptococcus pneumoniae maakt ze echter ongeschikt als middel van keuze in 
de algemene praktijk voor deze indicatie. 
Dit proefschrift 
II 
Bij de overweging quinolonen toe te passen bij patiënten met een 
luchtweginfectie veroorzaakt door Pseudomonas aeruginosa dient naast het 
voordeel van orale behandeling rekening gehouden te worden met een mogelijk 
snelle resistentievorming voor deze hele groep van antibiotica. 
Dit proefschrift 
III 
De metabole klaring van theofylline wordt krachtig geremd door gelijktijdige 
toediening van enoxacin en, in mindere mate, door ciprofloxacin en Pefloxacin. 
De bevinding dat tijdens toediening van ofloxacin geen interactie optreedt 
betekent een voordeel voor dit middel wat betreft de toepassing bij patiënten, 
die tevens worden behandeld met deze bronchusverwijder. 
Dit proefschrift 
IV 
Gezien de ernst van de waargenomen neurologische bijwerkingen tijdens 
behandeling met quinolonen dienen na registratie de aard, ernst en frequentie 
van deze bijwerkingen nauwgezet vervolgd en geëvalueerd te worden. 
Dit proefschrift 
ν 
In veel gevallen van verminderde inspanningstolerantie bij patiënten met een 
obstructief longlijden speelt een matige lichamelijke conditie door inactiviteit 
een belangrijke rol. Gerichte adviezen ter verbetering hiervan en zo mogelijk 
actieve begeleiding dienen dan ook deel uit te maken van de behandeling. 
VI 
Om het effect van een slechte nierfunctie op het geheel van de klaringsprocessen 
van een geneesmiddel te kunnen beoordelen, is het noodzakelijk om niet alleen 
de moederverbinding, maar tevens eventuele metabolieten te meten. 
VII 
Tijdens de behandeling met tuberculostatica is het geven van borstvoeding niet 
absoluut gecontraindiceerd. 
Snider et al. Arch Intern Med 1984; 144: 589-90. 
VIII 
Alhoewel roken voor velen lijkt bij te dragen aan levensgeluk, blijkt hun 
vertrouwen in levensverwachting vaak te vroeg in rook op te gaan. 
IX 
Het rookvrij maken van de ziekenhuizen wordt belemmerd door de van 
rechtswege gegronde mogelijkheid van de medewerkers om het roken voort te 
zetten. 
χ 
Aangezien besloten is het Openlucht Museum in Arnhem voorlopig voort te 
laten bestaan verdient het aanbeveling het nog slechts uit cultuur-historisch 
oogmerk belangrijke 'glazen huis' van de jonge allergische patiënt aldaar een 
rustplaats te bieden. 
XI 
Nu het recente enthousiasme over de zijreflectoren op tweewielige voertuigen 
enigszins is geluwd, mag worden verwacht dat de verkeersveiligheid verder zal 
toenemen, als de politie haar controles van de eveneens bij wet verplichte 
fietsverlichting weer opneemt en intensiveert. 
XII 
De zonnebank kan een adembenemend effect geven; de sauna daarentegen lucht 
op. 
Deventer, 11 september 1987 




